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Abstract
External beam radiotherapy (EBRT) plays a vital role in the treatment of cancer, with
close to half of all cancer patients receiving EBRT at some point over their course of
treatment. Although EBRT is a well-established form of treatment, there are a number of
ways in which EBRT could still be improved in terms of quality and efficiency for
treatment planning and radiation dose delivery. This thesis reports a series of
improvements made to EBRT.
First, we developed and evaluated a new treatment planning technique called unified
intensity-modulated arc therapy (UIMAT) which combines the optimization and delivery
of rotational volumetric modulated arc therapy (VMAT) and fixed-gantry intensitymodulated radiation therapy (IMRT). When retrospectively compared to clinical
treatment plans using VMAT or IMRT alone, UIMAT plans reduced the dose to nearby
critical structures by as much as 23% without compromising tumour volume coverage.
The UIMAT plans were also more efficient to deliver. The reduction in normal tissue
dose could help lower the probability of treatment-related toxicities, or alternatively
could be used to improve tumour control probability, via dose escalation, while
maintaining current dose limits for organs at risk.
Second, we developed a new fast inverse direct aperture optimization (FIDAO) algorithm
for IMRT, VMAT, and UIMAT treatment planning. FIDAO introduces modifications to
the direct aperture optimization (DAO) process that help improve its computational
efficiency. As demonstrated in several test cases, these modifications do not significantly
impact the plan quality but reduced the DAO time by as much as 200-fold. If
implemented with graphical processing units (GPUs), this project may allow for
applications such as on-line treatment adaptation.
Third, we investigated a method of acquiring tissue density information from cone-beam
computed tomography (CBCT) datasets for on-line dose calculations, plan assessment,
and potentially plan adaptation using FIDAO. This calibration technique accounts for
ii

patient-specific scattering conditions, demonstrated high dosimetric accuracy, and can be
easily automated for on-line plan assessment.
Collectively, these three projects will help reduce the normal tissue doses from EBRT,
improve the planning and delivery efficiency, and pave the way for application like online plan assessment and adaptive radiotherapy in response to anatomical changes.
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Chapter 1 – Introduction
1.1 Cancer statistics
Cancer is a highly prevalent disease and a leading cause of death worldwide [1-5]. In
2018, the Canadian Cancer Society projects that about one in two Canadians will be
diagnosed with cancer at some point in their lifetime, and about one in four Canadians
will die with this disease [1]. Fortunately, the cancer mortality rates are declining in many
countries – including Canada – due to earlier detection and intervention, greater access to
treatment, and from advancements in cancer treatments, including radiation therapy [4,5].

1.2 Radiation Therapy Overview
Radiation therapy plays a vital role in the treatment of cancer, with more than half of
all cancer patients receiving radiation therapy at some point over their course of treatment
[3,5]. In radiation therapy, the patient is exposed to one or more sources of ionizing
radiation (i.e. high-energy x-rays, gamma rays, and/or charged particles). This ionizing
radiation can penetrate through the patient’s body, damaging and killing cells along its
trajectory [6,7]. The goal of radiation therapy is to preferentially deliver radiation to the
tumour volume while minimizing the amount of healthy tissue exposed and collaterally
damaged by treatment.
A commonly used metric in radiation therapy is the absorbed dose. Absorbed dose
measures the amount of energy (in joules, J) that is deposited per unit mass of an
absorber (in kilogram, kg), by ionizing radiation [6]. Absorbed dose is measured in the SI
unit Gray (Gy), where 1 Gy = 1 J/kg. The higher the absorbed dose in a volume, the more
likely that lethal cell damage will occur in that volume, and the more likely that cells
within that volume will transform or perish [7]. Therefore, the goal of radiation therapy is
to achieve a high absorbed dose in defined target regions containing cancerous tissue, and
a lower absorbed dose in regions containing normal tissue.
Radiation treatments are often administered over multiple treatment sessions. The
motivation for this fractionation comes from various radiobiological principles [7]. For
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instance, healthy tissue can repair faster from radiation damage than most cancerous cells
[7]. Therefore, by administering the treatment over multiple treatment sessions, we can
offer the healthy tissue more repair than cancerous cells. Furthermore, between treatment
sessions, the tumour volume can re-oxygenate, and its cells can enter into more
radiosensitive phases of the cell division cycle. As a result, the tumour volume becomes
more susceptible to radiation damage in future treatment sessions, and the therapeutic
ratio can be improved with fractionated-radiotherapy. A typical radiation treatment will
deliver 60 Gy to the tumour volume over 30 sessions (i.e. in 2 Gy / fraction over 30
fractions).
Radiation therapy can be administered in one of two ways: externally, through a
treatment known as external beam radiotherapy (EBRT), or internally, through a
procedure known as brachytherapy [6]. In brachytherapy, radioactive sources are
permanently or temporarily implanted in the patient, within or in close contact with the
tumour volume [6]. As the radionuclide decays, it emits ionizing gamma rays and/or
charged particles capable of damaging the nearby cells [6,7]. By placing the
radionuclides near or within the tumour volume, the absorbed dose is highest in the
cancerous tissue and reduces rapidly in the distal healthy tissue. Due to the invasiveness
of this procedure, brachytherapy is often only performed in a subset of patients where the
surgical procedure is well tolerated or minimally invasive (e.g. cervical, esophageal, or
localized prostate cancer) [6]. Instead, most cancer patients are treated using EBRT. This
thesis will focus exclusively on EBRT. In EBRT, beams of high-energy x-rays or charged
particles are generated by a medical linear accelerator and directed towards the patient’s
cancerous tissue [6]. While medical linear accelerators (also referred to as a linacs) can
be used to deliver megavoltage electron or x-ray beams, this thesis will deal exclusively
with x-ray beams. A medical linear accelerator and its treatment head (collimator) is
shown in Figure 1.1. To reach deeply seated tumours, the x-ray beam must first travel
through – and deposit dose into – healthy tissue. Due to the dosimetric properties of xrays, more dose will be deposited in the shallow healthy tissue than in the deep-seated
cancerous tissue [6]. To minimize the healthy tissue dose, EBRT treatments will use
multiple cross-fired beams, delivered from various gantry, couch and collimator angles,
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that intersect at the tumour volume. By doing this, less dose is deposited in the healthy
tissue, while a high cumulative dose is deposited in the cancerous tissue. Components
within the collimator, such as the jaws and multileaf collimator (MLC) shown in Figure
1.1, can also be used to attenuate and shape the beams. The plan beams can be optimized
to limit normal tissue dose and to improve the cumulative dose received by the target
volume [6]. In order to determine which beam configuration, beam shapes, and exposure
times to use for each patient, a treatment planning procedure is required as described in
the following section.

Figure 1.1: Picture of a linac [left] and the linac’s treatment head (collimator) [right].
Note that these images have been recolored to help identify each component. [left] The
patient lies on the treatment couch (orange) during treatment. Ionizing radiation is
delivered from the gantry (green) towards the patient, as illustrated by the yellow cone.
The gantry (and therefore the beam) can fully rotate around the patient, while the couch
can be rotated, elevated, and repositioned as well. Some linacs possess onboard imaging
capabilities for patient positioning and setup. The x-ray source and detector of this linac’s
imaging unit is highlighted blue and red, respectively. [right] The beam can be attenuated
and shaped using the jaws (blue) and the multileaf collimator (MLC, purple) within the
collimator of the linac. The rotation angle of the collimator can also be adjusted.
3

1.3 EBRT Treatment Process
The EBRT treatment planning process consists of the following major steps: (1)
image acquisition, (2) delineation of target volumes and organs at risk (contouring), (3)
beam selection, (4) plan optimization, (5) plan evaluation, (6) quality assurance, and (7)
plan delivery. Details of each step that are relevant to this thesis, are provided in the
following subsection.

1.3.1

Image Acquisition

Treatment planning begins by acquiring three-dimensional (3D) image sets of the
patient. To calculate the absorbed dose from EBRT treatment in the patient, 3D maps of
the tissue electron density (in electrons per cm3) are needed [8-10]. These maps can be
easily generated from the pixel values (Hounsfield Units (HU)) of x-ray computed
tomography (CT) scans [9,10]. These CT scans are acquired in the intended treatment
position and will include any immobilization equipment that will be for treatment. For
instance, personalized immobilization masks are often used for patients with brain and
head-and-neck cancer to hold their head in the same reproducible position during the CT
scan and in each of the treatment sessions. These masks are securely fastened to the
couch of the linac. Similarly, abdominal compressors may be used in patients with lung
cancer to help suppress respiratory tumour motion during the CT scan and treatment.
These CT scans are often referred to as the ‘planning CT’ or ‘CT-sim’ as they are used to
plan and simulate the treatment.
In some cases, it may not be possible to differentiate healthy tissue from cancerous
tissue on the planning CT images, as the borders of the tumour may not be well defined
on this type of scan. Moreover, additional information such a metabolic activity or water
diffusivity may be helpful for differentiating cancerous lesions from healthy tissue,
staging the cancer, or visualizing nearby critical structures (e.g. hippocampus). Therefore,
additional scans of the patient may be acquired using other imaging modalities such as
magnetic resonance imaging (MRI) and positron emission tomography (PET) [11].
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1.3.2

Contouring and Prescription

The image sets (planning CT, MRI, PET) of the patient are imported into a
commercial treatment planning system (TPS). If MRI or PET scans were acquired of the
patient, these image sets are co-registered with the patient’s planning CT using rigid or
deformable image registration (DIR) techniques [12]. The patient’s tumour(s), organs,
and healthy tissue are then delineated on the planning CT with the assistance of the coregistered MRI or PET scans [13]. The delineated tumour – as it is visible on the MRI,
PET, and/or CT scan – is referred to as the gross tumour volume (GTV).
Cancerous lesions are typically encapsulated by microscopic disease that cannot be
clearly visualized on MRI, PET, or CT scans. To ensure that all cancerous tissue is
treated, a treatment margin is added to the GTVs. This expansion of the GTV is referred
to as the clinical target volume (CTV) [13].
Some patients may have their gross tumour(s) surgically resected prior to radiation
therapy. If no gross tumour is left behind from surgery, the tumour bed will be contoured
instead and labelled as the CTV [13].
In some patients, there may be concerns that the disease has spread into the nearby
lymphatic tissue; even when there is no clear GTV in these regions. In these cases, the
lymphatic tissue may be delineated and treated prophylactically [13]. This is done to
mitigate the risk of local reoccurrence and the risk of the disease spread (metastasis) to
other regions of the body.
Lastly, a margin is added to the CTVs to account for the interfraction variability in
patient positioning, intrafraction motion such as breathing, and the general uncertainties
associated with treatment delivery. This expansion of the CTV is called the planning
target volume (PTV). Each PTV is prescribed a specific absorbed dose level. Primary
PTVs containing the GTV will be prescribed a high absorbed dose that will result in a
high tumour control probability (e.g. 70 Gy). Meanwhile, PTVs containing the lymphatic
tissue will typically be treated with a lower absorbed dose (e.g. 56 Gy). Finally, the
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radiotherapy plan is normalized so that 95% of primary PTV is covered by 100% of the
prescription dose.

1.3.3

Beam Selection

In this step, a treatment planner specifies what type of beam the linac will deliver (xrays or electrons); the energy of each beam; the gantry, collimator, and couch angles of
the beams; and how the linac will deliver this radiation. While there are many EBRT
techniques available today, such as electron beams and 3D conformal radiotherapy, the
majority of advanced EBRT treatments use x-ray beams delivered via one of two delivery
techniques: fixed-gantry intensity-modulated radiation therapy (IMRT) and rotational
volumetric modulated arc therapy (VMAT).
In fixed-gantry IMRT, the gantry, couch and collimator angles will remain fixed
while the x-ray beam is being delivered. However, during beam delivery, the linac can
alter the shape of the beam using the MLC and jaws shown in Figure 1.1 [14]. The MLC
(and in some cases, jaws) can move while the beam is being delivered, in a technique
known as sliding-window IMRT. Alternatively, the jaws and MLC can only be moved
when the beam is shut off, known as step-and-shoot IMRT [6]. By modulating the shape
of the beam during treatment, the net intensity (or fluence) delivered from each gantry
angle is spatially varied, hence the name intensity-modulated radiation therapy. This
intensity modulation can be used to improve PTV dose coverage and to minimize the
dose to organs-at-risk (OAR) along the beam trajectories [6]. With the wise selection of
gantry angles, IMRT can generally minimize the healthy tissue exposure and generate
steep dose gradients to spare nearby critical structures, as demonstrated by the whole
breast radiotherapy case in Figure 1.2.
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Figure 1.2: Axial view of a left-sided whole breast radiotherapy plan using two parallel
and opposing IMRT beams. These beams are visualized as the red and green cones
intersecting with the patient. With this beam setup, dose is limited primarily to the breast
tissue. Meanwhile, the steep dose gradient (illustrated by the isodose lines, with each colour
indicating the region receiving the corresponding dose (or more) in the legend on the right)
generated by the beam edge is used to spare the nearby lung and heart.
In VMAT, radiation is delivered as the linac gantry continuously rotates the beam
around the patient. Along the arc trajectory, the beam’s dose-rate (i.e. the beam flux) and
shape is modulated [15-16]. The treatment planner specifies the arcs to be used in the
treatment plan and their arc range. While VMAT has limited intensity-modulation at any
given gantry angle, the wide range of deliverable angles allows for more conformal dose
distributions when treating quasi-spherical target volumes, like the prostate PTV shown
in Figure 1.3. The wide range of deliverable angles in VMAT may result in a large
volume of healthy tissue receiving low levels of dose, whereas the limited number of
beams used by fixed-gantry IMRT may result in a smaller volume of healthy tissue being
exposed but receiving higher levels of dose (as illustrated by the isodose lines in Figure
1.2). VMAT treatments are also typically more efficient to deliver than fixed-gantry
IMRT.
7

Figure 1.3: Axial view of a prostate radiotherapy plan using a single 360° VMAT arc
(beam is not shown to improve visibility). With its wide range of deliverable angles,
VMAT can produce dose distributions that are very conformal to the PTV.

1.3.4

Plan Optimization

It will be helpful for this section to first go over how medical linear accelerators are
instructed to deliver IMRT and VMAT treatment plans. During delivery, a linac follows a
series of programmed instructions known as control points (CP) [17]. Each CP specifies
the position of each machine components (i.e. the couch position and angle, the gantry
angle, the collimator angle, each jaw position, and each MLC leaf position) and the
cumulative number of monitor units (MUs) that the machine is to deliver by the next CP.
Note that the MU is a calibrated radiation unit that is measured by a monitoring ion
chamber inside the linac head during beam delivery [6]. MU is calibrated to deliver a
certain dose to a reference point in a water phantom under specific condition.
Specifically, one MU is typically calibrated to deliver one cGy to a reference point in a
water phantom at depth 5 cm and source to detector distance 100 cm for a beam with a
field size of 10x10 cm2. In step-and-shoot IMRT, the linac moves the components to the
positions specified in the first CP. It then delivers the number of MUs specified for the
first CP, while holding each machine component stationary. Once the MUs have been
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delivered, the linac moves the components to the positions specified in the next CP, then
delivers the MUs specified for that CP. Conversely, in VMAT and sliding-window
IMRT, the linac moves the machine components between the positions specified in the
first and second CP while delivering the number of MUs that are to be delivered by the
second CP. It continues transitioning the components and delivering the MUs
simultaneously until the last CP is reached.
The goal of plan optimization is to determine what the CPs parameters of the
treatment plan should be. This process begins with the treatment planner creating a list of
plan objectives (sometimes referred to as IMRT objectives). This list will consist of, for
instance, a homogeneous prescribed absorbed dose to each PTV and a maximum dose
permitted for each OAR. A weighting factor is also assigned to each of the planning
objectives, indicating the relative importance of the objective.
When optimizing the treatment plan, each IMRT objective is represented by a scalar
objective function [18]. This function reaches a global minimum value of zero when the
3D dose distribution of the plan satisfies the corresponding IMRT objective. The goal of
plan optimization is to determine the CP parameters whose 3D dose distribution
minimizes the weighted sum of these objective functions (i.e. that simultaneously
satisfies as many of the IMRT objectives as possible). Unfortunately, these objective
functions often have multiple minima, and so there is a risk that conventional
deterministic optimization methods like gradient-descent could become trapped at a local
minimum (i.e. at a sub-optimal solution). This issue can be avoided by using stochastic
optimization techniques, such as simulated annealing, which can ‘escape’ from local
minima [19]. However, stochastic optimization methods are typically much slower than
deterministic methods, and so most commercial treatment planning systems use
deterministic optimization algorithms (as described in Chapter 3 and Chapter 4). Briefly,
these optimization algorithms perform the following IMRT/VMAT treatment planning
procedure which will initialize the CP parameters as close to the global minimum of the
objective function as possible.
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IMRT plan optimization begins with fluence map optimization (FMO). FMO
optimizes each beam’s fluence map based on the planning objectives [20]. A more
detailed summary of FMO can be found in Chapter 3.2.1. FMO tells us what the ideal
beam fluence should be after a beam is delivered, but it does not tell us how many CPs
are needed or what the CP parameters should be to generate the optimal fluence map. To
get this CP information, an aperture-sequencing algorithm is executed on the optimized
fluence maps [14]. These sequencing algorithms decompose the fluence map into a
collection of segments, with each segment having a single homogeneous intensity. These
segments can be easily converted into equivalent CP information. Usually, the number of
CPs needed to faithfully recreate the optimal fluence map, is too high for delivery to be
practical [19]. Therefore, sequencing algorithms are typically forced to approximate the
ideal fluence map using a limited number of CPs. Due to this approximation, plan quality
often degrades after aperture sequencing. To recoup this plan degradation, direct aperture
optimization (DAO) are typically used [19,21-27]. These DAO algorithms iteratively
optimize the MLC, jaw, and MUs values of each CP while also taking into consideration
the delivery limitations of the specific linear accelerator. A more detailed introduction to
DAO can also be found in Chapter 3.2.2. Some DAO algorithms optimize the aperture
shapes after FMO and aperture sequencing [22], while others incorporate the aperture
sequencing step into the FMO algorithm [23]. Both types of DAO use the same planning
objectives as FMO. The result of these DAO algorithms is the CPs necessary for
achieving the desired planning objectives.
The plan optimization algorithm used for VMAT treatment planning is dependent on
the commercial TPS [16,28,29]. For this thesis, only the SmartArc VMAT planning
algorithm is introduced [29]. Upon starting VMAT optimization, SmartArc performs
FMO and aperture sequencing at fixed-gantry angles every 24 degrees between the userspecified starting and stopping angle. It then selects the two CPs with the highest number
of open leaf pairs from each beam, while discarding all the rest of CPs. The selected CPs
are then redistributed around their original gantry position. Additional CPs are then
created between the selected and repositioned CPs, via linear interpolation, until a
minimum angular spacing between consecutive CPs (typically 2° or 4°) is achieved. This
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process is referred to as arc sequencing and is illustrate in Figure 1.4. DAO is then
performed on the CPs of the VMAT arc, using the same planning objectives as before.
Note, the DAO algorithms used for VMAT also incorporate any VMAT related delivery
constraints, such as the maximum dose rate and gantry rotation speed.

Figure 1.4: Illustration of the SmartArc planning process. FMO and aperture sequencing
is performed at 24° increments. The two CPs with the highest number of open leaf pairs
are selected from each beam, while the rest (CPs 1a & 2a) are discarded. The selected
CPs are then repositioned along the arc (crosses). Additional CPs are generated via linear
interpolation (circles) until a maximum distance between consecutive CPs (typically 4°)
is achieved. This figure is reproduced from Bzdusek et al. [29], with permission from
John Wiley and Sons (Appendix B.1).
The accuracy and efficiency of plan optimization relies heavily on the dose calculation
algorithm that is used for plan optimization [10]. High dosimetric accuracy is needed so
that the plan parameters are correctly optimized, and the optimization converges to the
users-specified plan objectives. However, the dose calculation should be sufficiently fast
for the optimization to complete in a practical amount of time. A common approach is to
perform an accurate but less efficient dose calculation (e.g. collapsed cone convolution
(CCC)) in the middle of the optimization. Then, during DAO, the algorithm uses a fast
but less accurate dose engine (e.g. singular value decompositions (SVD)) to ‘perturb’ the
dose distribution, based on the difference between the current plan parameters and plan
parameters at the time of the accurate dose calculation [22,30]. This allows for fast
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optimization without a substantial decrease in the dosimetric accuracy. At the end of
optimization, a more accurate dose calculation algorithm such as CCC will be used again
for the final dose computation of the plan.

1.3.5

Plan Evaluation

The plan quality will be evaluated once plan optimization is completed. The
following tools are commonly used to assess EBRT plan quality: (1) the 3D dose
distributions, (2) cumulative dose-volume histograms (DVH), and (3) dose metrics [6].
3D dose distributions and isodose lines (as shown in Figure 1.2 and Figure 1.3) can
be used to evaluate the conformity of the dose distribution to the PTVs and doses to
organs at risk.
Cumulative DVHs gives a compact summary of the 3D dose distribution for selected
regions of interest (ROIs). Each DVH is plotted with the volume (absolute or relative) of
a ROI on the vertical axis that is receiving more than or equal to the dose on the
horizontal axis. An example of a DVH for a VMAT lung case is shown in Figure 1.5.
Each of the PTV and OAR volumes are plotted separately on the DVH. Ideally, PTV
DVHs will be as close to the top right as possible, indicating a high dose to as much of
the PTV as possible. Conversely, all OAR DVHs should be bunched as close to the
bottom left as possible, indicating that as little of the OAR is exposed to as low of a dose
as possible. Many planning objectives, like the minimum and maximum dose, can be
visualized with point markers on the DVH plot.
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Figure 1.5: A sample dose-volume histogram from VMAT lung case. Common dose
metrics for the lungs, esophagus and PTV are labelled.
Dose metrics are typically points on the DVH (e.g. the maximum dose as described
above) or quantify some property about a DVH (e.g. conformity of the PTV coverage).
̅ ), the maximum point dose (𝐷𝑚𝑎𝑥 ), the
Common dose metric include: the mean dose (𝐷
minimum dose received by 𝑥 volume in cubic centimeters (𝐷𝑥 𝑐𝑐 ), the minimum dose
received by 𝑥 % of the volume (𝐷𝑥% ), and the percent volume receiving 𝑥 dose or more
(𝑉𝑥 𝐺𝑦 ). Various dose metrics have been labelled on the DVH in Figure 1.5. Several dose
metrics have been correlated with patient outcome data [31]. For instance, the lungs
𝑉20𝐺𝑦 (the volume of the lungs receiving 20 Gy or more, shown in Figure 1.5) has been
shown to be predictive of the patient developing pneumonitis after radiotherapy [32]. It is
recommended that the lung 𝑉20𝐺𝑦 be below 30% for treatment (it is about 7% in the plan
shown in Figure 1.5).
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If the dose distribution, the DVHs, or any of the dose metrics don’t meet the clinical
goal (e.g. the 𝑉20𝐺𝑦 objective above), the plan will be re-optimized with modified
planning objectives and/or objective weights. This cycle is repeated, in a trial-and-error
approach, until a satisfactory treatment plan is achieved.

1.3.6

Quality Assurance

Once a satisfactory plan has been obtained, a series of quality assurance (QA) checks
are performed to ensure that the treatment plan is safe, effective, and can be delivered
accurately [33]. One QA test that will be relevant to this thesis is the patient-specific plan
QA. First, the patient’s treatment plan is delivered to a phantom that can measure and
record the cumulative dose at numerous points in space. Let the spatial location of these
measurements be denoted by, 𝑟𝑚 , and the dose that is recorded at these points be,
𝐷𝑚 (𝑟𝑚 ). The measured dose is then compared with the dose distribution calculated by the
TPS, via a gamma analysis [34]. Specifically, let 𝐷𝑐 (𝑟𝑐 ) be the dose calculated by the
TPS at the location 𝑟𝑐 . For each measurement point 𝑟𝑚 , the gamma analysis will find the
𝑟𝑐 that yields the lowest value to the function:
2

𝐷𝑐 (𝑟𝑐 ) − 𝐷𝑚 (𝑟𝑚 )
𝑑(𝑟𝑐 , 𝑟𝑚 ) 2
Γ(𝑟𝑚 , 𝑟𝑐 ) = √(
) +(
) .
ΔD
Δ𝑑
That is,
𝛾(𝑟𝑚 ) =

min
Γ(𝑟𝑚 , 𝑟𝑐 ) .
𝑟𝑐

Note, 𝑑(𝑟𝑐 , 𝑟𝑚 ) is the Euclidean distance between 𝑟𝑐 and 𝑟𝑚 , and ΔD and Δ𝑑 are the dose
difference and distance-to-agreement acceptance criteria set by the user. Any
measurement points where 𝛾(𝑟𝑚 ) > 1 indicates a region where the measured dose and
calculated dose disagree by more than the composite acceptance criteria. The gamma
pass-rate gives the percentage of points where the measured dose agrees with calculated
dose within the acceptance criteria. A common criteria is that 95% or more of the
phantom dose measurements agree with the calculated dose, when the gamma analysis is
performed with a 3% dose difference and 3 mm distance-to-agreement acceptance
criteria.
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1.3.7

Plan delivery

During a treatment session, the patient will be set up on the treatment couch (see
Figure 1.1) in the same treatment position as the planning CT. Planar x-ray images or
cone-beam computed tomography (CBCT) images may be acquired with linac’s on-board
imaging system (shown in Figure 1.1) and compared with the planning CT, to ensure
accurate patient positioning [6]. Alternative image guidance technique like megavoltage
x-ray CT, MRI, or optical guidance systems may also be used, if available, for patient
positioning [35]. Once the patient is in the planned treatment position, the linac will
deliver the patient’s treatment plan. The patient will be treated with this plan, once or
twice a day, Monday to Friday, for up to several weeks.
Over the course of treatment, the patient may undergo anatomical changes such as
weight loss or tumour regression [36]. These changes may impact the effectiveness of the
patient’s immobilization equipment, leading to possible setup errors. Moreover, these
changes may alter how radiation dose is distributed in the patient, leading to sub-optimal
outcomes or unintended treatment-related side-effects [37].
To ensure that the patient receives adequate treatment, the patient may be referred for
a new planning CT when their immobilization equipment is no longer effective or if large
anatomical changes are observed between the patient’s original planning CT and a CBCT
acquired on-line. The patient’s new planning CT will be contoured and registered with
the patient’s original planning CT. The patient’s plan will then be ‘copied’ onto the new
planning CT for dose calculation and plan assessment. If the plan quality is deemed
inadequate, a new treatment plan will be generated on an accelerated timeline. The
patient will then resume treatment with this new treatment plan. This is the process of
treatment plan adaptation

1.4 Research Motivation
There are a number of ways in which the EBRT process described above, could be
altered to improve plan quality, planning efficiency, and delivery efficiency.
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First, EBRT treatments typically use either IMRT or VMAT delivery techniques.
However, due to the complementary dosimetric properties of VMAT and IMRT, there
could be an advantage to combining both VMAT and IMRT together in the same plan, as
opposed to using one or the other. Currently, TPS do not support the simultaneous
optimization of VMAT and IMRT. Instead, hybrid VMAT-IMRT treatment plans can
only be created by optimizing the VMAT and IMRT portions separately [38]. This calls
into question whether the treatment plan is truly optimal, as the plan parameters are never
truly optimized together at the same time. Moreover, this planning approach will require
that the IMRT and VMAT beams be delivered separately, making treatment delivery
much less efficient.
Another source for improvement is the time spent optimizing IMRT, VMAT, as well
as any future hybrid VMAT-IMRT treatment plans. Due to the computational complexity
of the DAO problem, and the current trial-and-error approach to plan optimization,
treatment planning can sometimes take several hours or even days to complete in some
very complex cases. Furthermore, when there is limited time for treatment planning (e.g.
for re-planning), sub-optimal treatment plans may be deemed acceptable for treatment, so
that treatment delivery is uninterrupted. While newer TPS offer DAO algorithms that are
implemented on fast parallelized graphical processing units (GPU), they are still not fast
enough for applications like: (1) multi-criteria optimization [39,40] where numerous
treatment plans are generated and compared, and (2) on-line adaptive radiotherapy (ART)
where treatment re-planning is performed at the linear accelerator – while the patient is
immobilized and awaiting treatment – using the 3D image sets acquired on-line (e.g.
CBCT, MRI) [41,42].
Finally, even if fast DAO algorithms were available for on-line ART, another hurdle
for ART is getting accurate electron density information from the 3D data sets acquired
on-line, for dose calculations and plan optimization. For instance, MRI lacks a one-to-one
correspondence between the voxel (3D pixel) intensity and electron density [43].
Meanwhile, patient-specific scattering conditions in CBCT can influence the accuracy of
electron density maps [44]. Several methods of calibrating CBCTs for accurate dose
calculation have been implemented, such as intensity-based deformable image
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registration (DIR) algorithms that warp the accurate planning CT data onto the patient
anatomy obtained from the CBCT. However, these DIR algorithms often introduce
localized deformation errors which could potentially impact the densitometric, dosimetric
and contouring accuracy within the region (see Chapter 5 for details). Therefore, more
precise methods of acquiring electron density information from these image sets are still
needed.
Even if fast DAO algorithms are unavailable for on-line ART, these electron density
maps will be helpful for on-line dose calculations and plan assessment to judge whether
treatment re-planning is truly necessary. Specifically, the effectiveness of the patient’s
immobilization equipment and the anatomical changes viewed on CBCT may not always
be good indicators that treatment intervention and re-planning is necessary. It is not
uncommon for a new planning CT to be acquired, contoured, and the plan copied over for
plan assessment, only to find that the plan quality has not changed significantly to
warrant re-planning. More importantly, these markers could be failing to identify patients
that do need treatment intervention.
The overarching goal of this research is to address these critical areas of improvement
in EBRT. Note that this is by no means an exhaustive list of how EBRT could be
improved for gains in clinical outcomes. Many other areas for improving EBRT and
patient outcome are currently under investigation at institutions around the world, such as
the use of heavy-ion beams (e.g. proton, carbon-ion) [6], hypo-fractionation treatment
regimens for the treatment of primary and oligometastatic cancer [45,46], and
immunotherapy and its possible synergistic effects with radiation therapy [47], to name a
few.

1.5 Research Hypothesis
We hypothesize that a fast plan optimization algorithm that unifies rotational
volumetric modulated arc therapy and fixed-gantry intensity-modulated radiation therapy
will improve radiotherapy plan quality, planning and delivery efficiency, and will provide
a stepping-stone towards future on-line (interactive) plan adaptation.
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1.6 Chapter Objectives
In Chapter 2, we evaluate a plan optimization algorithm called unified intensitymodulated arc therapy (UIMAT) on complex head-and-neck cases. This UIMAT
algorithm simultaneously optimizes both rotational VMAT and fixed-gantry IMRT
delivery techniques and combines their delivery. That is, UIMAT sequences the plan CPs
such that, at delivery, the linac will deliver just like a VMAT beam. However, when this
UIMAT beam reaches a gantry angles selected for IMRT delivery, it will halt gantry
rotation and begin delivering like a step-and-shoot IMRT beam. After delivering this
IMRT portion, the UIMAT beam will resume VMAT delivery. Delivery efficiency is
improved by combining VMAT and IMRT’s delivery in this way. Since this UIMAT
algorithm was initially developed before entering this PhD program, details of this
UIMAT plan optimization algorithm are provided in Appendix A.
In Chapter 3, a new DAO algorithm called fast inverse direct aperture optimization
(FIDAO) is developed. FIDAO introduces modification to the equations used in DAO.
These modifications greatly reduce the computation time of repeated calculations
performed in the DAO process. By reducing the time of these calculations, DAO will be
able to execute faster and improve the treatment planning efficiency, potentially allowing
for on-line applications. Chapter 3 describes and evaluates this FIDAO algorithm for
fixed-gantry IMRT treatment planning, while Chapter 4 evaluates FIDAO for rotational
VMAT treatment planning.
In Chapter 5, a patient-specific CBCT calibration technique for on-line dose
calculation and plan assessment is developed. By performing dose calculations and plan
assessment on-line with these CBCT datasets, we can better differentiate the patient that
truly require treatment re-planning from those who do not, saving resources and time.
Moreover, with a fast DAO algorithm like the one developed in Chapter 3 & Chapter 4,
the treatment re-planning could be potentially performed on-line with the calibrated
CBCTs.
Finally, Chapter 6 summarizes the findings of this thesis, the potential clinical impact
of these project, their limitations, future work, and specifically how these projects could
18

be combined as a package for an advanced on-line treatment planning and plan
adaptation procedure. All of these developments are aimed at improving the clinical
outcomes in patients treated with state-of-the-art radiation therapy.
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Chapter 2 – Evaluation of unified intensity-modulated arc
therapy (UIMAT) for the radiotherapy of head-and-neck
cancer
This chapter was adapted from the published article entitled “Evaluation of unified
intensity-modulated arc therapy for the radiotherapy of head-and-neck cancer” by
Michael MacFarlane, Douglas A. Hoover, Eugene Wong, Nancy Read, David Palma,
Varagur Venkatesan, Alex Hammond, Jerry J. Battista, and Jeff Z. Chen, Radiotherapy
and Oncology, 119 (2): 331-336 (2016). Permission to reproduce this article was granted
by Elsevier and is provided in Appendix B.2. Supplemental tables and figures for this
chapter are provided in Appendix C.

2.1 Introduction
Volumetric modulated arc therapy (VMAT) and fixed-gantry intensity-modulated
radiation therapy (IMRT) are two commonly used external beam radiotherapy techniques
for the treatment of cancers. Although these two delivery modalities are often treated in
practice and literature as disparate or competing techniques, they are in fact both
mechanically and dosimetrically complementary to each another.
The fixed-angle delivery used in IMRT allows for the creation of steep dose gradients
at the field edges and highly modulated intensity patterns from each beam direction. With
the wise selection of beam orientations, substantial sparing of select organs at risk (OAR)
is possible with this technique [1,2]. However, for more rotationally symmetric target
volumes, a larger number of beams may be required to achieve sufficient dose coverage
and conformity while still sparing the surrounding OARs, resulting in reduced delivery
efficiency. In such cases, the rotational delivery of VMAT is preferred as the wide range
of deliverable angles can create very conformal dose distributions in a timely and
efficient manner [3-7]. However, the requirements of continuous gantry motion and high
delivery efficiency limit the degree of intensity modulation achievable at any given beam
angle.
Many groups have demonstrated that the combination of IMRT and VMAT within a
single plan provides a therapeutic advantage over treatments using either IMRT or
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VMAT alone, as it utilizes the dosimetric advantages of both techniques [8-13]. This
could be particularly advantageous in complex sites such as the head and neck where, in
general, no consistent dosimetric advantage is observed between VMAT and IMRT [14].
It should be noted that with these previous hybrid techniques, IMRT and VMAT have not
been fully integrated during either the inverse-optimization or beam delivery process.
Recently, our group developed a method called unified intensity-modulated arc
therapy (UIMAT) which permits the simultaneous inverse optimization and concurrent
delivery of VMAT and IMRT in a single arc [15]. Specifically, during the arc delivery,
the gantry rotation can be reduced to a near-stop in order to deliver IMRT beam segments
at opportune gantry angles. Details of this UIMAT algorithm can be found in Appendix
A. This current study evaluates the potential benefit of UIMAT for the radiotherapy of
complex head-and-neck cancer, compared to strictly VMAT or IMRT treatment plans.
This site was selected based on promising preliminary results obtained in the previous
feasibility study [15].

2.2 Methods and materials
Thirty previously treated head-and-neck cases were arbitrarily selected for this study.
Fifteen of these cases were treated with dual-arc VMAT while the other fifteen cases
were treated with a variable number of step-and-shoot (SS) IMRT beams. No factors
related to the patient, primary disease site, or the prescribed dose was considered during
the selection. A summary of the selected cases is provided in Supplementary Table 2.1.
UIMAT plans were generated for each patient using custom scripts developed for
Pinnacle3 v9.6 Radiation Therapy Planning System (Philips Healthcare, Fitchburg, USA).
Technical details of the UIMAT method were previously described by Hoover et al. [15]
and can be found in Appendix A however, the method can be roughly divided into five
stages:
(1) Fluence Map Optimization: Multiple static beams are evenly distributed along the
arc range and their fluences are optimized.
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(2) MLC Sequencing: Optimized fluences are converted into deliverable MLC
segments.
(3) UIMAT Sequencing (Re-assignment): Deliverable beams are sequenced via a script
into VMAT or IMRT phases based on the number of MLC segments in a beam. Beams
with fewer segments are converted to VMAT phases, while beams with more segments
are converted to IMRT phases with near-constant gantry angles as shown in Figure 2.1.
(4) Direct Aperture Optimization (DAO): Both VMAT and IMRT phases are
optimized simultaneously using Pinnacle’s DAO algorithm.
(5) Unification: The optimized VMAT and IMRT phases, which are treated as separate
beams within Pinnacle, are merged by script into a single UIMAT arc for final dose
calculation and delivery.

Figure 2.1: Illustration showing IMRT phases (lavender) and VMAT phases (orange)
generated by the UIMAT script.
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All UIMAT plans were created by a single planner (MM) and treatment planning
times were recorded. Planning objectives for each UIMAT plan were copied from the
clinical plan and set so that 95% of the planning target volume (PTV) would receive at
least 95% of the prescription dose, while OAR doses were kept as low as achievable.
Without exception, all OAR doses in both clinical and UIMAT plan were kept below our
institutional standards, which originate from recommendations by Radiation Therapy
Oncology Group (RTOG) clinical trials (RTOG 0225, 0513, 0522, 0615, and 0619), and
Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC) guidelines
[16].
UIMAT plans were optimized using the same (or very similar) objectives as the
clinical plans. OAR objectives were set to reduce global OAR doses as opposed to the
dose to any specific endpoint. Individual dose objectives were made more stringent if
their relative contribution to the total objective function approached zero. In this way, the
dose to all OARs was pushed as low as possible, in an unbiased manner. No explicit
attempt was made to surpass the clinical plan; rather, UIMAT optimization was
continued until the plan reached its highest potential. This is similar to how our clinical
cases are planned.
The completed UIMAT plans were then evaluated against the clinically delivered
plans in terms of target volume coverage, conformity index (CI), as well as clinically
relevant OAR dose metrics. Wilcoxon signed rank tests were performed in SPSS (IBM
Corp., Armonk, USA) to test for statistically significant differences between the UIMAT
plans and the clinically delivered plans. The threshold for statistical significance was set
to 5%. For plans with multiple PTVs (each having a different dose level), the average of a
PTV metric was used in the analysis. For instance, if a plan had a PTV70Gy with a mean
dose of 102% (relative to 70 Gy), and a PTV56Gy with a mean dose of 110% (relative to
56Gy), then the PTV mean dose used in the analysis would be 106%.
The conformity index used here is similar to the one introduced by Oozeer et al. [17]:
𝐶𝐼 = (𝐶𝑜𝑣𝑒𝑟 𝑓𝑎𝑐𝑡𝑜𝑟) × (𝑆𝑝𝑖𝑙𝑙 𝐹𝑎𝑐𝑡𝑜𝑟)
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𝑉95 (𝑃𝑇𝑉)
𝑉95 (𝑃𝑇𝑉)
=(
)×(
)
𝑉𝑃𝑇𝑉
𝑉95 (𝐵𝑜𝑑𝑦)

(1)

where V95(PTV) and V95(Body) are the volumes of the PTV and body, respectively,
receiving at least 95% of the prescription dose, and VPTV is the volume of the PTV. This
equation was defined initially for a single dose level. To handle the case where multiple
dose levels exist, the PTV volume with a lower prescription dose will also include all
higher dose PTV volumes. For example, for a plan with PTV70Gy, PTV63Gy, and PTV56Gy,
to calculate the conformity index for the PTV with the lowest prescription dose (56 Gy),
the PTV in equation (1) will be the union of the three PTV volumes.
Treatment plans were validated with an ArcCheck phantom (Sun Nuclear Corp.,
Melbourne, USA), using a TrueBeam linear accelerator (Varian Medical Systems, Palo
Alto, USA) operating in clinical mode. Absolute dose distributions were compared
between plans and ArcCheck measurements, using gamma parameter thresholds of 3%
dose difference and 3 mm distance-to-agreement [18]. Delivery times were also measured
during the ArcCheck delivery.

2.3 Results
The median (range) time required to generate a UIMAT plan was 3 (1.5-6) hours,
which is comparable to the typical clinical planning time logged at our institution.
Dosimetric comparisons for individual VMAT and IMRT cases are tabulated respectively
in Supplementary Table 2.2 and Supplemental Table 2.3 (available online at
www.thegreenjournal.com). In Table 2.1, median and ranges of the target and OAR dose
metrics are compared for UIMAT plans against the stand-alone clinical IMRT plans,
VMAT plans, and both clinical IMRT or VMAT plans.
Conformity indices were found to be lower in IMRT and UIMAT when compared to
VMAT. A slight improvement in the dose coverage (D95) was observed for UIMAT
relative to the IMRT (98.0% vs 96.7%, respectively, p < 0.01), but not when comparing
UIMAT to the VMAT (98.2% vs 98.0%, respectively, p = 0.70). The mean PTV doses
were slightly higher in UIMAT relative to VMAT (102.3% vs 101.5%, respectively, p <
0.01) and to IMRT (102.2% vs 101.8%, respectively, p = 0.01).
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Median OAR dose metrics were universally reduced by the application of UIMAT.
On average, OAR max doses were reduced by 5.4 Gy when compared to VMAT, and 5.3
Gy when compared to IMRT. Similarly, OAR mean doses were reduced, on average, by
2.5 Gy when compared to VMAT, and 3.9 Gy when compared to IMRT. All dose metrics
were significantly reduced with the exception of the mean larynx and mean parotid doses
when compared to VMAT. Average OAR dose-volume histograms are shown in Figure
2.2. Average OAR dose-volume histograms between just the VMAT and UIMAT
techniques, as well as between IMRT and UIMAT techniques, are provided in
Supplemental Figure 2.1. Sample dose distributions of two representative cases are
shown in Figure 2.3.
In terms of deliverability, a significant reduction of the median delivery time was
observed for UIMAT plans compared to the IMRT plans (147 s vs 269 s, p = 0.001),
while no significant difference was observed between UIMAT and VMAT median
delivery times (135s vs 168s, p = 0.39). A significant reduction in median monitor units
(MU) was observed for UIMAT compared to IMRT (449 MU vs 596 MU, p < 0.01) and
to VMAT (486 MU vs 635 MU, p < 0.01). Median IMRT QA pass rates were found to be
significantly lower with UIMAT when compared to VMAT (97.5% vs. 98.8 %, p = 0.03)
and IMRT (97.6 % vs. 99.2 %, p = 0.02).
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Figure 2.2: Comparison of average DVHs for various organs at risk. The clinical average
DVH is plotted with the dashed line while the UIMAT average DVH is plotted with a
solid line.
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Table 2.1: Median (Min, Max) metric value between our UIMAT plans and the clinically delivered plans. Summaries are
provided for VMAT cases (patients 1 – 15), IMRT cases (patients 16 – 30), and all cases. PTV mean doses and D95s (dose to
95% of the PTV) are given as percentages of the prescribed dose to the PTV. Reported max dose is the dose to 2% of the
volume. Statistically significant differences are indicated by *.
Region
of
Interest

VMAT Only (Cases: 1-15)
Metric
CI

PTV

Mean (%)
D95 (%)

Norm. Tiss.

Mean (Gy)

Oral Cavity

Mean (Gy)

Lt. Parotid

Mean (Gy)

Rt. Parotid

Mean (Gy)

Larynx

Mean (Gy)

Cord

Max (Gy)

Brainstem

Max (Gy)

Lt. Cochlea

Max (Gy)

Rt. Cochlea

Max (Gy)

VMAT

UIMAT

0.73
(0.51,0.92)
101.5
(100.7,104.3)
98.0
(95.8,100.8)
6.4
(1.0, 11.2)
29.2
(4.7, 44.0)
25.3
(2.0, 43.9)
27.2
(1.3, 60.9)
33.8
(0.2, 65.8)
35.8
(7.3, 41.6)
25.7
(4.3, 57.3)
11.9
(2.3, 64.6)
16.1
(1.2, 50.0)

0.70
(0.46, 0.87)
102.3
(100.7, 105.6)
98.2
(94.9, 100.2)
6.2
(1.0, 10.5)
21.3
(3.0, 43.0)
22.6
(2.0, 44.3)
25.5
(1.1, 60.8)
26.2
(0.2, 67.1)
29.4
(5.6, 40.0)
11.7
(2.8, 56.9)
5.9
(1.6, 65.5)
8.2
(1.0, 50.0)

IMRT Only (Cases: 16-30)
P

0.003*
0.001*
0.695
0.691
0.002*
0.173
0.071
0.173
0.001*
0.001*
0.011*
0.001*

IMRT

UIMAT

0.67
(0.15,0.81)
101.8
(100.3,104.6)
96.7
(94.9,98.7)
7.4
(4.2, 13.4)
33.9
(14.0, 61.3)
29.1
(3.4, 52.0)
27.2
(4.7, 58.6)
37.4
(0.7, 71.3)
35.3
(25.3, 41.5)
25.4
(3.4, 46.9)
8.5
(0.7, 59.9)
9.5
(0.9, 25.2)

0.67
(0.14, 0.83)
102.2
(101.3, 104.3)
98.0
(95.6, 99.5)
7.4
(3.5, 13.8)
27.5
(10.0, 57.7)
26.7
(2.6, 48.3)
18.4
(2.7, 58.3)
30.9
(0.6, 70.6)
30.3
(15.9, 39.6)
22.2
(4.5, 41.0)
5.9
(0.6, 56.3)
5.7
(0.9, 17.7)

All Cases (Cases: 1-30)
P

0.256
0.011*
0.004*
0.069
0.001*
0.005*
0.001*
0.002*
0.001*
0.001*
0.001*
0.001*

Clinical

UIMAT

0.69
(0.15,0.92)
101.7
(100.3,104.6)
97.5
(94.9,100.8)
7.2
(1.0. 13.4)
30.3
(4.7, 61.3)
28.0
(2.0, 52.0)
27.2
(1.3, 60.9)
35.3
(0.2, 71.3)
35.6
(7.3, 41.6)
25.6
(3.4, 57.3)
10.2
(0.7, 64.6)
12.2
(0.9, 50.0)

0.69
(0.14, 0.87)
102.3
(100.7, 105.6)
98.1
(94.9, 100.2)
7.2
(1.0, 13.8)
23.2
(3.0, 57.7)
26.1
(2.0, 48.3)
23.6
(1.1, 60.8)
29.3
(0.2, 70.6)
29.9
(5.6, 40.0)
21.2
(2.8, 56.9)
5.9
(0.6, 65.5)
6.8
(0.9, 50.0)

P
0.086
< 0.001*
0.01*
0.086
< 0.001*
0.001*
< 0.001*
0.001*
< 0.001*
< 0.001*
< 0.001*
< 0.001*

Abbreviations: Norm. Tiss., normal tissue (defined as external contour minus the PTV & OAR volumes); Rt, right; Lt, left;
D95, dose to 95% of the volume. †P-values were calculated using the Wilcoxon signed-rank test.
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Figure 2.3: Comparison of dose distributions between: (a) the clinical VMAT plan (left)
and UIMAT plan (right) for patient 1 with PTV64Gy in red and PTV60Gy in light green
color wash; (b) the IMRT plan (left) and the UIMAT plan (right) for patient 29 with
PTV70Gy in red, PTV63Gy in green, and PTV56Gy in cyan color wash.
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2.4 Discussion
The UIMAT technique exhibited many promising features, most notable being its
ability to reduce the dose to organs at risk (see Table 2.1). This is also evident from the
average DVH comparisons and sample dose distribution comparisons in Figure 2.2 and
Figure 2.3, respectively, where improved sparing of the various organs at risk can be
observed. In addition to this, Table 2.1 and Figure 2.2 shows that UIMAT was able to
reduce the dose to organs at risk without increasing the dose to the rest of the normal
tissue (defined here as all tissue outside of the reported PTVs and OARs), suggesting that
the reduction in OAR dose did not result from the redistribution of dose to unspecified
normal tissue, but rather from improved utilization of dose delivery. This reduction in
OAR dose has the potential to lower both the severity and frequency of toxicities
attributed to head-and-neck radiotherapy such as xerostomia, stomatitis, and
sensorineural hearing loss. Alternatively, these improvements in dose delivery could
allow for further dose escalation while maintaining a similar toxicity profile observed
today.
Some small variability was seen in the conformity indices for the target volumes, with
UIMAT conformity generally lying between that of IMRT and VMAT. This is not
entirely surprising given that UIMAT is a mixture of these two techniques. This could
also be a result of optimization technique, for example by imposing a higher priority on
OAR sparing compared to conformity. This result was not universally observed though,
as can be seen from the individual patient results in Supplementary Table 2.2 and
Supplemental Table 2.3. In addition to its dosimetric advantages, UIMAT plans required
fewer MUs and had comparable delivery times to VMAT.
Several areas of improvement for the UIMAT algorithm have been identified during
this retrospective planning study. For instance, the current algorithm does not enforce a
minimum MU or MLC segment area during plan optimization. As a result, UIMAT plans
may be susceptible to dosimetric errors introduced by small-field dosimetry and small
MU delivery [19-21]. This is likely the source of the lower IMRT QA gamma pass rates
observed relative to the clinical plans. To improve UIMAT delivery accuracy, future
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versions of the UIMAT algorithm may implement a filtration step, in which small fields
are removed, or a direct aperture optimization algorithm that enforces a minimum
segment area.
As with any retrospective planning study, this work was susceptible to certain biases
such as providing more resources to a new treatment technique compared with the
standard one. To combat this, treatment planning times were limited to a maximum of 6
hours (for the most complex cases) in order to match clinical time constraints. While it
may appear that reusing the clinical objectives for UIMAT optimization gave our planner
a head start, this was not the case. Most of the plan setup is automated within our
institution, whereas our UIMAT method is still a manual process, and so any amount of
time gained by copying (rather than populating) the objective list was easily lost in the
UIMAT plan setup. The selection of endpoints may also be viewed as a source of bias.
The metrics that have been reported here are, what we believe to be, the most clinically
relevant based on literature as well as local standards. Additional efforts to avoid bias
were made by preventing the planner from “over-optimizing” certain objectives. For
example, an objective’s dose or weight was only modified when the objective’s relative
contribution to the total objective function approached zero. Furthermore, we attempted
to minimize the global dose to all OARs (including those which were not reported here)
as a medical dosimetrist would, without favoring the specific endpoints presented in this
work. This can be observed from the comparison of average dose-volume histograms in
Figure 2.2.
The clinical and UIMAT plans presented here were also not selected based on multicriteria optimization (MCO) or Pareto fronts. Therefore, the presented plans may not
represent the Pareto-optimal solutions and one could question whether the observed
dosimetric advantages result from suboptimal clinical beam configurations rather than
from the superiority of our UIMAT technique. Although Pareto fronts have been
previously implemented within Pinnacle [22], such an investigation is beyond the scope
and capabilities of the current study. Notwithstanding, the clinical and UIMAT plans
likely represent near-Pareto optimal solutions, since OAR dose objectives were pushed
until further dose reduction in OARs would compromise target volume coverage.
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This technique has a similar treatment planning and delivery processes as VMAT,
which would allow cancer clinics to easily transition from VMAT to UIMAT. For
example, a planner need only select the starting and stopping angles for the UIMAT plan,
similar to VMAT planning, as the beam angles for static delivery are chosen
automatically by the algorithm. Similarly, a radiation therapist would not need to perform
any additional steps for UIMAT setup and delivery than what is currently required for
stand-alone VMAT. Of course, UIMAT would require standard commissioning and
testing prior to clinical implementation.

2.5 Conclusion
Compared to stand-alone VMAT or IMRT for head-and-neck cancer, UIMAT plans
exhibited comparable target volume coverage and dose conformity while significantly
reducing the dose to the surrounding organs at risk. Furthermore, UIMAT plans required
only a single arc and fewer MUs on average than either VMAT or IMRT plans. We
expect that this technique will also yield dosimetric benefits for other complex treatment
sites.
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Chapter 3 – A fast inverse direct aperture optimization
algorithm for intensity-modulated radiation therapy
This chapter was adapted from the published article entitled “A fast inverse direct
aperture optimization algorithm for intensity-modulated radiation therapy” by Michael
MacFarlane, Douglas Hoover, Eugene Wong, Pedro Goldman, Jerry J. Battista, and Jeff
Z. Chen, Medical Physics 2019; 46(3): 1127-39. Permission to reproduce this article was
granted by John Wiley and Sons and is provided in Appendix B.3. Supplemental tables
and figures for this chapter are provided in Appendix D.

3.1 Introduction
Direct aperture optimization (DAO) is a frequently used tool in external beam
radiotherapy treatment planning [1-9]. A DAO algorithm optimizes the beam aperture
shapes [i.e. multi-leaf collimator (MLC) positions] and intensities based on the treatment
planning objectives while adhering to any dosimetric or machine-specific delivery
constraints.
Due to the size and complexity of the DAO problem, it may take several hours to
attain an optimal treatment plan using a DAO algorithm, particularly when dealing with a
large high-resolution dataset or when multiple optimization trials are needed to
adequately satisfy the clinical treatment objectives. Treatment plans may therefore be left
at a sub-optimal solution when there is insufficient time for treatment planning.
Furthermore, applications such as online treatment planning and adaptation for changing
patient anatomy may be impractical as an updated treatment plan is needed within
minutes while the patient remains immobilized on the treatment unit.
A major source of computational inefficiency in DAO comes from the repeated
evaluation of the objective function and its gradient vector [7,9-12]. To calculate these
components, the DAO algorithm must first compute the 3D dose distribution based on the
plan parameters of the current iteration. This computation involves several gigabytes
worth of dose data, which often results in a computational bottleneck in the optimization
process. This bottleneck can be mitigated by performing the calculation in parallel over
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multiple central or graphical processing units (CPU/GPUs) [7,9-12]. However, the
computational speed gained by parallelizing these calculations is still insufficient for
emerging applications such as online or real-time plan optimization.
In this work, we propose reformulating the objective function used in DAO so that
the computational workload associated with evaluating the objective function and
computing its gradient vector is greatly reduced. Specifically, we adapted the objective
function used in a previously developed fluence map optimization algorithm called Fast
Inverse Dose Optimization (FIDO) to optimize the aperture shapes and intensities of
IMRT beams [13,14]. The number of operations performed when evaluating the adapted
FIDO objective function and its gradient vector is substantially lower than that of the
conventional objective function, resulting in substantially faster plan optimization.
For clarity, a brief summary of the FIDO algorithm is provided in the following
section. We then describe the proposed fast inverse direct aperture optimization (FIDAO)
algorithm. Finally, we present the results of a treatment planning study comparing a
prototype FIDAO algorithm with a conventional DAO algorithm. For simplicity, both
DAO algorithms use a singular value decomposition (SVD) dose computation algorithm
but note that a more sophisticated and accurate dose calculation algorithm can also be
used.

3.2 Materials and Methods
3.2.1

Introduction to FIDO

In fluence map optimization (FMO), each beam is decomposed into an array of
smaller, finite-sized pencil-beams. Each pencil-beam is assigned a unique index, 𝑖, and
intensity, 𝜏𝑖 . A large but sparse pencil-beam-based dose matrix, 𝒅, is then computed
using any dose calculation algorithm and it is stored in memory. The dose matrix element
𝒅𝑥𝑖 specifies the dose deposited to voxel 𝑥 per unit intensity of pencil-beam 𝑖. During
optimization, the FMO algorithm can compute the 3D dose distribution by multiplying
this pre-calculated pencil-beam dose matrix with a vector containing the pencil-beam
intensities.
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FMO algorithms optimize the beam fluence maps by finding the minimum solution of
an objective function (𝑓) such as the following,
2

2

(1)

𝑓(𝜏⃗) = 𝑝𝑝𝑡𝑣 ∑ (∑ 𝒅𝑥𝑖 𝜏𝑖 − 𝑑𝑝𝑡𝑣 ) + 𝑝𝑜𝑎𝑟 ∑ (∑ 𝒅𝑥𝑖 𝜏𝑖 ) ,
𝑥∈𝑃𝑇𝑉

𝑖

𝑥∈𝑂𝐴𝑅

𝑖

where 𝑝𝑅𝑂𝐼 is the penalty weight assigned to each region of interest’s (ROI) objective
(PTV or OAR), and 𝑑𝑝𝑡𝑣 is the dose prescribed to the planning target volume (PTV). This
objective function approaches a global minimum when the dose to each voxel in the PTV
approaches the prescribed dose, while the dose to all surrounding organs at risk (OAR) is
as close to zero as possible. Notice, however, that a minimum could be obtained by
combining positive and negative pencil-beam intensities. Since negative pencil-beam
intensities represent a non-physical process (the removal of radiation from the patient),
most FMO algorithms include a non-negative pencil-beam intensity constraint, resulting
in the following FMO problem,
2

minimize
𝜏

2

𝑝𝑝𝑡𝑣 ∑ (∑ 𝒅𝑥𝑖 𝜏𝑖 − 𝑑𝑝𝑡𝑣 ) + 𝑝𝑜𝑎𝑟 ∑ (∑ 𝒅𝑥𝑖 𝜏𝑖 ) ,
𝑥∈𝑃𝑇𝑉

subject to

𝑖

𝑥∈𝑂𝐴𝑅

(2)

𝑖

𝜏𝑖 ≥ 0.

The solution to this FMO problem can be found through a variety of iterative
constrained optimization techniques [3,11,12,15]. However, solving this FMO problem
with an iterative method can be very inefficient. This is due to the frequency with which
these constrained optimization algorithms must compute the objective function value
(and its gradient vector if the algorithm is gradient-based) as it must first compute the
product of the very large pencil-beam dose matrix, 𝒅, and the vector containing the
pencil-beam intensities, 𝜏⃗, of the current iteration.
In FIDO, the objective function was reformulated as the following: [13,14]
2

𝑓(𝜏⃗) = 𝑝𝑝𝑡𝑣 ∑ (∑ 𝒅𝑥𝑖 𝜏𝑖 − 𝑑𝑝𝑡𝑣 ) + 𝑝𝑜𝑎𝑟 ∑ ∑ 𝒅2𝑥𝑖 𝜏𝑖2 .
𝑥∈𝑃𝑇𝑉

𝑖

𝑥∈𝑂𝐴𝑅

𝑖

In this formulation, the OAR objective function (which is the primary culprit leading to
negative pencil-beam weights) can no longer approach its minimum through the use of
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(3)

negative pencil-beam intensities. Instead, the OAR objective can only reach its minimum
when all pencil-beams depositing dose to the OAR have null intensity. Additional
regulative objectives can be added to the objective function to further suppress the use of
negative pencil-beam intensities by the PTV objective; however, previous experience has
found that these additional regulation terms are unnecessary [14].
Given that the FIDO objective function (Equation 3) is purely quadratic and that
constraints are not likely needed, its minimum can be found by differentiating with
respect to each pencil-beam’s weight and setting each equation to zero (which is
equivalent to Newton’s Method in Optimization) [15]. The resulting system of equations
can be written as,
𝜶𝜏⃗ = 𝛽⃗ ,

(4)

where
𝑇
𝑇
𝜶𝑗𝑖 = 𝑝𝑝𝑡𝑣 ∑ 𝒅𝑗𝑥
𝒅𝑥𝑖 + 𝑝𝑜𝑎𝑟 𝛿𝑖𝑗 ∑ 𝒅𝑗𝑥
𝒅𝑥𝑖
𝑥∈𝑃𝑇𝑉

𝑥∈𝑂𝐴𝑅

𝑇
𝛽𝑗 = 𝑝𝑝𝑡𝑣 𝑑𝑝𝑡𝑣 ∑ 𝒅𝑗𝑥
.
𝑥∈𝑃𝑇𝑉

This matrix equation can be efficiently solved via matrix inversion to give the globallyoptimal and physically-feasible fluence maps.

Multiple optimizations are often necessary to fine-tune the PTV coverage and/or
OAR sparing. To minimize the amount of work performed in subsequent optimizations,
FIDO stores each ROI’s contribution to 𝛽⃗ and 𝜶. When the OAR and/or PTV weights are
adjusted in subsequent optimizations, the FIDO matrix equation can be quickly computed
by rescaling and summing these stored matrices.

3.2.2

FIDAO Formulation

The relationship between voxel dose and MLC position is non-linear, and by
extension the objective function too will vary non-linearly with MLC-position. The MLC
positions are also subject to numerous mechanical delivery constraints. Therefore, it is
not possible to optimize the MLC positions by solving a single matrix equation as we had
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with the pencil-beam intensities in FIDO [15]. Instead, we are forced to use an iterative
constrained optimization technique as in the conventional FMO methods. Fortunately, as
will be discussed shortly, we can improve the efficiency of computing the objective
function value and its gradient vector by using a FIDO-like objective function. To do this,
we first need a method of converting the beam aperture information into equivalent
fluence maps.
Numerous DAO algorithms convert the plan’s MLC positions, 𝑙⃗, and aperture
intensity, 𝑤
⃗⃗⃗, into equivalent fluence maps, 𝜏⃗(𝑙⃗, 𝑤
⃗⃗⃗), so that the pre-calculated pencil-beam
dose matrix, 𝒅, can continue to be used during optimization, to compute the objective
function value and its gradient vector [3,9]. One method of converting the aperture
parameters into equivalent fluence maps is through the following approximate
relationship:
𝜏𝑗 (𝑙⃗, 𝑤
⃗⃗⃗) ≈ ∑ 𝑻𝑗𝜈 (𝑙⃗) 𝑤𝜈 ,

(5)

𝜈

where 𝑤𝜈 is the intensity of aperture 𝜈, and 𝑻𝑗𝜈 (𝑙⃗) is a non-convex piecewise linear
function describing the fractional transmission through pencil-beam 𝑗 by aperture 𝜈
[9,16]. An illustration of this transmission matrix is shown in Figure 3.1. If pencil-beam 𝑗
is completely blocked by aperture 𝜈, or if the pencil-beam belongs to another beam and
therefore cannot be exposed by this beam’s aperture, then the fractional transmission 𝑻𝑗𝜈
will be 0 (e.g. pencil-beams 1-3 in Figure 3.1). Conversely, if pencil-beam 𝑗 belongs to
the same beam as the aperture and is completely exposed by the aperture, then the
transmission matrix element will have value 1 (e.g. pencil-beam 8 in Figure 3.1). Finally,
if pencil-beam 𝑗 is partially exposed by the aperture, the fractional exposed area of the
pencil-beam is assigned to the transmission matrix (e.g. pencil-beams 7 and 11 in Figure
3.1). By multiplying this transmission matrix with a vector containing the aperture
intensities, we can approximate the fluence map produced when delivering all the beam’s
apertures. This conversion of the aperture information into equivalent fluence will be
sufficiently accurate so long as the size of the pencil beams are not too large. Otherwise,
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the fractional transmission may not adequately model the true fluence produce by
delivering the plan apertures.

Figure 3.1: Illustration of the transmission matrix. The left grid shows the index that
each pencil-beam was assigned (1-16) during FMO. The right grid shows the pencilbeam array superimposed with MLC of the first aperture (shown in blue). The
corresponding values assigned to the first column of the transmission matrix, due to the
first apertures shape, is provided in the right array.
Using the equivalent fluence maps from Equation 5, the standard FMO problem from
Equation 2 can be converted into the following generalized DAO problem:
minimize
𝑙⃗, 𝑤
⃗⃗⃗

2

2

𝑝𝑝𝑡𝑣 ∑ (∑ 𝒅𝑥𝑖 𝜏𝑖 (𝑙⃗, 𝑤
⃗⃗⃗) − 𝑑𝑝𝑡𝑣 ) + 𝑝𝑜𝑎𝑟 ∑ (∑ 𝒅𝑥𝑖 𝜏𝑖 (𝑙⃗, 𝑤
⃗⃗⃗)) , (6)
𝑥∈𝑃𝑇𝑉

subject to

𝑖

𝑥∈𝑂𝐴𝑅

𝑖

𝜏𝑖 (𝑙⃗, 𝑤
⃗⃗⃗) = ∑ 𝑻𝑖𝜈 (𝑙⃗) 𝑤𝜈 ,
𝜈

𝑤𝜈 ≥ 0,
𝑪(𝑙⃗) ≥ 𝑏⃗⃗,
where the aperture intensities, like the pencil-beam intensities, must be positive and the
constraint, 𝑪(𝑙⃗) ≥ 𝑏⃗⃗, describes all boundary, linear, and nonlinear machine-based
delivery constraints on the MLC (e.g. the minimum leaf gap, position limits, leaf
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interdigitation, or minimum open-area). Similarly, the equivalent fluence maps from
Equation 5 can be used with the FIDO objective function in Equation 3 to construct the
following aperture-based FIDO problem:
minimize
𝑙⃗, 𝑤
⃗⃗⃗

2

𝑝𝑝𝑡𝑣 ∑ (∑ 𝒅𝑥𝑖 𝜏𝑖 (𝑙⃗, 𝑤
⃗⃗⃗) − 𝑑𝑝𝑡𝑣 ) + 𝑝𝑜𝑎𝑟 ∑ ∑ 𝒅2𝑥𝑖 𝜏𝑖2 (𝑙⃗, 𝑤
⃗⃗⃗) ,
𝑥∈𝑃𝑇𝑉

subject to

𝑖

(7)

𝑥∈𝑂𝐴𝑅 𝑖

𝜏𝑖 (𝑙⃗, 𝑤
⃗⃗⃗) = ∑ 𝑻𝑖𝜈 (𝑙⃗) 𝑤𝜈 ,
𝜈

𝑤𝜈 ≥ 0,
𝑪(𝑙⃗) ≥ 𝑏⃗⃗.
Like the FMO problem (Equation 2), these DAO problems can be solved using an
iterative (often gradient-based) constrained optimization technique [1-10]. However,
these DAO algorithms will be inefficient from repeatedly computing the product of the
large pencil-beam dose matrix and the effective fluence maps produced by the plan
parameters of the current iteration.
Another way of evaluating the objective function is through its Taylor series
expansion. Specifically, since the objective function is purely quadratic with respect to
the pencil-beam intensity, its value can be computed without approximation using a
second-order Taylor series expansion, such as the following expansion centered at 𝜏⃗ = 0:
𝑓(𝜏⃗) = 𝑓(0) + ∇𝑓(0) ⋅ 𝜏⃗ +

1 𝑇
𝜏⃗ 𝐇[𝑓] 𝜏⃗,
2

where ∇𝑓(0) denotes the gradient vector of the objective function evaluated at 𝜏⃗ = 0 and
𝐇[𝑓] denotes the Hessian matrix of the objective function. It is advantageous to use this
Taylor series expansion as the Hessian matrix will often be several orders of magnitude
smaller than the pencil-beam dose matrix. Therefore, fewer operations will be performed
when evaluating the objective functions with its Taylor series expansion as opposed to its
non-expanded form. Furthermore, since the Hessian matrix is also symmetric, we can
reduce the amount of computer memory taken up during optimization, and possibly avoid
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any von Neumann bottlenecks (where the computation is limited by the data transfer
rates) during optimization [12].
While the Taylor series expansion may reduce the number of operations performed
when evaluating the objective function, it does require us to compute the objective
function’s Hessian matrix prior to optimization which could be computationally intensive
in itself. This is where using the FIDO objective function becomes advantageous. First,
note that the Hessian matrix of the FIDO objective function is proportional to the 𝜶
matrix in Equation 4, [15] while the Hessian matrix of the standard objective function is,
𝑇
𝑇
𝐇[𝑓] = 𝑝𝑝𝑡𝑣 ∑ 𝒅𝑗𝑥
𝒅𝑥𝑖 + 𝑝𝑜𝑎𝑟 ∑ 𝒅𝑗𝑥
𝒅𝑥𝑖 .
𝑥∈𝑃𝑇𝑉

𝑥∈𝑂𝐴𝑅

Notice that, while similar, the equations for 𝜶 and the standard objective function’s
Hessian matrix differ by a Krönecker-delta function in the OAR term. This means that
the OAR objectives will contribute to every element in the Hessian matrix of the standard
objective function, whereas the OAR objectives will only contribute to the diagonal
elements of the 𝜶 matrix in FIDO. As a result, we can compute the Hessian matrix of the
FIDO objective function far more efficiently than that of the standard objective function,
especially when large OARs such as the normal unspecified tissue have planning
objectives. Additional modifications can be made to the FIDO objective function so that
dose-volume objectives can be included in the optimization. These modifications take
into consideration the total number of operations performed when updating 𝜶 and 𝛽⃗
matrices during optimization and will be discussed in further detail in the following
section.
The Taylor series expansion of the FIDO objective function can be written as,
𝑓(𝜏⃗) = 𝑓(0) + 𝜏⃗ ⋅ ( 𝛂 𝜏⃗ − 2𝛽⃗ ),
where 𝑓(0) is a constant. Since this constant term will have no effect on the optimal
solution, it can be omitted from computations during the optimization. Therefore, like
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(8)

Equation 7, a fast inverse direct aperture optimization (FIDAO) problem can be
formulated as the following generalized problem:
minimize
𝑙⃗, 𝑤
⃗⃗⃗

𝜏⃗(𝑙⃗, 𝑤
⃗⃗⃗) ⋅ ( 𝛂 𝜏⃗(𝑙⃗, 𝑤
⃗⃗⃗) − 2𝛽⃗ ),

(9)

𝜏𝑖 (𝑙⃗, 𝑤
⃗⃗⃗) = ∑ 𝑻𝑖𝜈 (𝑙⃗) 𝑤𝜈 ,

subject to

𝜈

𝑤𝜈 ≥ 0,
𝑪(𝑙⃗) ≥ 𝑏⃗⃗.
If we are using a gradient-based optimization technique, the derivatives of the
objective function with respect to each aperture 𝜇’s intensity, 𝑤𝜇 , and with respect to the
(𝜇)

leaf position of each leaf k in each aperture 𝜇, 𝑙𝑘 , can be computed using the following:
∂𝑓
𝑇 ⃗
= 2 ∑ 𝑻𝜇𝑗
(𝑙 ) ( 𝛂 𝜏⃗(𝑙⃗, 𝑤
⃗⃗⃗) − 𝛽⃗ )𝑗 ,
𝜕𝑤𝜇

(10𝑎)

𝑗

∂𝑓
(𝜇)

𝜕𝑙𝑘

= 2 ∑ 𝑤𝜇
𝑗

𝑇 ⃗
𝜕𝑻𝜇𝑗
(𝑙 )
(𝜇)

𝜕𝑙𝑘

( 𝛂 𝜏⃗(𝑙⃗, 𝑤
⃗⃗⃗) − 𝛽⃗ )𝑗 .

(10𝑏)

For convenience, the pencil-beam array is aligned with the MLC leaf banks as shown in
Figure 3.1. Therefore, any leaf motion will either expose or block the pencil-beam(s) that
currently coincide with the MLC leaf position (for instance, pencil-beam 7 or 11 in
Figure 3.1) and we can use the following piecewise approximation when evaluating
Equation 10b for each leaf in each aperture, [9,16]
𝑇 ⃗
𝜕𝑻𝜇𝑗
(𝑙 )
(𝜇)

𝜕𝑙𝑘

1
,
= { ℎ𝑝𝑏
0,
±

(𝜇)

𝑙𝑒𝑎𝑓 𝑘 𝑜𝑓 𝑎𝑝𝑒𝑡𝑢𝑟𝑒 𝜇 (𝑙𝑘 ) 𝑐𝑜𝑖𝑛𝑐𝑖𝑑𝑒𝑠 𝑤𝑖𝑡ℎ 𝑝𝑒𝑛𝑐𝑖𝑙 𝑏𝑒𝑎𝑚 𝑗

(11)

𝑜𝑡ℎ𝑒𝑟𝑤𝑖𝑠𝑒

with ℎ𝑝𝑏 being the width of the pencil-beams. The sign (±) of this piecewise function will
depend on whether the differentiated leaf 𝑘 is a member of the left or right leaf bank, and
whether a change in its position in the positive direction of motion will lead to the
coinciding pencil-beam becoming more exposed or blocked. If a leaf resides exactly
between two pencil beams (e.g. the leaf between pencil beam 2 and 6 in Figure 3.1), the
leaf will be considered to coincide with the pencil beam on the right unless the leaf is on
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the right boundary of the calculated pencil beam array (e.g. the leaf on the edge of pencil
beam 16 in Figure 3.1) in which case it will be considered to coincide with the pencil
beam on the left [16].

3.2.3

Dose-volume objectives

Often a treatment plan must satisfy a variety of clinical dose-volume objectives such
as a minimum PTV dose or a maximum dose to some volume of an OAR. Dose-volume
objectives are typically included as a separate term in the objective function, such as the
following for a minimum PTV dose objective:
2
(𝑝𝑡𝑣)
𝑓𝑚𝑖𝑛−𝑑𝑣ℎ (𝜏⃗)

= 𝑝𝑝𝑡𝑣 ∑ Θ (𝑑𝑚𝑖𝑛 − ∑ 𝑑𝑥𝑖 𝜏𝑖 ) (𝑑𝑚𝑖𝑛 − ∑ 𝑑𝑥𝑖 𝜏𝑖 ) ,
𝑥∈𝑃𝑇𝑉

𝑖

𝑖

where Θ is the Heaviside function and 𝑑𝑚𝑖𝑛 is the minimum threshold dose [16]. Note
that a similar equation is used for maximum dose objectives in the PTV and OARs.

Like the standard objective function (Equation 1), these dose-volume objective
functions will contribute to every element in the Hessian matrix and gradient vector.
Moreover, their contribution to the Hessian matrix and gradient vector will have to be
updated throughout the optimization, as the dose distribution changes and non-compliant
voxels begin to comply with the dose-volume objectives and vice versa. This repeated
computation of the Hessian matrix and gradient vector could be very time-consuming and
so we propose the following approach.
Similar to the original FIDO publication, we use a voxel-based OAR penalty weight,
𝑝𝑜𝑎𝑟 (𝑥), and prescribed dose, 𝑑𝑝𝑡𝑣 (𝑥), in the FIDO objective function (Equation 3) to
include dose-volume objectives [14]. The amount that these terms are varied by is based
on: (1) whether the voxel is contributing to the violation of a dose-volume objective, (2)
the amount of dose or volume that the voxel or ROI is violating a dose-volume objective
by, and (3) the penalty weight assigned to the dose-volume objective. Details on how the
prescribed dose and OAR penalty weight are spatially varied can be found in Section
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3.6Appendix, along with examples demonstrating its effectiveness. By doing this, the
equations for 𝜶 and 𝛽⃗ become,
𝑇
𝑇
𝜶𝑗𝑖 = 𝑝𝑝𝑡𝑣 ∑ 𝒅𝑗𝑥
𝒅𝑥𝑖 + 𝛿𝑖𝑗 ∑ 𝑝𝑜𝑎𝑟 (𝑥) 𝒅𝑗𝑥
𝒅𝑥𝑖
𝑥∈𝑃𝑇𝑉

𝑥∈𝑂𝐴𝑅

𝑇
𝛽𝑗 = 𝑝𝑝𝑡𝑣 ∑ 𝑑𝑝𝑡𝑣 (𝑥) 𝒅𝑗𝑥
.
𝑥∈𝑃𝑇𝑉

By spatially varying these specific terms, we can include dose-volume objectives in
the optimization while also minimizing the number of elements in 𝜶 and 𝛽⃗ that need to
be updated during optimization. Specifically, we only need to update the diagonal
elements of the 𝜶 matrix when OAR dose-volume objectives are included, and the
elements of 𝛽⃗ only when PTV dose-volume objectives are included. A similar approach
was used in the original FIDO algorithm to enforce minimum and maximum point dose
objectives [14]. Specifically, after solving the FIDO matrix equation (Equation 4), the
FIDO algorithm would re-compute and solve the matrix equation a second time with a
spatially varying prescribed dose and penalty weights based on the previous solution to
the FIDO matrix equation [14]. With sufficient weighting of the dose-volume objectives,
the second solution to the FIDO matrix equation will improve the maximum or minimum
point dose objectives.

3.2.4

Implementation & testing of the prototype algorithm

A proof-of-concept FIDAO algorithm was developed in MATLAB v9.4 (Mathworks
Inc, Natick, MA) using an open-source treatment planning toolkit called matRad v2.2.
[16]. This toolkit includes a graphical user interface for creating and evaluating the
treatment plan, a singular value decomposition (SVD) dose computation algorithm for
calculating the pencil-beam dose matrix, MLC leaf-sequencing algorithms for generating
apertures from fluence maps, and sample datasets. It also includes a built-in experimental
DAO algorithm, which we used as an independent benchmark for our FIDAO algorithm
[16].
The prototype FIDAO algorithm used the open-source interior-point optimization
(IPOPT) package to solve the FIDAO problem in Equation 9 [15]. This IPOPT package
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was made available through the computational infrastructure for operations research
(COIN-OR) initiative [17]. This algorithm was selected so that a fair comparison could
be made between our FIDAO algorithm and matRad’s DAO algorithm, as it too uses the
same IPOPT package to solve the standard DAO problem in Equation 6. Our goal for this
planning study was to compare the time it took each algorithm to converge to similar
plans, using the same optimization algorithm but different equations for the objective
function and its gradient vector. Therefore, the same planning objectives, starting
apertures, convergence criteria, delivery constraints, and optimization settings were used
by both algorithms.
IMRT treatment plans were created on the Common Optimization for Radiation
Therapy (CORT) datasets that were included with the matRad toolkit [16,18]. This library
includes the AAPM TG-119 box phantom (shown in Figure 3.2 below) as well as sample
prostate, liver, and head-and-neck clinical cases. The voxel size for dose calculations and
plan evaluation were: 3x3x2.5 mm3 in the TG-119 case, 3x3x3 mm3 in the prostate case,
3x3x2.5 mm3 in the liver case, and 3x3x5 mm3 in the head-and-neck case. Pencil beams
were set to 5x5 mm2 in size. The couch and gantry angles were set to the suggested
values in the CORT study for IMRT treatment [18].
For the planning study, the plans first underwent FMO optimization using matRad’s
built in FMO algorithm and the planning objectives listed in Table 3.1 [16]. The plan
then underwent aperture sequencing using matRad’s leaf-sequencing algorithm [19]. The
matRad leaf-sequencing algorithm was modified slightly so that the total number of
apertures in a plan could be restricted. Specifically, if the sequencer produced more
apertures than a user-defined limit, the apertures with the smallest open area were
discarded. The maximum number of apertures in the plan was set to 10 times the number
of beams.
After aperture sequencing, one copy of the post sequencing plan underwent DAO
with the standard DAO algorithm implemented in matRad, and another copy underwent
DAO with the FIDAO algorithm. Both algorithms used the same planning objectives
listed in Table 3.1. Identical objective penalty weights were also used in both plans,
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except for the TG-119 phantom case, where marginally higher OAR penalty weights
were necessary in the FIDAO plan to achieve similar OAR sparing as the standard DAO
plan.
Table 3.1: Optimization objectives used by both algorithms.
No.
1.

Site
TG-119

2.

Liver

3.

Prostate

4.

HN

Beams
(Apertures)
5 (50)
•
•
•
7 (70)
•
•
•
5 (50)
•
•
•
10 (100)

•
•

Optimization Objectives
Uniform 50 Gy dose to the C-shaped Target.
Minimal dose to the core OAR and body.
Maximum point dose of 50 Gy in the body, and 25 Gy in the core OAR.
Uniform 45 Gy dose to the PTV.
Minimal dose to the healthy liver, heart & normal tissue.
Maximum point dose of 40 Gy in the normal tissue.
Uniform 68 Gy and 56 Gy dose to the PTV and Nodes.
Minimal dose to the rectum, bladder & normal tissue.
Maximum point dose of 50 Gy in the normal tissue, rectum, and
bladder.
Uniform dose to each PTV (70 Gy, 63 Gy, and 56 Gy).
Minimal dose to the cord, brainstem, parotid glands & normal tissue.

Prior to DAO, FIDAO computed and stored each ROI’s contribution to 𝜶 and 𝛽⃗ .
Furthermore, FIDAO also performed aperture weight optimization prior to DAO by
solving the matrix equation,
𝑤
⃗⃗⃗ = (𝑻𝑇 𝜶 𝑻)−1 (𝑻𝑇 𝛽⃗ ).
This FIDO-like aperture weight optimization equation is acquired by setting Equation
10a to zero. Its solution gives the optimal aperture weights based on the aperture
information approximated by 𝑻. This aperture weight optimization was performed prior
to DAO in an effort to reduce the number of iteration performed in FIDAO, as the
equation and its solution can be computed efficiently and the solution will place the plan
significantly closer to a minimum of the objective function.
During DAO, both algorithms enforced a non-negative aperture weight constraint and
position limits on the MLC leaves. These constraints are linear and are enforced during
each iteration of the optimization [17]. Both methods used the default IPOPT termination
criteria that came with the matRad software (v2.2.0) [16,17]. The maximum number of
iterations was set to 500 and the threshold for termination was set to 1x10-8.
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If dose-volume objectives were included in the optimization, FIDAO would update 𝜶
and 𝛽⃗ twice during the optimization; once at the beginning of the optimization and a
second-time after half of the maximum number of iterations were completed. If the
optimization exited before the half-way point, the update would be performed then, and
the optimization would automatically be executed a second time.
These optimizations were performed on the same desktop computer running
Windows 10 with an Intel i7-4790 (3.6 GHz) CPU and 16 GB of RAM. To the best of
our knowledge, no CPU or GPU parallelization was utilized in matRad’s DAO
algorithm’s code [16]. Similarly, no parallel processing was used in FIDAO’s code. The
FIDAO and matRad optimized plans were then compared based on their dose-volume
histograms, 3D dose distributions, and optimization time.

3.3 Results
Details about the test cases and the algorithms’ performance are listed in Table 3.2.
Note that the size of the square Hessian matrix (𝜶) is proportional to the number of pencil
beams (column 3) in the plan, while the size of the pencil-beam dose matrix is the
number of pencil beams x the number of voxels (column 4). Also, note that the listed
computation times for FIDAO’s 𝜶 and 𝛽⃗ (column 7) refers only to their initial
computation time prior to DAO. The time spent updating 𝜶 and 𝛽⃗ when dose-volume
objectives were present is included in the total FIDAO optimization time (column 8).
Table 3.2: Information related to the size of the optimization problem, and each algorithm’s
performance.
Pencil
Voxels
No.
Site
Beams [x 106]
1.
TG-119
1,857
3.60
2.
Liver
1,971
7.91
3. Prostate
3,034
3.05
4.
HN
13,749
1.72
Abbreviations: Iter, Iterations.

Non-zero
dxi [x 106]
91.8
159.0
159.6
235.5

Voxels in
PTV [x103]
7.5
7.0
16.3
30.6
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⃗⃗
𝛂, β
Initialization
2.1 s
4.5 s
6.2 s
60.6 s

Optimization Time (Iter.)
FIDAO
Standard
0.3s (17)
56.7 s (50)
2.0s (28) 134.1 s (57)
2.5s (26) 180.6 s (107)
6.7s (20) 469.4 s (245)

Dose-volume histograms (DVH) and sample dose distributions for each site are
shown in Figure 3.2 through Figure 3.5. To demonstrate the effectiveness of these DAO
algorithms, Figures 3.2-3.5 also include sample dose distributions and DVHs of the plan
before DAO (post FMO and aperture sequencing). In the prostate, liver and head-andneck cases, there were too many critical structures to display all the DVHs in one plot.
Therefore, additional DVHs are available for these cases in Supplemental Figure 3.1
through Supplemental Figure 3.3. PTV and OAR dose metrics are also supplied in
Supplemental Table 3.1 and Supplemental Table 3.2, respectively. As demonstrated by
the comparisons of the dose-volume histograms and the sample dose distributions,
FIDAO and standard DAO algorithm converged to nearly identical plans. However,
FIDAO obtained the optimal solution substantially faster than the standard DAO
algorithm in matRad (approximately 70-200 times faster; or up to 23 times faster when
including the pre-calculation times for the 𝜶 and 𝛽⃗ matrices), and in fewer iterations.
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Figure 3.2: Dose-volume histograms (upper) and sample dose-distributions (lower) of
the AAPM TG-119 phantom plan after undergoing FMO and aperture sequencing (dotted
line) and when optimized with the FIDAO (solid line) and the standard (dashed line)
DAO algorithms. The cross-section of the axial, sagittal, and coronal planes are shown as
dashed lines on the dose distributions.
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Figure 3.3: Dose-volume histograms (upper) and sample dose-distributions (lower) of
the prostate case after undergoing FMO and aperture sequencing (dotted line) and when
optimized with the FIDAO (solid line) and the standard (dashed line) DAO algorithms.
The cross-section of the axial, sagittal, and coronal planes are shown as dashed lines on
the dose distributions.
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Figure 3.4: Dose-volume histograms (upper) and sample dose-distributions (lower) of
the liver case after undergoing FMO and aperture sequencing (dotted line) and when
optimized with the FIDAO (solid line) and the standard (dashed line) DAO algorithms.
The cross-section of the axial, sagittal, and coronal planes are shown as dashed lines on
the dose distributions.
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Figure 3.5: Dose-volume histograms (upper) and sample dose-distributions (lower) of
the head-and-neck case after undergoing FMO and aperture sequencing (dotted line) and
when optimized with the FIDAO (solid line) and the standard (dashed line) DAO
algorithms. The cross-section of the axial, sagittal, and coronal planes are shown as
dashed lines on the dose distributions.
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3.4 Discussion
The algorithms used for DAO and FMO are computationally demanding. This is
primarily due to the repeated use of the pencil-beam dose matrix, 𝒅, to evaluate the
objective function and compute its gradient vector during optimization. As shown in
Table 3.2, this matrix has millions of elements and takes several gigabytes of memory to
store. The size of this matrix not only impacts the amount of memory required to perform
FMO or DAO, but also the time it takes to execute a computation involving it, as the
computation speed will be limited by the rate at which the computer can transfer the dose
matrix elements from memory to the processor’s arithmetic unit as well as the
processor’s clock speed [10,12]. In response to this limit, many academic and
commercial groups have developed FMO and DAO algorithms that utilize the multiple
processors available on modern CPUs and GPUs [7,9-12]. With these multicore units, the
computation can be performed in parallel, allowing for the individual computations and
the overall optimization to be completed faster. Others have also developed using a novel
non-voxel-based broad-beam (NVBB) framework when deriving the DAO problem,
which eliminates the pencil-beam dose matrix from the DAO problem entirely [20,21].
In this work, we extended a previously developed FMO algorithm called FIDO to
perform DAO. This algorithm uses the objective function’s Hessian matrix and a
reference gradient vector (or 𝜶 and 𝛽⃗ as they were denoted in the original FIDO papers),
via second-order Taylor series expansion, to compute the objective function value and its
gradient vector during optimization [13-15]. Using the 𝜶 and 𝛽⃗ matrices is advantageous
as they often have considerably fewer elements than the pencil-beam dose matrix, and
therefore any computations involving them will have smaller data transfer overheads and
require fewer operations. This can be illustrated with some of the values found in Table
3.2. If the pencil-beam dose matrix is stored in a compressed sparse row or column
format, the number of operations performed during matrix-vector multiplication with the
pencil-beam dose matrix (e.g. 𝒅𝜏⃗ in the standard objective function) is proportional to the
number of non-zero elements in the matrix [22]. On the other hand, the same operation
with 𝜶 (e.g. 𝜶𝜏⃗ in the FIDAO objective function) is proportional to the squared number
of pencil-beams in the plan. From Table 3.2, we can see that the squared number of
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pencil-beams in each plan is substantially smaller than the number of non-zero element in
the pencil-beam dose matrix. As a result, FIDAO could evaluate the objective function
value or compute its gradient vector substantially faster, resulting in an overall faster
optimization.
While a similar algorithm could have been formulated from the standard objective
function’s (Equation 1) Hessian matrix and gradient vector, this formulation would likely
have been less efficient than FIDAO due to the computation times for the Hessian matrix.
Notice from Table 3.2 that a relatively large amount of time is spent pre-calculating 𝜶
and 𝛽⃗ . This time is mostly spent on computing the PTV component of 𝜶, as the PTV
objectives contributes to every element in 𝜶 whereas the OAR objectives only contribute
to the diagonal elements of 𝜶. The fact that the OARs only contribute to the diagonal
elements of 𝜶 is a result of the reformulation of the OAR objective function in FIDO. If
we were to use the standard objective function, the OARs would then contribute to every
element in 𝜶, which would substantially increase the computation time for the Hessian
matrix especially when very large OARs have planning objectives such as the normal
unspecified tissue. Furthermore, if we were to use the standard equations for dose-volume
objectives, we would have to update every element in 𝜶 and 𝛽⃗ as opposed to just 𝛽⃗ and
the diagonal elements of 𝜶 when using the spatially varying penalty weight and
prescribed dose in FIDO. Collectively, this makes computing and updating the Hessian
matrix and gradient vector of the FIDO objective function substantially easier than with
the standard objective function.
If given the same penalty weight, 𝑝𝑜𝑎𝑟 , and effective fluence map, 𝜏, the standard
equation for the OAR objective will contribute more to the objective function value than
the reformulated FIDO equation. That is,
2
2 2
𝑝𝑜𝑎𝑟 ∑ (∑ 𝑑𝑥𝑖 𝜏𝑖 ) ≥ 𝑝𝑜𝑎𝑟 ∑ ∑ 𝑑𝑥𝑖
𝜏𝑖 .
𝑥

𝑖

𝑥

𝑖

This inequality means that FIDAO may need a higher OAR penalty weight than the
standard objective function in order to achieve similar OAR sparing, as was observed in
the TG-119 phantom case from this study. Moreover, this reformulation could cause
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FIDAO to be less sensitive to OAR maximum doses as FIDAO penalizes the individual
dose contributed by each pencil beam instead of the net dose contributed by all pencil
beams. This can be counteracted by spatially increasing the OAR penalty weight in
voxels with a net dose above some tolerance dose, as demonstrated in Figure 3.6 in the
Appendix.
The optimization times obtained with FIDAO are similar to the reported optimization
times of GPU-based DAO algorithms. For instance, Men et al. showed that their GPUbased DAO algorithm could optimize an IMRT treatment plan in 0.7s to 3.8s, whereas
our FIDAO algorithm could optimize a plan in 0.3s to 6.7s without any parallelization
[7]. Note that the fast optimization times reported in their study can be partially attributed
to the down-sampling of unspecified tissue (i.e. voxels that were outside the PTV or
contoured OARs), which resulted in much smaller pencil-beam dose matrices than in our
present study. For instance, the number of non-zero elements in 𝒅 in their study was at
least 25 times smaller than in this study. Therefore, their GPU-based DAO algorithm
would take considerably longer if executed on the same cases reported here. That said,
our FIDAO algorithm does require an additional 2 to 60 s to pre-compute 𝜶 and 𝛽⃗
whereas the GPU-based method does not. This computation, however, can be parallelized
in addition to the evaluation of FIDAO’s objective function and the computation of its
gradient vector.
Note that the much better OAR sparing in the post sequencing prostate plan (Figure
3.3) and head-and-neck plan (Figure 3.5) was only achievable due to the severe and
clinically unacceptable under-dosing of the PTVs (more than 25% under-dosing for D95
of PTVs). The plans obtained with FIDAO and the standard DAO algorithm are more
clinically relevant as they provide the best possible OAR sparing achievable while also
obtaining a clinically acceptable level of PTV coverage.
It is well known that gradient-based DAO methods may become trapped at a local
minimum due to the non-convex nature of the objective function. However, this problem
can be minimized by starting the DAO at a good starting point as done in many
commercial treatment planning systems. For instance, we can first perform fluence map
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optimization with FIDO which finds the global minimum of the objective function. After
MLC leaf sequencing, we can then fine-tune these apertures using FIDAO. We can also
employ stochastic optimization methods like simulated annealing and genetic algorithms
in lieu of a gradient-based approach, as these algorithms can escape from local minima.
For this proof-of-concept study, we chose to use a gradient-based optimization method
due to its accessibility and the wide-spread use of gradient-based DAO methods in
commercial treatment planning systems. However, similar performance improvements
should be expected when using FIDAO with any stochastic, greedy, or other first-order
optimization methods due to the much more efficient evaluation of the expanded FIDO
objective function compared to the standard objective function.
FIDAOs optimization time is minimally impacted by the size or resolution of the dose
grid. Specifically, only the initial computation and updating of the 𝜶 and 𝛽⃗ matrices will
be affected by the resolution or size of the dose grid, whereas the computation of the
objective function value and its gradient vector during optimization is only affected by
the number of pencil-beams in the plan. This makes FIDAO very desirable for optimizing
stereotactic body radiation therapy (SBRT) and stereotactic radiosurgery (SRS) treatment
plans, where an isotropic high-resolution dose grid size of 2 mm or less is recommended
[23]. Conversely, it is unclear whether FIDAO may be suitable for optimizing volumetric
modulated arc therapy (VMAT) plans, as VMAT plans typically have tens of thousands
of pencil-beams which could drastically decrease the efficiency of evaluating the FIDAO
objective function. Moreover, interior point methods are known to be inefficient for
large-scale optimization problems such as those in VMAT planning, so a different
optimization method may also be necessary. This will need to be assessed in a future
study that incorporates VMAT-related delivery constraints such as the maximum MLC
distance due to maximum MLC-travel speeds and gantry-rotation speeds.

3.5 Conclusions
In this work, a fast inverse direct aperture optimization (FIDAO) algorithm was
developed based on the fast inverse dose optimization (FIDO) method. A prototype of
this algorithm was developed in MATLAB and compared against an independent DAO
60

algorithm on four test cases. In all four cases, the prototype algorithm produced
comparable step-and-shoot IMRT plans with gains of 70-200 times in optimization speed.
The study demonstrates promising speed enhancements for direct aperture optimization
using FIDAO without necessitating parallel computing strategies.

3.6 Appendix
Let 𝑑(𝑥) be the dose deposited to voxel 𝑥, and let 𝑝𝑑𝑣ℎ and 𝑑𝑡𝑜𝑙 be the objective
penalty weight and tolerance dose assigned to a dose-volume objective. Also, let
Δ𝑑(𝑥) = 𝑑(𝑥) − 𝑑𝑡𝑜𝑙 and 𝑚(𝑥) denote the percent that the voxel dose is above or below
the tolerance dose,
𝑚(𝑥) = |

Δ𝑑(𝑥)
|.
𝑑𝑡𝑜𝑙

If a maximum or minimum point dose objective is applied to the PTV, FIDAO uses a
spatially varying prescription dose to increase or decrease the dose in non-compliant
voxels. By varying the prescription dose instead of the penalty weight, FIDAO can avoid
having to recompute the full Hessian matrix. Specifically, the prescription dose of voxels
above or below the threshold point dose will vary according to:
(1 ± (
𝑑𝑝𝑡𝑣 (𝑥) =

𝑝𝑑𝑣ℎ
) 𝑚(𝑥)) 𝑑𝑝𝑡𝑣 , 𝑖𝑓 𝑚(𝑥) < 0.03
𝑝𝑝𝑡𝑣

𝑝𝑑𝑣ℎ
(1 ± (
) 0.03) 𝑑𝑝𝑡𝑣 , 𝑖𝑓 𝑚(𝑥) > 0.03
𝑝𝑝𝑡𝑣
{

,

while all other voxels will maintain the user prescribed 𝑑𝑝𝑡𝑣 dose [14]. Note that the ±
sign will be positive if it’s a minimum dose objective, and negative if it’s a maximum
dose objective. This equation is equivalent to increasing or decreasing the prescription
dose by up to 3%, when the penalty weight of the dose-volume objective is the same as
𝑝𝑝𝑡𝑣 . If the dose-volume objective is weighted more than the homogeneity objective
(𝑝𝑑𝑣ℎ > 𝑝𝑝𝑡𝑣 ), the prescription dose will be varied by more than 3% and vice versa.
If a maximum point dose objective is applied to an OAR, the OAR objective penalty
weight 𝑝𝑜𝑎𝑟 (𝑥) for voxels above the tolerance dose is varied by,
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𝑝𝑑𝑣ℎ Δ𝑑(𝑥)
(1 + (
)
) 𝑝𝑜𝑎𝑟 , 𝑖𝑓 Δ𝑑(𝑥) < 𝑑𝑡ℎ𝑟𝑒𝑠ℎ
𝑝𝑜𝑎𝑟
𝑑1
𝑝𝑜𝑎𝑟 (𝑥) =
,
𝑝𝑑𝑣ℎ 𝑑𝑡ℎ𝑟𝑒𝑠ℎ
(1 + (
)
) 𝑝𝑜𝑎𝑟 , 𝑖𝑓 Δ𝑑(𝑥) > 𝑑𝑡ℎ𝑟𝑒𝑠ℎ
𝑝𝑜𝑎𝑟
𝑑1
{
where 𝑑𝑡ℎ𝑟𝑒𝑠ℎ is a threshold dose chosen to be 9 Gy, and 𝑑1 = 1 Gy so that the
penalty weight remains dimension-less. This equation is equivalent to increasing the
penalty weight by up to a factor of 10 when the penalty weight of the dose-volume
objective is the same as 𝑝𝑜𝑎𝑟 . If the dose-volume objective is weighted more than the
OAR objective (𝑝𝑑𝑣ℎ > 𝑝𝑜𝑎𝑟 ), the penalty weight will be increased by more than a factor
of 10 [14].
If the minimum (or maximum) dose-volume objective for the PTV is volume based,
the prescribed dose is increased (or decreased) more for voxels that are closer to the
threshold dose. Similarly, if the dose-volume objective for an OAR is volume based, the
penalty weight is increased more for voxels that are closer to the threshold dose.
Figure 3.6 shows the DVHs of the prostate case from this study after FIDAO
optimization with (solid line) and without (dashed line) a minimum PTV dose objective
(upper), a maximum dose objective to 50% of the rectum and bladder (middle), and a
maximum rectum point dose objective (lower).
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Figure 3.6: Dose-volume histograms of the prostate case after DAO with FIDAO with
(solid) and without (dashed) a minimum 64.6 Gy PTV dose objective (upper), a
maximum 35 Gy dose objective to 50% of the rectum and bladder (middle), and a
maximum 60 Gy point dose objective to the rectum (lower) as indicated by the circles
and arrow markers.
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Chapter 4 – A fast inverse direct aperture optimization
algorithm for volumetric modulated arc therapy
This chapter describes initial work on a FIDAO algorithm for VMAT planning. It will
be converted to a manuscript for a technical note entitled “A fast inverse direct aperture
optimization algorithm for volume-modulated arc therapy” by Michael MacFarlane,
Douglas Hoover, Eugene Wong, Jerry J. Battista, and Jeff Z. Chen.

4.1 Introduction
In a recent article, our group developed a new direct aperture optimization (DAO)
algorithm called fast inverse direct aperture optimization (FIDAO) [1]. FIDAO extends a
previously implemented fluence map optimization algorithm called fast inverse dose
optimization (FIDO) for DAO [1-3]. Specifically, instead of using the conventional
objective function, FIDAO used a modified quadratic objective function (similar to
FIDO) to efficiently compute the objective function value and gradient vector during
DAO.
The advantage of FIDAO is that the number of operations (𝑚) performed when
evaluating the modified quadratic objective function is proportional to the squared
number of pencil beams in the plan, whereas the number of operations (𝑛) performed
when evaluating the conventional objective function is proportional to the number of
non-zero elements in a pre-calculated dose matrix. For fixed-gantry intensity-modulated
radiotherapy (IMRT), 𝑚 ≪ 𝑛, as a result FIDAO executes up 200-times faster when
compared to standard DAO methods as described in Chapter 3 [1]. No significant
differences in plan quality was observed between the plans optimized with FIDAO and
the standard method.
For volume-modulated arc therapy (VMAT) plans, the number of pencil beams in a
plan can be significantly larger than in IMRT plans. As a result, it is possible for 𝑚 ~ 𝑛
or 𝑚 > 𝑛, especially if the pre-calculated dose matrix is down-sampled in unspecified
normal tissue, as is done by some DAO algorithms for optimization [4,5]. Furthermore,
VMAT uses a different planning procedure than IMRT and requires additional
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constraints, which could possibly impact the performance of FIDAO. Therefore, the goal
of this work was to extend FIDAO for VMAT planning, and to evaluate whether FIDAO
can also offer a performance advantage for VMAT treatment planning, as it did for fixedfield IMRT.

4.2 Methods and Materials
A prototype FIDAO algorithm for VMAT treatment planning was developed in
MATLAB v9.4 (Mathworks Inc, Natick, MA) using the open-source treatment planning
toolkit matRad (v2.2 – dev_VMAT build) [6,7]. This version of the matRad toolkit
includes an implementation of the SmartArc VMAT planning algorithm [7,8].
Specifically, to generate a VMAT plan, this algorithm first performs fluence map
optimization (FMO) and aperture sequencing on a set of coarsely equispaced beams [9].
The sequenced apertures are then redistributed along the arc trajectory at a finer angular
spacing (typically 4°). Afterwards, the arc undergoes DAO where VMAT-related
delivery constraints are enforced.
VMAT treatment plans were created on the AAPM TG-119 phantom dataset as well
as the sample prostate and liver cancer cases that are supplied with the matRad toolkit
[6,10]. The voxel size of these datasets was 3x3x2.5 mm3 in the TG-119 case, 3x3x3
mm3 in the prostate case, and 3x3x2.5 mm3 in the liver case. The dose calculation matrix,
𝒅𝑥𝑖 , was pre-calculated using matRad’s singular value decomposition (SVD) dose
computation algorithm [11]. The size of the pencil beams was set to 5x5 mm2. To
improve the standard DAO and FMO algorithms speed, the dose calculation matrix was
down-sampled by a factor of 2 in the unspecified normal tissue. Note, however, that the
full (non-down-sampled) dose calculation matrix was used, after optimization, for the
final dose calculations and plan evaluation. In all three cases, the plans underwent FMO
at an angular spacing of 28°, followed by aperture sequencing and arc sequencing with a
4° angular spacing. The planning objectives that were used in each plan are listed in
Table 4.1. After arc sequencing, the plans underwent DAO using either the standard
VMAT DAO algorithm that was included with the matRad toolkit, or the FIDAO
algorithm.
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The standard DAO algorithm used an interior-point optimization method to solve:
minimize
𝑙⃗, 𝑤
⃗⃗⃗

𝑓1 (𝑙⃗, 𝑤
⃗⃗⃗)

subject to

𝑪(𝑙⃗, 𝑤
⃗⃗⃗) ≥ 𝑏⃗⃗

[6,12]. In this problem, 𝑙⃗ and 𝑤
⃗⃗⃗ stand for the aperture leaf positions and weights
respectively, 𝑓1 (𝑙⃗, 𝑤
⃗⃗⃗) is the conventional objective function [6], and 𝑪(𝑙⃗, 𝑤
⃗⃗⃗) ≥ 𝑏⃗⃗ are the
constraints which include a non-negative aperture weight constraint, boundary limits on
the leaf positions, minimum and maximum leaf travel speed of 0 cm/s and 6 cm/s,
minimum and maximum gantry rotation speed of 0 °/s and 6 °/s, and a minimum and
maximum monitor unit (MU) dose rate of 75 MU/min and 600 MU/min, respectively [7].
These were the default machine-based delivery constraint that came with the matRad
toolkit.
FIDAO used the same interior-point optimization method to solve its DAO problem.
Compared to the standard DAO algorithms, FIDAO had the following changes: (1) prior
to optimization, FIDAO computed and stored the modified objective function’s Hessian
matrix (𝜶) and 𝛽⃗ via Equation 4 in Chapter 3.2.1; (2) Equations 8 & 10 in Chapter 3.2.2
were used for computing the objective function value and its gradient vector,
respectively; and (3) if dose-volume objectives were included in the optimization, an
intermediate recalculation of the Hessian matrix would be performed as describe in
Chapter 3.2.3.
Effectively, FIDAO and the standard DAO algorithm are the same as they were in
Chapter 3, with the exception that both VMAT DAO problems are limited to a single
aperture at each gantry angle per arc, and that the DAO problems in this study include
additional VMAT-related delivery constraints such as maximum gantry-rotation speed
and dose rate.
Planning was performed on the same desktop computer running Windows 7 with an
Intel i7-3930K (3.2 GHz) CPU and 64 GB of RAM. To the best of our knowledge, no
CPU or GPU parallelization was utilized in matRad’s DAO algorithm’s code [6,7].
Similarly, no parallel processing was used in the code for FIDAO. The total optimization
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time and number of iterations were recorded for both FIDAO the standard DAO
algorithm. The FIDAO and matRad optimized plans were also compared based on their
dose-volume histograms and 3D dose distributions.
Table 4.1: Optimization objectives used by both algorithms.
No.
1.

Site
TG-119

2.

Liver

3.

Prostate

Beams
(Apertures)
1 360° Arc •
(91)
•
•
1 360° Arc •
(91)
•
•
1 360° Arc •
(91)
•
•

Optimization Objectives
Uniform 50 Gy dose to the C-shaped Target.
Minimal dose to the core OAR and body.
Maximum point dose of 50 Gy in the body, and 25 Gy in the core OAR.
Uniform 45 Gy dose to the PTV.
Minimal dose to the healthy liver, heart & normal tissue.
Maximum point dose of 40 Gy in the normal tissue.
Uniform 68 Gy and 56 Gy dose to the PTV and Nodes.
Minimal dose to the rectum, bladder & normal tissue.
Maximum point dose of 50 Gy in the normal tissue, rectum, and
bladder.

4.3 Results
Details about the test cases and the algorithms’ performance are listed in Table 4.2.
Note that the size of the Hessian matrix (𝜶) is proportional to the squared number of
pencil beams (column 3) in the plan, while the size of the pencil-beam dose matrix is the
number of pencil beams times the number of voxels (column 4). Also, note that the listed
computation times for FIDAO’s 𝜶 and 𝛽⃗ (column 7) refers to their one-time initial
computation time prior to DAO. The time spent updating 𝜶 and 𝛽⃗ when dose-volume
objectives were present is included in the total FIDAO optimization time (column 8).
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Table 4.2: Information related to the size of the optimization problem, and each algorithm’s performance.
No.

Site

Pencil
Beams

Voxels
[x 106]

Non-zero
dxi [x 108]

Voxels in
PTV [x103]

⃗⃗
𝛂, β
Initialization

1.

TG-119

32,123

3.60

4.88

7.5

40.9 s

2.

Liver

20,293

7.91

8.38

7.0

18.7 s

3.

Prostate

52,234

3.05

10.52

16.3

197.8 s

Optimization Time (Iter.)
FIDAO
Standard
64.9 s
602 s
(245)
(275)
25 s
803 s
(85)
(159)
98.6 s
754.3 s
(174)
(149)

Abbreviations: Iter, Iterations.

Sample dose-volume histograms (DVH) for each case are shown in Figure 4.1-Figure
4.3. To demonstrate the effectiveness of these DAO algorithms, Figure 4.1-Figure 4.3
also include DVHs of the plan prior to DAO (post FMO, aperture and arc sequencing).
As demonstrated by the comparison of DVHs, FIDAO and the standard DAO
algorithm converged to plans of similar quality. In the liver case however, the FIDAO
plan spared the stomach slightly more whereas the standard DAO plan spared the spinal
cord slightly more. Similarly, in the prostate case, the standard DAO plan and FIDAO
plan spared the femoral heads and rectum slightly differently. In terms of optimization
time, FIDAO obtained its solutions about 7-32 times faster than the standard DAO
algorithm, or 2.5-18.3 times faster if the one-time calculation time for 𝜶 and 𝛽⃗ is
included.
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Figure 4.1: Dose-volume histograms of the AAPM TG-119 phantom plan after
undergoing FMO and aperture sequencing (dotted line) and when optimized with the
FIDAO (solid line) and the standard (dashed line) DAO algorithms.

Figure 4.2: Dose-volume histograms of the liver plan after undergoing FMO and
aperture sequencing (dotted line) and when optimized with the FIDAO (solid line) and
the standard (dashed line) DAO algorithms.
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Figure 4.3: Dose-volume histograms of the prostate plan after undergoing FMO and
aperture sequencing (dotted line) and when optimized with the FIDAO (solid line) and
the standard (dashed line) DAO algorithms.

4.4 Discussion
In this work, we extended FIDAO for VMAT treatment planning and evaluated its
performance relative to a standard VMAT DAO algorithm in three cases. As shown in
Table 4.2, FIDAO reduced the optimization time for VMAT by up to a factor of 18
(when the pre-calculation times for 𝜶 and 𝛽⃗ are included). The plan quality obtained with
FIDAO was on par with the standard DAO method, although some minor differences
could be observed when using the same planning objectives (Figure 4.1 - Figure 4.3).
The source of FIDAO’s superior performance lies in the lower computational cost of
computing FIDAO’s objective function value and gradient vector. As discussed in the
introduction, the number of operations (𝑚) performed when evaluating FIDAO’s
objective function is proportional to the squared number of pencil beams in the plan
(Table 4.2, column 3 squared), whereas the number of operations (𝑛) performed when
evaluating the conventional objective function is proportional to the number of non-zero
elements in a pre-calculated dose matrix (Table 4.2, column 5). In most cases, 𝑚 is much
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lower than 𝑛, meaning that FIDAO can compute its objective function value and gradient
vector more efficiently. Moreover, FIDAO’s gradient vector can be computed with little
additional cost once the objective function value is computed, and vice versa, by storing
the result of 𝒂𝜏⃗ − 𝛽⃗ . This cannot be done when using the standard objective function.
The optimization times observed in this study are approaching the reported
optimization times by commercial treatment planning systems, and by Men et al. for their
GPU-based DAO algorithm, for VMAT planning [13]. For instance, Men et al. reported
VMAT optimization times in the range of 18 – 31 s when parallelized on an NVIDIA
Tesla C1060 GPU, whereas we observed optimization times of 25 – 98.6s, on a standard
desktop CPU, without any parallelization. There are a few key differences between our
study and Men et al. that are worth noting. First, the plans optimized by Men et al. are
considerably smaller than the test cases presented in this study. The largest plan in their
patient cohort had 5.5x107 non-zero elements in its dose calculation matrix, whereas the
smallest plan in this study has 4.8x108 non-zero elements. Therefore, it would likely take
considerably longer than 18 – 31 s for their algorithm to execute on the cases presented in
this study. Secondly, the algorithm implemented by Men et al. is a column generation
approach that sequentially adds apertures to the plan based on a pricing problem [5,13]. It
does not perform DAO after aperture and arc sequencing as is done in SmartArc (Philips
Healthcare, Fitchburg, USA) and the algorithm implemented in this study. Therefore, to
make a fair comparison, we should also incorporate the 𝜶 computation times (column 7
of Table 4.2) and the approximate 120 s that was spent on FMO, aperture and arc
sequencing performed in our method. While this adds a considerable amount of time to
FIDAO’s overall planning time, note that the 𝜶 calculation can be accelerated greatly
with GPUs (Equation 4 in Chapter 3.2.1 is a data-heavy computation) and we can
eliminate most of the FMO time by performing FMO with FIDO [2,3]. Therefore,
collectively, we anticipate that FIDAO would take less time than the algorithm developed
by Men et al. when implemented on the same system and tested on the same cases.
While the time complexity (number of operations) of FIDAO may be lower, the
spatial complexity (memory usage) of FIDAO is considerably higher. Specifically,
FIDAO requires us to compute and store the objective function’s Hessian matrix (𝜶).
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When stored in a compressed upper or lower triangular format (notice 𝜶 is symmetric) at
double precision, the Hessian matrix for the TG-119, liver and prostate cases took an
additional 4.1 GB, 1.6 GB, and 10.9 GB of memory, respectively. Furthermore, we were
unable to optimize the head-and-neck cancer case that is included with the matRad toolkit
due to the memory limitations of our system [6,10]. For a full 360° arc, this head-andneck case contained 130,676 pencil beams, so the Hessian matrix would require an
additional 68.3 GB of memory, which is more memory than our machine possessed. This
highlights a potential limitation of current implementation of FIDAO. This may
particularly be an issue when we attempt to use FIDAO for non-coplanar VMAT, which
may have even more pencil beams in its plan. In a future study, we will investigate
whether low-rank approximations of the Hessian matrix could be used to help reduce the
memory used in FIDAO [14]. Furthermore, we will implement FIDAO within a
commercial treatment and compare the FIDAO optimization to a clinically relevant DAO
algorithm as opposed to the research DAO algorithm used in this and the previous study.
Finally, we will parallelize FIDAO’s computations on a GPU and evaluate its
performance.

4.5 Conclusion
In this work, a prototype FIDAO algorithm for VMAT planning was developed and
compared to a standard DAO algorithm. In the three cases that were tested, FIDAO
produced plans of similar quality in at least half the time. This study demonstrates
promising speed enhancement for the DAO of VMAT plans using FIDAO. Further
opportunities for speed gain are possible with parallel processing technology.
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Chapter 5 – Patient-specific calibration of cone-beam
computed tomography images for dose tracking and
treatment plan assessment
This chapter was adapted from the published article entitled “Patient-specific
calibration of cone-beam computed tomography data sets for radiotherapy dose
calculations and treatment plan assessment” by Michael MacFarlane, Daniel Wong,
Douglas A. Hoover, Eugene Wong, Carol Johnson, Jerry J. Battista, and Jeff Z. Chen,
Journal of Applied Clinical Medical Physics, 19 (2): 249-257 (2018). Permission to
reproduce this article was granted by John Wiley and Sons and is provided in Appendix
B.4. Supplemental data for this chapter is provided in Appendix E.

5.1 Introduction
Radiation treatments generally span several weeks and during this time, changes in
patient weight, tumour volume and organ positioning can occur [1]. These changes may
substantially alter the radiation dose distribution within the patient, potentially resulting
in degraded plan quality and suboptimal clinical outcomes [2].
To ensure that a patient receives adequate treatment, a new re-planning CT (reCT)
data set may be acquired to dosimetrically assess plan quality and to evaluate whether
treatment re-planning has become necessary. Unfortunately, this workflow is often
inefficient as it is difficult to distinguish a priori which patients require a reCT from
those who do not. A promising solution is to use cone-beam computed tomography
(CBCT) image sets to dosimetrically assess plan quality, since these image sets are
already routinely acquired prior to treatment for patient setup and monitoring. However,
to perform dose calculations, accurate tissue density information must be extracted from
the CBCT voxel values.
Normally, tissue density information is obtained through CT calibration curves,
which are generated by scanning a plastic phantom containing various inserts of known
electron density [3]. For CBCT scans, the Hounsfield Units (HU) of an image set are
highly dependent on many factors, including the size and material of the phantom, the
materials placed in the phantom, and the imaging protocol used [4-7]. Furthermore,
78

scattering conditions often differ between phantoms and patients when using a conebeam geometry. Due to this variability, HU-to-density calibration curves obtained with
phantoms for CBCT lack sufficient robustness to be applicable to all patients and across
all anatomical sites [6]. Consequently, alternative methods of inferring tissue density
have been suggested, such as: (1) population-based calibration curves [6,7], (2) multilevel thresholding or bulk assignment of the HU or density values [7-10], and (3) voxelto-voxel mapping using deformable image registration (DIR) [10-12].
Although these CBCT calibration techniques have demonstrated some promising
results, each method may have limitations in certain situations. For instance, populationbased calibration methods require unique calibration curves for each treatment site, and
for each imaging protocol used. Bulk assignment techniques are dependent on the
accuracy of automatic segmentation or thresholding of tissue regions, correct density
assignments, or the time allotted to manually correct improperly delineated volumes.
Similarly, DIR methods depend on the accuracy of the DIR algorithms, as regional DIR
errors may significantly distort local anatomy and hence affect the density and dose
evaluation within the region [13]. This may be particularly problematic in sites such as
the pelvis and thorax where large deformation errors frequently occur. Moreover,
regional DIR errors could also alter the delineation of critical structures, thereby further
affecting organ dose assessment and dose-volume metrics.
To potentially resolve these limitations, we began development on an alternative
patient-specific CBCT calibration (PSC) technique that, while using DIR algorithms, is
less sensitive to DIR uncertainties. Briefly, rather than mapping CT numbers voxel-byvoxel with DIR, we generate a systematic but patient-specific calibration curve for each
CBCT slice after registering CBCT to planning CT with DIR (see next section for
details). This slice-specific calibration curve is then applied to the CBCT slice to convert
the voxel values to their ‘planning CT equivalent’ values, without altering the patient
geometry through regional DIR errors. Calibration curves are generated on a per-slice
basis since scattering conditions may vary axially and thereby affect the relationship
between CBCT and planning CT HU values.
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To evaluate whether this new PSC method improves dosimetric accuracy, we
performed a retrospective patient study of 15 head-and-neck clinical cases, and a
phantom study. The dosimetric accuracy of this PSC method was compared to a replanning CT (serving as the gold standard) and to other CBCT calibration methods
implemented in literature (DIR mapping and bulk density assignment).

5.2 Materials and Methods
5.2.1

Patient Selection

Fifteen head-and-neck cancer patients were selected at random from our institution
database, all of whom had completed their treatment course and were referred for a reCT
study at some point during their treatment course. This tumour site was selected due to
the high frequency of treatment re-planning. In order to minimize the dosimetric error
resulting from anatomical differences, CBCTs acquired around the acquisition date of the
reCT were reviewed and the CBCT with the most acceptable anatomical agreement with
the reCT image set was selected. Patient and treatment related information are
summarized in Supplemental Table 5.1.

5.2.2

Imaging

All CT and CBCT images were acquired as part of the patient’s routine treatment
course.
Original planning CT and re-planning CT images were acquired on a Philips
Brilliance Big Bore 16-slice CT scanner (Philips Healthcare, Cleveland, OH). CT images
were acquired with a full-fan 120 kVp beam. The scanning parameters used to acquire
each planning and re-planning CT, can be found in Supplemental Table 5.2 and
Supplemental Table 5.3, respectively. The CT images were reconstructed using the
device’s default filtered back-projection algorithm, with a default slice thickness of 3 mm
and slice size of 512 x 512. The voxel size varied between image sets as the CT operator
would select the smallest field of view (FoV) required to cover the patient [14].
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CBCT images were acquired with either a Varian Truebeam or Clinac iX On-Board
Imaging (OBI) system (Varian Medical Systems, Palo Alto, CA). CBCT scans were
acquired with either a standard (20 mA) or low dose (10 mA) protocol using a full-fan
100 kVp beam with a full bow-tie filter. The scanning parameters used to acquire each
CBCT can be found in Supplemental Table 5.4. CBCT scans were reconstructed by the
treatment unit’s OBI software (v 2.0-2.1) which uses a Feldkamp-Davis-Kress (FDK)
reconstruction algorithm with a Ram-Lak filter [15,16]. Image slices were 384 x 384 in
size when acquired with the Clinac iX’s system, and 512 x 512 when acquired with the
Truebeam’s system.

5.2.3

Creation of calibrated CBCT image sets

Figure 5.1 outlines the general steps performed for each calibration method in this
study. Details specific to each method will be described below.

Figure 5.1: Schematic of the process used to generate a calibrated CBCT data set for
dose calculation (left). The gold standard reCT data set is rigidly registered with the final
calibrated CBCT data set for comparison (right).
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5.2.4

Patient-specific calibration (PSC) Method

The CBCT image sets were imported into a research version of the Pinnacle treatment
planning system (v9.7, Philips Healthcare, Fitchburg, WI) along with the patient’s
original treatment planning CT data set (containing the CT scan, treatment plan, contours,
and points of interest). The CBCT image set was first rigidly registered with the planning
CT image set. The planning CT image set was then deformably registered to the CBCT
image set using a fast-symmetric Demon’s algorithm implemented in Pinnacle [17],
resulting in a deformed planning CT image set that was registered with the CBCT image
set. The resulting deformed planning CT and the CBCT image sets were exported to
Matlab (v2015a, MathWorks Inc, Natick, MA) for the patient specific calibration.
A correlation plot of the voxel values was then generated for each slice between the
deformed planning CT and CBCT image sets (Figure 5.2a). While deformation errors
may have affected the correlation of HU values for some voxel pairs (such as those
highlight by the arrows in Figure 5.2a), most voxels within the slice will have been
properly mapped by the DIR algorithm to planning CT HU values. Therefore, a strong
relationship between the planning CT and CBCT HU values could be regressed from
these correlation plots. With this relationship, we could scale the CBCT HU values to
their CT-equivalent values without introducing the regional DIR errors.
Linear calibration curve specific to each slice were obtained by least-squares fitting of
the correlation plots, and applied to each slice of the CBCT data set. These calibration
curves were slice-specific since scatter conditions will vary between slices of the CBCT,
and therefore the relationship between CBCT and planning CT HU values (the model
parameters regressed) may change.
As a final image processing step, the calibrated CBCT images were merged with the
original planning CT images to extend the FoV, as shown in Figure 5.2b. Before
merging, the calibrated CBCT images were rigidly registered with the original planning
CT (using R1 in Figure 5.1) and resampled with a linear interpolation algorithm so that
the resolution of the CBCT matched that of the planning CT. Regions that were outside
of the calibrated CBCT FoV or truncated during reconstruction were substituted with
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voxel values from the original planning CT images. Slices on the superior/inferior border
with poor correlation between the voxel values of the CBCT and the deformed planning
CT image set (R2 < 0.8) were also replaced by the planning CT images. This usually
occurred in the shoulder region where the CBCT FoV was insufficient to cover the whole
patient, resulting in large deformation errors. By removing these slices, we could improve
the anatomical matching at the junction of the CBCT and the original planning CT image
set.

Figure 5.2: Illustration of the patient-specific calibration (PSC) method. a) An HU
correlation plot is generated for each slice, between corresponding voxels of the CBCT
and the deformed planning CT. Despite the presence of DIR errors (highlighted by the
arrows), a strong slice-specific linear calibration curve of the CBCT HU values to the
planning CT HU values, can be obtained by least square fitting. b) Once the linear
mappings are applied, the calibrated CBCT image set is then rigidly registered, resampled
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and merged with the original planning CT image set to extend its field-of-view. Slices
with poor correlation between the CBCT and the deformed planning CT voxel values (R2
< 0.8; outside of dashed lines) were replaced by the original planning CT.

5.2.5

Voxel-to-voxel DIR method

For the DIR method, the deformable image registration proceeded exactly as it did for
the PSC method. Provided there are no significant DIR errors, a deformed planning CT
will match the target CBCT while containing HU values from the source planning CT.
Therefore, the deformed planning CT data set can be directly used to calculate the dose
received at the time of treatment. After DIR, the deformed planning CT image set has the
same dimensions and coordinates as the CBCT image set. Therefore, the deformed
images were also rigidly registered, resampled, and merged with the original (undeformed) planning CT images to extend the field-of-view. Like the PSC method, the
same slices on the superior/inferior border with poor correlation between the voxel values
of the CBCT and the deformed planning CT (R2 < 0.8) were replaced by the planning CT
slices.

5.2.6

Density-override method

In the density-override method, the CBCT image set was first rigidly registered with
the original planning CT image set. Regions where soft tissue had become air (e.g.
weight loss) or where air had been replaced by soft tissue (e.g. closed air cavity) were
manually delineated on the original planning CT image set and assigned either water or
air equivalent densities, accordingly. With these modifications, the major anatomical
changes can be accounted for on the planning CT dataset, while continuing to use the
original planning CT’s HU values for dose calculations. This technique is similar to the
algorithm implemented by van Zijtveld et al. [8] and is illustrated in Figure 5.3.

5.2.7

Gold standard (reCT) for dose evaluation

The CBCT image sets calibrated by each method were imported back into the
research version of Pinnacle, along with the patient’s re-planning CT data set (including
contours). The calibrated CBCTs inherit the coordinate system of the original planning
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CT study, which may not be registered with the re-planning CT. Therefore, for accurate
plan dose comparison, each of the image sets was rigidly registered with the reCT image
set (R2 in Figure 5.1), taking care to match the original plan isocenter to the same
anatomical location. The original treatment plan was then transferred to the reCT data set
and dose was recomputed while maintaining the original beam layout and monitor units
per beam. Dose was calculated on each data set using Pinnacle’s Adaptive Collapsed
Cone Convolution algorithm with inhomogeneity corrections [18]. The dose grid was set
to cover the entire patient CT images with 3 mm resolution in all directions. To minimize
dosimetric errors, regions with metal streaking artifacts were delineated on each image
set and assigned tissue equivalent densities for dose computation. Dose-volume metrics
evaluating tumour volume coverage and organ-at-risk (OAR) exposure were tabulated
and served as the gold standard results.
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Figure 5.3: Illustration of the density-override method. Regions of weight loss (shown in
a teal colourwash) were assigned a density of 0 g/cm3 for dose calculations.

5.2.8

Contouring and dose metrics

The contours from the reCT data set were rigidly copied onto each calibrated CBCT
image set based on the rigid registration R2. If necessary, these contours were manually
adjusted to match the patient anatomy as seen on the calibrated image set. Dose metrics
evaluating tumour volume coverage and organ-at-risk (OAR) exposure were again
tabulated and compared to the gold standard results.

5.2.9

Gamma analysis

Dose distributions computed on each of the calibrated image sets were compared to
the gold standard dose distribution using the SlicerRT extension (v 0.18.0) of 3D Slicer
(v 4.6.2) [19,20]. A 3D gamma analysis was restricted to a region inside the original
CBCT volume and excluded voxels within 3 mm of the surface so that uncertainties in
surface dose were omitted. The analysis was performed with a low-dose threshold of 10%
(relative to the maximum point dose on the reCT data set), and acceptance criteria of 3%
dose-difference and 3 mm distance-to-agreement. The gamma pass rate (percentage of
voxels with γ < 1) was tabulated.

5.2.10

Statistical Analysis

A one-way repeated measures MANOVA was performed in the Statistical Package
for the Social Sciences (SPSS v23, IBM Corp, Chicago, IL) to assess whether the image
set used for dose calculations influenced the collective dose metric values. Univariate
analysis followed when the MANOVA test was significant, along with post-hoc pair-wise
Student’s t-tests when appropriate. A one-way repeated measure ANOVA was also
performed to find statistical differences between the gamma pass rates. A 5% threshold
for statistical significance (p = 0.05) was used.
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5.2.11

Phantom Study

A phantom study was also performed to assess the accuracy of the DIR and PSC
CBCT calibration methods. A planning CT and CBCT (Clinac iX) scan were acquired of
the CIRS 062 inner ‘head’ phantom with various material inserts (Computerized Imaging
Reference Systems Inc, Norfolk, VA).
To simulate weight loss with the phantom, a simulated reCT image set was created by
reducing the planning CT’s in-plane dimensions by 5% (yielding an equivalent depth
reduction of 4.5 mm) as shown in Figure 5.4. Similarly, the in-plane dimensions of the
CBCT images were reduced by 5% to match the simulated reCT.
The original planning CT, simulated reCT and CBCT image sets were imported into
the research version of Pinnacle. The CBCT was then calibrated using both the DIR and
the PSC CBCT calibration methods described above. Merging of the calibrated CBCT
image sets with the original planning CT was not required as the CBCT FoV was
sufficient to capture the entire phantom. The calibrated CBCT images were then rigidly
registered with the reCT image set. The inserts in the phantom were manually delineated
on each image set (as shown in Figure 5.4) and the average density and Sørensen-Dice
similarity coefficient (compared to the reCT contour) were calculated for each insert and
each image set.

Figure 5.4: The image sets and contours produced for the phantom study. A simulated
reCT was produced by reducing the Planning CT’s in-plane voxel size by 5%. The CBCT
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voxel size was also adjusted by 5%. The CBCT was then calibrated using both the PSC
and DIR methods. The inserts were delineated on each image and the average density and
Dice Coefficient (relative to the reCT) was computed for comparison.

5.3 Results
Table 5.1 shows the difference of various dose metrics compared to the gold standard
values, averaged over all patients and normalized to the prescription dose (due to
different prescription doses between patients). Figure 5.5 and Figure 5.6 show the
average dose-volume histogram of the 15 patients and a sample patient dose distribution,
respectively.
Table 5.1: Mean (standard deviation) dose metric differences
compared to the gold standard reCT, normalized by the prescribed
dose. Dose metrics that were significantly different to the reCT are
indicated with the asterisk (p < 0.05) and dagger (p < 0.01).

ROI
PTV
Brainstem
Cord
Lt. Parotid
Rt. Parotid

Dose
Metric
D95%
Mean
D2%
D0.1cc
D0.1cc
Mean
Mean

PSC
Method

DIR
Method

[%]
-1.1 (1.0)
-0.5 (0.8)
0.0 (1.3)
0.6 (1.0)
-2.0 (2.5) *
0.7 (1.5)
0.5 (2.2)

[%]
-0.9 (1.0)
-1.0 (0.8) †
-0.8 (1.2) †
0.0 (1.2)
-3.0 (3.3) †
0.3 (2.4)
0.2 (3.1)

DensityOverride
[%]
-0.8 (2.8)
-1.5 (0.8) †
-1.5 (1.3) †
-0.5 (1.5)
-3.4 (3.1) †
0.5 (1.9)
-0.4 (2.4)

Abbreviations: ROI, region of interest; PSC, patient-specific calibration;
DIR, deformable image registration; DXX, minimum dose to the most
irradiated XX volume, specified in percent or cubic centimeters (cc), as
indicated.

On average, dose metric differences were ≤ 1.1% for all three methods, with the PSC
method providing marginally better agreement (-0.3 ± 1.0%, mean ± standard deviation)
compared to the DIR (-0.7 ±1.1%) and density-override (-1.1 ± 1.2%) methods.
Multivariate testing revealed that the image set used for dose calculation had a
statistically significant effect on the dose metric values (p < 0.001). Further univariate
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analysis and pair-wise t-testing found that the spinal cord maximum dose D0.1cc metric
was systematically underestimated by all three methods (p < 0.05). Furthermore, both
DIR and density-override methods also systematically underestimated both the PTV
mean dose metric (p < 0.01) and D02 metric (p < 0.01), whereas the PSC method did not.
The level of statistical significance of the Student’s t-test is indicated by asterisks (p <
0.05) and daggers (p < 0.01) in Table 5.1.

Figure 5.5: Average dose-volume histograms of fifteen plans, calculated with the goldstandard reCT image set (dashed line), and the CBCT calibrated with the patient-specific
calibrated method (PSC, solid line), and the DIR method (DIR, dotted line).
The results of the 3D gamma analysis were found to be similar across all three
techniques (p = 0.41), with the average (standard deviation) gamma pass rates of 95.0%
(3.0%), 96.1% (3.3%), and 94.4% (4.4%) for the PSC, DIR, and density-override
methods, respectively.
Results from the CIRS phantom study are provided in Table 5.2. Relative to the reCT
scan, the DIR calibrated CBCT provided very similar densities for every insert in the
phantom. However, significant distortions were introduced into the image set as a result
of the DIR errors, as evident by the Dice coefficient values and by visual inspection of
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the deformed CT in Figure 5.4. Conversely, the PSC calibrated CBCT provides better
anatomy matching than DIR, with higher Dice coefficients. Despite the presence of
crescent artifacts, the PSC method also improves the average density accuracy for most
materials, relative to the uncalibrated CBCT, as shown in Table 5.2.

Figure 5.6: (Upper) Sample dose distributions from patient 1 for the plans calculated on
the gold standard reCT (left), PSC calibrated CBCT (middle), and DIR calibrated CBCT
(right) image sets. (Lower) Differences between the PSC, DIR calculated dose
distribution and the reCT calculated dose distribution.
On average, it took about 30 minutes to perform the full DIR and PSC calibration
workflow, with the bulk of the time spent on dose calculations and transferring the image
sets between systems for merging and/or calibration. Of those 30 minutes, under a minute
90

was spent running the DIR, and only a few seconds were spent calibrating and merging
the CBCT with planning CT image set using the PSC method. The density-override
techniques took longer (~50 minutes) because the contours delineating anatomical
changes were generated manually.
Table 5.2: The average density and Sørensen-Dice similarity coefficient
(compared to the reCT) calculated for each insert in the CIRS 062 phantom,
and for each image set.
Material
Computed Density [g/cm3]
Dice Coefficient
3
(True density [g/cm ])
DIR
PSC
CBCT
PSC
DIR
0.53
0.52
0.47
0.98
0.96
Exhaled Lung (0.52)
0.93
0.90
0.87
0.99
0.94
Adipose (0.93)
1.05
1.04
1.02
0.96
0.77
Liver (1.05)
1.05
1.04
1.00
0.97
0.73
Muscle (1.05)
0.26
0.27
0.21
0.97
0.97
Inhaled Lung (0.24)
1.55
1.58
1.57
0.86
0.80
Dense Bone (1.55)
0.96
0.95
0.91
0.96
0.79
Breast 50/50 (0.96)
1.19
1.21
1.20
0.94
0.92
Trabecular Bone (1.20)

5.4 Discussion
We have developed a patient-specific method of calibrating CBCTs for dose tracking
and plan assessment and compared it with other methods for the head-and-neck site
[8,11]. The results show that slightly better dosimetric agreement with the gold standard
reCT can be obtained when using this patient-specific calibration (PSC) method, although
each method demonstrated sufficient accuracy for plan re-assessment during
radiotherapy.
It is worth noting that the spinal cord dose was poorly estimated by all three methods
(D0.1cc in Table 5.1, Figure 5.5). This was caused by a few select patients who had slight
variations of the spinal cord positioning in regions of steep dose gradients (due to
differences in setup between the reCT and the CBCT studies). It should also be noted that
the gamma pass rates presented in this study are lower than other published results. For
example, both van Zijtveld et al. [8] and Veiga et al. [11] reported similar gamma pass
rates for the head-and-neck site when using a stricter 2%, 2 mm acceptance criteria. The
difference in gamma pass rates could be attributed to differences in the study design. For
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instance, Veiga et al. [11] performed their DIR method on simulated CBCTs, which were
created by deforming the selected CBCT to match the reCT.
The results from this study illustrate the pros and cons of the three CBCT calibration
methods. While the density override method is easy to implement on available treatment
planning systems, it cannot account for internal anatomical changes and it can be very
time consuming to perform. Furthermore, the observed dosimetric accuracy of this
technique is not as high as the other CBCT calibration techniques (Table 5.1). The DIR
method is less sensitive to the CBCT artifacts (such as the crescent artifact visible in
Figure 5.4) and provides sufficiently accurate tissue density and dosimetric information
(Table 5.2, Figure 5.5). However, DIR methods may introduce distortions into the image
through DIR errors (Figure 5.2a, Figure 5.4, Table 5.2) that can affect OAR delineations
and their dosimetric evaluations (Table 5.1). On the other hand, the PSC method is less
sensitive to regional DIR errors as it maintains the patient anatomy from the CBCT,
resulting in higher Dice similarity coefficients as shown in Table 5.2. While the PSC
method preserves the patient anatomy, it also preserves the noise and any artifacts present
in the CBCT images (Figure 5.4). It also produces slightly less accurate densities than the
DIR methods (Table 5.2). Neither of these limitations appeared to have considerable
influence on the dosimetric performance of the PSC method (Table 5.1, Figure 5.5).
While distortions introduced by DIR calibration did not have substantial influence on
the dosimetric accuracy in the head-and-neck site studied here (Table 5.1, Figure 5.5 &
Figure 5.6), the same may not be true in sites such as pelvis or thorax where large DIR
distortions are commonplace at tissue-air interfaces, such as the bowel. Therefore, the
PSC method could be potentially advantageous for these sites and will be investigated in
the future.
Based on Table 5.2, the PSC method improves the average density accuracy of the
uncalibrated CBCT, for most materials inserted in the phantom. However, since there
were relatively low amounts of high-density (bone) material in each slice, the calibration
curves used by the PSC method were primarily fitted for lower density materials and not
higher density materials. As a result, the density of higher density materials were not
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corrected by the PSC method. A future version of this PSC method could potentially be
improved by using a piece-wise continuous linear calibration curves that calibrates both
lower and higher density materials separately. Furthermore, the limited FoV, noise, and
artifacts present in CBCTs may pose additional challenges in sites such as the pelvis or
thorax [21,22]. Therefore, more sophisticated methods of extending the CBCT field-ofview (such as fusion-aligned reprojection techniques [23]), and reducing the noise and
artifacts present in the CBCT, will be investigated in the future. The performance of this
method will also need to be verified on other CBCT imaging systems, and in other
treatment sites.
Finally, in addition to calibrating CBCT for dose calculations, the calibration curves
used in the PSC method can also be used to quickly identify regions of potential DIR
error on a deformed CT. For example, if one highlights the voxels outside of the 95%
confidence interval of the calibration curve, regions where the CBCT and the deformed
CT differed substantially can be easily visualized. An example of this application is
provided in Figure 5.7.

5.5 Conclusion
A patient-specific CBCT calibration method has been developed and tested for the
head-and-neck site. Compared to a gold standard reCT dose distribution, average
differences in dose metric values were ≤ 1.1% for all calibration methods tested, although
the PSC method showed slightly better performance. Some advantages of the PSC
method are that it preserves the patient anatomy, accounts for variable scattering per CT
slice, can be uniquely applied to each patient, is computationally efficient, and may also
be used to display errors introduced by DIR algorithms.
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Figure 5.7: Illustration of how the linear calibration tool may be used to highlight
regions of deformation error. The bottom frame shows the correlation plot generated for
this slice. The linear mapping used to calibrate the slice is shown in orange, while the
upper and lower bounds of the 95% confidence interval (CI) are shown as the dashed
green lines. Data-points falling outside of the 95% CI are labelled in red and blue on the
plot and are also highlighted on the top-right deformed planning CT to show regions
where the CBCT (top-left) and deformed planning CT (top-middle) differ due to DIR
errors.
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Chapter 6 – Summary & Future Work
6.1 Contributions and Findings
This thesis presented a number of improvements to the EBRT planning process that
enhance patient plan quality as well as the efficiency of the treatment planning and beam
delivery procedures. This work also made progress towards long-awaited applications
like on-line plan assessment and adaptive radiation therapy.
In Appendix A, we presented initial work on a new treatment planning algorithm
called unified intensity-modulated arc therapy (UIMAT) which combines the
optimization and delivery of rotational VMAT and fixed-gantry IMRT. Specifically,
UIMAT automatically selects which subset of gantry angles to deliver as fixed-gantry
IMRT, and which arc ranges to deliver as rotational VMAT. It then simultaneously
optimizes the VMAT and IMRT beams and merges their control point (CP) information
for efficient delivery – merging the best qualities of these complementary techniques.
A retrospective planning study of 15 lung, head-and-neck, and prostate cancer
patients was performed, comparing the clinically approved treatment plans with the plans
obtained with this UIMAT algorithm. The results of this planning study showed that
UIMAT could obtain similar PTV coverage while also providing modest dose reductions
to the surrounding OARs in the lung and prostate cases (as demonstrated by Figure A.4 &
Figure A.5, respectively), and substantial dose reductions to OARs in head-and-neck
cases (as demonstrated in Figure A.3). These findings motivated a larger retrospective
planning study of 30 head-and-neck patients that was presented in Chapter 2. When
compared to the clinically approved dual-arc VMAT or step-and-shoot IMRT plan, the
UIMAT plans provided similar or better PTV coverage while also reducing the dose to
nearly all OARs (Figure 2.2, Table 2.1). This OAR dose reduction was achieved without
increasing the dose to unspecified normal tissue (i.e. by relocating the dose elsewhere). It
was also found that UIMAT plans could be delivered more efficiently than clinical IMRT
or VMAT plans, both in terms of average delivery time and total delivered MU.
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This reduction in OAR dose means that UIMAT could potentially reduce the severity
or frequency of treatment-related toxicities such as dry mouth (xerostomia), mouth sores,
and difficulty swallowing (dysphagia) in head-and-neck cancer patients [1]. Conversely,
the lower OAR doses could allow for dose escalation to the PTV to achieve even better
tumour control while continuing to adhere to OAR dose limits.
DAO algorithms are needed to create VMAT, IMRT, and UIMAT treatment plans.
Due to the dimensionality and computational complexity of the DAO problem, and the
current inefficient trial-and-error approach to plan optimization, treatment planning can
sometimes take several hours or even days to complete in complex cases. Furthermore,
when there is limited time for treatment planning (e.g. for re-planning), sub-optimal
treatment plans may be accepted so as to not interrupt or delay treatment delivery. In
Chapter 3 and Chapter 4, we developed and evaluated a new fast DAO algorithm called
fast inverse direct aperture optimization (FIDAO). FIDAO extends a previously
established FMO algorithm called fast-inverse dose optimization (or FIDO) for fast
DAO. When compared to conventional DAO algorithm, FIDAO reduced DAO times by
as much as 23 times in IMRT plans (Chapter 3) and by as much as 18 times in VMAT
plans (Chapter 4). Similar plan quality was observed between the plans obtained with the
standard DAO algorithm and FIDAO, though some minor (but clinically insignificant)
differences could be observed between the VMAT plans. Given that UIMAT plans
consist of just as many pencil beams as a VMAT plan, we anticipate that faster DAO will
also be observed with a FIDAO algorithm implemented for UIMAT planning.
FIDAO, like conventional DAO algorithms, is well suited for parallelization on
GPUs. When compared to their runtimes on CPUs, standard DAO algorithms
implemented on GPUs have achieved an average speed gain of about 37 times in IMRT
and 15 times in VMAT [2,3]. If similar gains were to be obtained with FIDAO, the
FIDAO optimization times could be in the millisecond range for IMRT plans, and in a
few seconds range for VMAT plans. This could drastically reduce the time spent on
treatment planning, allowing the treatment planner to focus on the plan quality instead of
the plan deadline. It could also make applications like multicriteria optimization (MCO)
faster and allow for new applications such as interactive treatment planning and on-line
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adaptive radiotherapy. In order to perform on-line adaptive radiotherapy, accurate dose
information is needed from image sets acquired on-line, which leads us to the final
project.
In Chapter 5, we developed a patient-specific CBCT calibration (PSC) technique for
on-line dose calculations and plan assessment. This PSC method demonstrated high
dosimetric accuracy when compared to the dose calculated with a gold-standard replanning CT data set, and when compared to other established CBCT calibration
techniques. One of the key features of this PSC method is that it does not introduce
geometric distortions (via deformation errors) and it accounts for slice-by-slice scattering
conditions. Furthermore, this PSC technique can be used to flag regions of DIR error on
deformed image sets. The calibrated CBCT could be used instead of acquiring a new
planning CT, to assess whether treatment re-planning has become necessary due to
anatomical changes such as weight-loss or tumour regression. This will help make sure
that the patient receives their intended treatment and minimize the risk of a suboptimal
clinical outcome. Moreover, this will help avoid unnecessary re-planning procedures that
potentially waste resources and cause treatment delays. Finally, if combined with FIDAO
and automated precise target/OAR delineation techniques, treatment re-planning could
potentially take place on-line while the patient is immobilized and awaiting their
treatment.
In summary, this thesis has developed new methods of improving plan quality and
delivery efficiency, improving planning efficiency, and assuring accurate EBRT
treatment delivery in the presence of ongoing anatomical changes. It also brings
applications like on-line adaptive radiotherapy within the realm of feasibility.

6.2 Limitations and Future Work
The future projects of FIDAO, UIMAT, and PSC are shown as a diagram in Figure
6.1. The section number describing each future project is stated along each arrow.
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Figure 6.1: Visual diagram of proposed future work. The section number describing each
future project is stated along each arrow.

6.2.1

UIMAT

A. Robustness
The UIMAT algorithm presented in Section A.2.1 is only capable of producing
hybrid VMAT-IMRT treatment plans, as well as single-arc VMAT treatment plans (when
2 apertures are sequenced for every beam). However, a truly unified approach to VMAT
and IMRT planning should be able to produce VMAT-only, IMRT-only, or hybrid
treatment plans, should they be the optimal treatment method for the patient.
Development is currently underway on a new, more robust UIMAT algorithm. Briefly,
this new algorithm is inspired by recent work on beam orientation optimization using
sparse optimization techniques [4,5]. Specifically, this UIMAT algorithm begins by
performing FMO and aperture sequencing at 4° gantry angle increments. The goal of this
step is to create a large collection of CPs at many gantry angles, as illustrated in Figure
6.2a. Next an accelerated proximal gradient method optimizes the CP shapes and
weights, while simultaneously minimizing a regularizer acting on the CP weights [6,7].
As this DAO progresses, the regularizer forces the DAO algorithm to eliminate CPs from
the treatment plan, while simultaneously trying to improve the plan quality. The idea is
that gantry angles that can use higher intensity-modulation to improve plan quality, will
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retain their apertures, while all other gantry angles will have their CPs removed. This step
is illustrated in Figure 6.2b. In cases where IMRT-only is the optimal treatment plan, we
expect this DAO to only keep CPs at select gantry angles. Conversely, in cases where
VMAT-only is the optimal treatment plan, we expect this DAO to eliminate CPs
uniformly from all gantry angles.

Figure 6.2: Illustration of the new UIMAT algorithm. A) FMO and aperture sequencing
(each CP illustrated as a square) is performed at 4° increments. B) DAO with a CP
weight regularizer is performed. As this DAO progresses, the regularizer eliminates CPs
from the treatment plan. C) The results of this DAO are parsed and VMAT (green) or
IMRT (purple) beams are sequenced using the CPs from B). A final DAO is then
performed.
When this DAO terminates, the treatment plan may still have too many apertures for
treatment delivery to be practical. Therefore, the UIMAT algorithm next evaluates each
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individual CP and gantry angle’s delivery efficiency and their contribution to the
treatment plan. It then sequences VMAT arcs and/or IMRT beams from these CPs. This
step is visualized in Figure 6.2c. The newly sequenced VMAT and IMRT beams then
undergo a final DAO, without the CP weight regularizer described above, and where the
VMAT- or IMRT-related delivery constraints are enforced.
This new UIMAT algorithm is currently being implemented in MATLAB v9.4
(Mathworks Inc, Natick, MA) using the open-source treatment planning toolkit matRad
(v2.2 – dev_VMAT build) [8,9]. Preliminary results of this UIMAT algorithm on a
prostate, head-and-neck, and a right-sided whole breast radiotherapy case are provided in
Figure 6.3. The plans obtained with this new UIMAT algorithm were compared to
conventional dual-arc VMAT plans in the prostate and head-and-neck cases, and a
tangent-field IMRT plan in the whole breast radiation therapy case.
In the whole breast radiotherapy case, the UIMAT algorithm produced a hybrid
treatment plan using a single VMAT arc and two tangent IMRT beams (similar to the
plan visualized in Figure 6.2c). Slightly lower OAR doses were obtained with the
UIMAT algorithm, as visible from the DVHs. In the prostate case, the UIMAT algorithm
also produced a dual 360° arc VMAT plan. However, the plan quality of the UIMAT plan
was noticeably better, as can be seen by the DVH curves. Finally, in the head-and-neck
case, the UIMAT algorithm produced a hybrid plan consisting of a single 360° VMAT
arc and 5 IMRT beams. Superior OAR sparing was observed with the UIMAT plan,
supporting the observations of the previous UIMAT studies.
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Figure 6.3: Preliminary DVH [left] and sample dose distributions [right] from the new
UIMAT algorithm.
Further development is still needed for this algorithm. If the regularizer is not
adequately enforced during the first DAO, the optimization will fail to eliminate enough
CPs from the plan, and the subsequent beam sequencing step will create an impractical
number of beams. Similarly, we have not yet settled on a single metric for determining a
CP’s or gantry angle’s ‘contribution’ to the treatment plan. Currently, the algorithm looks
at the median PTV voxel dose that is delivered from each gantry angle (as shown in
Figure 6.2c) as a measure of each gantry angle’s contribution to the plan. Better metrics
(such as the gantry angle’s relative contribution to the objective function value) may be
suitable.
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B. Constraints
As discussed in Section 2.4, the DAO algorithm currently used by UIMAT cannot
enforce a minimum MU or MLC segment area during optimization. This could make
UIMAT susceptible to dosimetric errors introduced by small field and small MU
dosimetry and could explain why lower gamma passing rate were observed with UIMAT
in the head-and-neck study [10-12]. Therefore, a future UIMAT algorithm should use a
custom DAO algorithm – such as FIDAO – where these delivery constraints can be
enforced.
C. Additional Applications for UIMAT
Additional future work includes integrating FIDAO into this UIMAT algorithm. This
fast UIMAT algorithm could then be implemented on GPUs, and potentially used for
online adaptive radiotherapy using the PSC CBCT technique or other on-line 3D image
sets. Finally, one can also investigate a UIMAT algorithm that uses non-coplanar arcs or
that can select IMRT beams outside of the VMAT arc range. Moreover, one can
investigate a UIMAT algorithm that also incorporates couch rotations during beam
delivery (a 4𝜋 UIMAT algorithm) [13].

6.2.2

FIDAO

A. Memory
FIDAO’s greatest limitation at the moment is the computer storage requirements for
the Hessian matrix. As discussed in Section 4.4, we were unable to optimize a head-andneck VMAT plan as FIDAO’s Hessian matrix required much more memory (68 GB) than
was available on the tested computer system (64 GB). This memory issue will continue to
grow as we evaluate FIDAO on larger treatment plans, including non-coplanar VMAT
and 4𝜋 plans (where the couch is also allowed to rotate during beam delivery [13]). This
is because the size of the Hessian matrix grows quadratically with the number of pencil
beams in the plan. This storage issue can potentially be mitigated by using a low-rank
approximation of the Hessian matrix, via singular value decomposition (SVD) [14].
Specifically, SVD can help identify a set of vectors whose memory requirements are
much smaller, and whose product closely approximates the full Hessian matrix.
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Alternatively, FIDAO could perform successive optimizations on a random sampling of
the plan parameters, allowing for smaller Hessian matrices during each individual
optimization cycle. With this memory issue resolved, future studies will continue to
develop and evaluate FIDAO’s performance on larger co-planar and non-coplanar
VMAT plans, UIMAT plans, and potentially 4𝜋 plans.
B. Dosimetric Accuracy
Another source for improvement in FIDAO is in the selection of its dose calculation
algorithm. SVD dose calculation algorithms are commonly used in plan optimization due
to their superior speed [15]. However, SVD’s superior speed comes at the cost of reduced
dosimetric accuracy when compared to slower dose calculation algorithms such as
collapsed cone convolution (CCC) and Monte Carlo simulation [16,17]. The time gained
with FIDAO’s fast optimization could be re-allocated to executing slower, but more
accurate, dose computation algorithm for calculating 𝜶 and 𝛽⃗ . Alternatively, some
commercial DAO algorithms first perform an accurate dose calculation (e.g. CCC) of the
plan prior to DAO. They then use the more approximate SVD dose engine to ‘perturb’
the dose distribution based on the difference between the current plan parameters and
plan parameters at the time of the accurate dose calculation [15,17]. This allows for fast
DAO with only a slight loss of dosimetric accuracy. A future study could evaluate
whether this ‘perturbation’ approach is applicable to FIDAO.
C. Commercial Software Platforms
The interior-point DAO algorithm that has been used as a benchmark for FIDAO thus
far, may not be representative of the optimization times or the plan quality we would
obtain with a commercial treatment planning system. Therefore, another step in FIDAO’s
development is to implement FIDAO within a commercial treatment planning system and
to compare its performance to well established DAO algorithms like the simulated
annealing DAO algorithm in Eclipse (Varian Medical Systems, Inc., Palo Alto CA) [18]
or direct machine parameter optimization (DMPO) [15] in Pinnacle3 (Philips Healthcare,
Fitchburg, USA) and RayStation (RaySearch Laboratories AB, Stockholm SE).
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D. Future Applications of FIDAO
With FIDAO implemented in a commercial treatment planning system, one intriguing
study would be to compare FIDAO and the commercial DAO algorithm on stereotactic
radiosurgery (SRS) and stereotactic body radiotherapy (SBRT) cases. As discussed in
Section 3.4, it is recommended that the dose voxel size in SRS and SBRT plans be 2mm
or less [19]. These high-resolution dose grids will result in the standard DAO algorithm
running substantially slower. However, only the calculation times for 𝜶 and 𝛽⃗ will be
affected by the dose grid resolution in FIDAO. Therefore, a large difference in the
optimization time could be observed in SRS and SBRT cases.
Another future study will implement FIDAO on high-performance GPUs and
investigate its performance to a standard DAO method on a GPU. If ultra-fast
optimization times are achieved, this GPU-based FIDAO algorithm could be used for online adaptive radiotherapy using the on-line PSC CBCTs or MRI data-sets. It could also
be used to speed up multi-criteria optimization (MCO), or for interactive treatment
planning like dose-painting. Specifically, in dose painting, the treatment planner could
‘paint’ a desired dose distribution on the planning CT, or they could drag a point on the
DVH interactively instead of modifying IMRT objectives. The DAO algorithm would
then immediately update the treatment plan and dose distribution, ideally in real-time.
Finally, with the real-time imaging capabilities of MR-linacs, it may also be possible
to do intrafraction treatment adaptation with FIDAO. That is, during treatment delivery,
the undelivered beams could be re-optimized to compensate for any anatomical changes
that have occurred moments earlier during treatment delivery (e.g. changes in patient
positioning, their respiratory cycle, or gas passing through the rectum) [20]. This
intrafraction adaptive radiotherapy could potentially eliminate the need for certain
immobilization equipment, such as the very invasive head frames used for brain SRS (i.e.
frame-less SRS) [19].
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6.2.3

PSC

A. Limited Field-of-View
CBCTs have a limited field-of-view relative to planning CTs and do not provide
sufficient anatomical information of the patient, at the time of treatment, for on-line
adaptive radiotherapy. Therefore, methods of extending CBCT’s limited field-of-view,
rather than relying on the fusion with the planning CT scans, will be beneficial [21].
B. Artifacts
In addition to preserving the patient’s anatomical information, the PSC calibration
method also preserves any noise and imaging artifacts present in the CBCT. Iterative
reconstruction technique could be used instead of filtered back-projection to improve the
CBCT image quality, reduce artifacts, and potentially improve the dosimetric accuracy of
PSC [22]. Similarly, scatter-correction techniques – such as those using convolution
neural networks – could also enhance the PSC method by improving the CBCT image
quality, dosimetric accuracy, or calibration time [23-25].
C. Additional work
With these improvements, a future study could re-evaluate the dosimetric accuracy of
the PSC method in the head-and-neck site, relative to the gold-standard re-planning CT
and other CBCT calibration techniques. A future study could also assess the dosimetric
accuracy in other anatomical sites such as the pelvis, thorax, and abdomen sites. Finally,
a study could evaluate the feasibility of the PSC method for rapid on-line treatment
adaptation and re-optimization using FIDAO and/or UIMAT.

6.2.4

Summary

Medical linear accelerators have evolved rapidly over the last few decades, with the
integration of MLC systems, the addition of dynamic delivery capabilities (e.g. fixedgantry IMRT and rotational-VMAT) and on-board 3D imaging systems (i.e. CT, CBCT,
MRI, and soon PET). At the time of writing this thesis, EBRT has yet to utilize these
linac features to their fullest potential. Therefore, this research set out to introduce a
number of improvements to the EBRT process that enhance the use of modern-day linear
accelerators. Specifically, we hypothesized that a fast plan optimization algorithm that
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unifies rotational VMAT and fixed-gantry IMRT will improve radiotherapy plan quality,
planning and delivery efficiency, and will provide a stepping-stone towards future on-line
(interactive) plan adaptation.
This was demonstrated with a new UIMAT planning algorithm that combines the
optimization and delivery of rotational VMAT and fixed-gantry IMRT. This UIMAT
algorithm demonstrated lower normal tissue doses and improved delivery efficiency
compared to conventional IMRT and VMAT treatment plans. Next, a fast-direct aperture
optimization algorithm was established and applied to both IMRT and VMAT planning.
This algorithm exhibited superior plan optimization speed on both IMRT and VMAT
plans, and potential for implementation in UIMAT. Finally, a patient-specific CBCT
calibration technique was developed and tested on head-and-neck cases. This calibration
technique demonstrated high dosimetric accuracy and potential for on-line plan
adaptation. Collectively, these projects improve radiotherapy plan quality, planning and
delivery efficiency, as well as establish the foundation for an on-line plan adaptation
procedure. Additional applications of these projects include dose-painting, multi-criteria
optimization, as well as inter- and intra-fraction on-line adaptive radiotherapy in response
to anatomical changes. Ultimately, these developments could enhance the quality of life
and the survival rates of cancer patients, using existing technology that is widely
available today.
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Appendix A – Feasibility of a unified approach to intensitymodulated radiation therapy and volumetric modulated arc
therapy optimization and delivery
This chapter was adapted from the published article entitled “Feasibility of a unified
approach to intensity-modulated radiation therapy and volumetric modulated arc therapy
optimization and delivery” by Douglas A. Hoover, Michael MacFarlane, Eugene Wong,
Jerry J. Battista, and Jeff Z. Chen, Medical Physics, 42 (2): 726-34 (2015). Permission to
reproduce this article was granted by John Wiley and Sons, and is provided in Appendix
B.5.

A.1 Introduction
Volumetric-modulated arc therapy (VMAT) has been rapidly adopted by the
radiotherapy community due primarily to its delivery speed and monitor unit (MU)
efficiency, as well as the quality of conformal dose distributions achievable [1-3]. On the
other hand, intensity-modulated radiotherapy (IMRT) with its static beam directions
might be advantageous in cases where steep dose gradients or highly intensity-modulated
beam intensities are required in preferred directions [4]. While the community tends to
regard these two delivery techniques as disparate entities, they are in reality special cases
of one another. More specifically, there exists a unifying delivery technique which
bridges the gap between static-gantry IMRT and rotating-gantry VMAT. Such a unified
delivery, if properly implemented into an inverse-planning algorithm, would in general
lead to improved dose delivery capabilities as the algorithm could naturally optimize the
beam within a given arc range to be more IMRT-like, if greater beam intensity
modulation is required, or more VMAT-like, if increased conformity is required with less
beam intensity modulation. This combined approach would take advantage of the two
modes of beam delivery for targeting and normal tissue sparing.
IMRT or VMAT delivery is typically represented by control points—or multi-leaf
collimator (MLC) segments—which are essentially snapshots of the positions of the
relevant linear accelerator components taken at regular intervals. For example, a VMAT
beam can be stored as a series of control points specifying the machine parameters at
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regular 2 or 4 degree intervals of the rotating gantry. Due to the large number of degreesof-freedom required to specify a VMAT beam, all VMAT radiotherapy plans are created
using specialized optimization software, such as SmartArc in Pinnacle (Philips
Healthcare, Fitchburg, USA) or RapidArc in Eclipse (Varian Medical Systems, Palo Alto,
USA). Both commercial treatment planning systems optimize beam parameters
specifically for equally-spaced gantry positions. In addition to commercially-available
software, a number of research prototypes have been developed to test novel optimization
algorithms including the concept of unequally-spaced control points [5,6]. In principle,
VMAT and IMRT with and without gantry rotation, respectively, can be unified during
optimization and delivery. Instead of forcing the beam angle increments for arc therapy,
the fixed-gantry IMRT parameters can add additional degrees of freedom available to the
optimization engine.
The idea to combine VMAT and IMRT deliveries is not new, and various ideas have
been implemented to improve the current clinically-available VMAT implementations.
One suggestion, termed dense angularly sampled and sparse intensity modulated
radiation therapy (DASSIM-RT), proposes a method to search more thoroughly through
the parameter space of machine-deliverable radiotherapy plans [7]. One major hurdle
towards the clinical implementation of this method is that the scale of the optimization
problem is now immense and so much greater computer memory is required [8]. Another
proposal, Arc Modulated Radiation Therapy (AMRT), builds on previous work in
intensity modulated arc therapy (IMAT) [1]. AMRT is a sequencing algorithm that
allows multiple IMAT arcs to be delivered by a single arc. In one study, AMRT plans
required on the order of 200-400 segments and achieved similar plan quality to IMRT
[9].
Yet another proposal, termed FusionArc, has recently been published [10]. This paper
describes an in-house optimization software that begins with a full VMAT optimization
followed by an iterative conversion, at select gantry angles, from uniform to intensitymodulated fluence. Gantry angles are selected for conversion based on a gradient
function which attempts to predict conversions that will lead to the greatest reduction in
the cost function. Brainlab (Feldkirchen, Germany) has introduced a commercial platform
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which first optimizes a dynamic conformal arc delivery phase followed by an
optimization of an IMRT phase. However, the arc phase is restricted by constant angular
speed and dose rate. Furthermore, the arc ranges, the number of uniformly spaced IMRT
fields, and the relative weighting of arc and fixed-gantry IMRT phases must all be chosen
from the outset of optimization [11]. The quality of HybridArc plans has been shown to
depend on a proper selection of these initial parameters [12].
None of the solutions described above has yet embodied the fully-integrated and
unified approach that we advocate here. The purpose of this work is to create, as a proofof-principle, a unified intensity-modulated arc therapy (UIMAT) that combines IMRT
and VMAT optimization and delivery in order to produce efficient and superior radiation
treatment plans in a single optimization with concurrent VMAT and IMRT features

A.2 Material and Methods
A.2.1 Inverse Planning for UIMAT
Custom software was developed and integrated into a commercial treatment planning
system, Pinnacle3 v9.6 Radiation Therapy Planning Systems (Philips Healthcare,
Fitchburg, USA) for the purpose of testing whether UIMAT is superior to either standard
VMAT or IMRT. This software extends Pinnacle’s built-in VMAT optimization in a few
key ways. Firstly, it removes the restriction that control points within a dynamic arc must
have a uniform angular spacing. Importantly, this allows arc segments that would benefit
from increased intensity modulation to have more densely packed control points.
Furthermore, angles requiring this increased modulation are selected automatically during
the initial optimization stage, and this can be thought of as a form of beam-angle
optimization.
Our optimization algorithm begins by creating static beams uniformly distributed
between start and stop arc angles with an initially coarse control point spacing of twentyfour degrees, as suggested by Bzdusek [13]. Using Pinnacle’s inverse-planning system,
an optimized fluence pattern is determined for these initial beams. In general, these
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fluence patterns will not be machine-deliverable and so a sequencing step is then
performed which converts the fluence patterns into executable MLC control points.
Custom software is then initiated which reads in this beam information from Pinnacle
software. As a preparatory step, the code first re-orders the control points within each
individual beam, anticipating that these control points may later be distributed—or
fanned out—into other gantry angles to form an arc segment. The goals of this reordering step are: (1) to preferentially place higher-weighted control points towards the
middle of the order, thereby minimizing the dosimetric differences between the original
and the fanned-out beams (see Figure A.1); and (2) to minimize MLC motion between
control points, thereby improving delivery efficiency. Note that for any given solution,
there will always be a “symmetric” solution having the reverse control point order.
However, this symmetry is broken once neighboring beams are considered, and so for
each beam the software determines whether the original or reverse order will result in the
least MLC motion between the first and last control points of neighboring beams.

Figure A.1: Schematic showing how the control points from the initial fixed-beam
optimization are distributed into VMAT and IMRT phases. Control points within each
beam have been re-ordered to minimize MLC motion. As well, higher-weighted control
points are preferentially placed in the middle of the ordering to minimize the difference
between the initial and final gantry angles. Interpolated MLC segments are inserted as
necessary to maintain a maximum control point spacing of four degrees.
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The algorithm next determines which of these beams should remain as IMRT fields
and which should be converted into arc segments. In our current implementation, we
chose to convert those beams having fewer than four control points (low modulation) into
a “VMAT phase”, while those beams with four or more control points were retained for
the “IMRT phase” (high modulation). In this study, the threshold to distinguish between
low and high modulation corresponds approximately to the average number of control
points per beam which in turn depends on the MLC sequencing parameters chosen. Based
on the parameters we chose, on average, we had 4 control points per beam which we
found to work well practically for the anatomical sites tested.
Finally, the algorithm modifies the gantry angle associated with each beam segment
as shown in Figure A.1. Beams that have low modulation become VMAT phases where
their control points are distributed uniformly within the 24 degree spacing. In order to
maintain approximately four-degree spacing between control points, linear interpolation
of MLC leaves is used to create new interlaced control points as needed. Beams that have
high modulation become IMRT phases. In this case, the first and last control points have
their gantry angles shifted 8 degrees on either side of the initial gantry angle, as shown in
Figure A.1. These two boundary control points, together with linearly interpolated control
points, are used to facilitate a smooth transition from VMAT to IMRT phases. Next, the
central control points of high-modulation beams are fanned out around the initial gantry
angle in 0.2° increments. Interpolated control points are then added between these central
control points to arrive at a 0.1° spacing for the IMRT phase. The small gantry rotation
(almost stalled) for the IMRT phase approximates a static-gantry IMRT field and is a
work-around for the fact that Pinnacle v9.6 does not allow simultaneous DMPO
optimization of static-gantry IMRT and VMAT beams. At this stage, the beam control
points are re-imported into Pinnacle for a final optimization using the DMPO algorithm.
As an example, the start and stop angles for these partial arcs, as well as the angular
location of the IMRT phases, are shown in Figure A.2.
Certain “soft” deliverability constraints are relaxed for the IMRT-like portions of
delivery. Specifically, for the IMRT phases the maximum MU per degree is increased
from 20 to 200, and the gantry acceleration limit is removed. Within Pinnacle software,
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this is accomplished by defining a separate machine having these special properties and
associating the IMRT phases with this virtual machine. This is required in order to have a
reasonable number of MUs delivered during the more highly-modulated IMRT phase,
which may have up to ten control points within one degree angular spacing. It is
important to note that such a beam is still machine-deliverable as it does not violate any
physical constraints of the accelerator.

Figure A.2: A typical UIMAT plan. The angular ranges for three VMAT phases are
represented by arc segments while the fixed gantry angles corresponding to four IMRT
phases are represented by straight line pairs.
From this point on, optimization proceeds using the standard functionality within
Pinnacle. Machine parameters for both IMRT phases and VMAT phases are optimized at
the same time as multiple dynamic arcs in Pinnacle software. DMPO optimization is
continued until a clinically-acceptable plan is obtained using standard dose-volume
histogram (DVH) constraints. During optimization, the VMAT and IMRT phases are
treated as separate beams, and after optimization is complete, our custom software is used
to combine the VMAT and IMRT phases into a single UIMAT arc with variable gantry
speed for final dose calculation and delivery. The final dose is calculated by collapsedcone convolution algorithm in the Pinnacle treatment planning system.
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A.2.2 Treatment Plan Evaluation
In order to test our optimization algorithm, CT scans from 15 previously treated
patients were selected for planning comparison purposes. Five cases each were randomly
selected from head-and-neck, lung, and prostate sites to represent a variety of anatomy,
complexity levels, and delivery modalities. All clinical treatment plans were optimized
using the Pinnacle treatment planning system. A summary of the selected patient plans is
provided in Table A.1 with the estimated delivery times obtained from Pinnacle. Since
Pinnacle does not provide an estimate for step-and-shoot beams, the delivery time for
IMRT plans was measured on a Varian linear accelerator. The IMRT delivery time is
defined here as the total time from when the first beam turns on until the last beam turns
off and so includes the “mode-up” time as well as the time required to move to the
various gantry positions. Beams were ordered for the most efficient delivery. A paired,
two-tailed t-test was used to assess for statistically significant differences in delivery
times.
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Table A.1: Comparison of clinically-delivered treatments with UIMAT treatment plans. Note
that some patients had multiple target volumes with distinct dose levels (e.g. Patient 3 had
both a 70 Gy and a 56 Gy target volume). Approximate treatment delivery times are given.

Lung

Head & Neck

Patient Site

Beam Arrangement

Delivery Time [s]

Clinical

UIMAT

Clinical

UIMAT

1

Lt. Parotid

64/60/54 2x 210° (108 CP)

1x 210° (65 CP)

91

64

2

Rt. Parotid

60

2x 225° (116 CP)

1x 225° (55 CP)

95

68

3

Larynx/Neck

70/56

2x 360° (182 CP)

1x 360° (87 CP)

151

171

4

Parotids/Neck 70/56

2x 360° (182 CP)

1x 360° (89 CP)

151

201

5

Larynx

61/50

5 Fields (23 CP)

1x 260° (77 CP)

182

109

6

Lt. Lung

60

5 Fields (17 CP)

1x 230° (73 CP)

167

64

7

Lt. Lung

60

2x 225° (116 CP)

1x 225° (63 CP)

94

67

8

Rt. Lung

60

6 Fields (21 CP)

1x 192° (61 CP)

237

126

9

60

2x 210° (108 CP)

1x 210° (63 CP)

90

98

50

2x 360° (181 CP)

1x 360° (93 CP)

149

100

11

Rt. Lung
Lt. Lung &
Mediastinum
Prostate

76

1x 360° (91 CP)

1x 360° (99 CP)

79

129

12

Prostate Bed

66

2x 360° (182 CP)

151

200

13

Prostate

45

2x 360° (182 CP)

150

236

14

Prostate Bed

76/50.4

2x 360° (182 CP)

1x 360° (97 CP)
1x 360° (103
CP)
1x 360° (93 CP)

154

241

15

Prostate

66

2x 360° (182 CP)

1x 360° (96 CP)

151

139

10

Prostate

Dose
Pres.
[Gy]

Abbreviations: Pres, prescription; Rt, right; Lt, left; UIMAT, unified intensity modulated arc therapy;
CP, control points

The UIMAT plans were optimized based on our local treatment planning guidelines
used to generate the clinical plans. Without exception, critical structure tolerances such as
the spinal cord and brainstem were respected. For lung cases, the volume of both lungs
receiving at least 20 Gy (V20) was kept below 35% and a mean lung dose of < 20 Gy
was also maintained. The dose coverage goal for the planning target volume (PTV) was
to cover at least 95% of the PTV by at least 95% of the prescription dose. For non-critical
structures, DVH criteria from RTOG 0126 and QUANTEC [14] were used to guide the
planning process. All UIMAT plans were restricted to a single arc. Dynamic jaw
movements were allowed in order to facilitate the goal of a single-arc delivery. Dynamic
jaws were required when treating large volumes with a single arc due to the finite speed
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and length of the MLC leaves. It is noted that the clinical plans did not require dynamic
jaws, as all complicated VMAT plans standardly use two arcs.
To compare a UIMAT plan with the corresponding clinical VMAT or IMRT plan for
each patient, various dose metrics were selected and subjected to a paired, one-tailed ttest to assess statistically significant differences. Mean doses for PTVs and conformity
index (CI) were analyzed for all cases. The conformity index has been previously defined
as [15]:
𝐶𝐼 = (𝐶𝑜𝑣𝑒𝑟 𝑓𝑎𝑐𝑡𝑜𝑟) × (𝑆𝑝𝑖𝑙𝑙 𝐹𝑎𝑐𝑡𝑜𝑟)
=(

𝑉100 (𝑃𝑇𝑉)
𝑉100 (𝑃𝑇𝑉)
)×(
)
𝑉𝑃𝑇𝑉
𝑉100 (𝐵𝑜𝑑𝑦)

(1)

where 𝑉100(𝑃𝑇𝑉) and 𝑉100(𝑏𝑜𝑑𝑦) are the volumes of the 100% prescription dose
within the PTV and body, respectively, and VPTV is the volume of the PTV. For head-andneck cases, mean doses for parotids, oral cavity, larynx, and maximum doses for cord,
brainstem, and larynx were analyzed. For lung cases, mean doses for lung, esophagus,
and heart were recorded as well as the lung V20 and the maximum cord dose. For
prostate cases, mean doses for rectum, bladder, bowel, and femurs were analyzed. The
threshold for statistical significance was set at a p-value of 0.05.
The deliverability of UIMAT plans was tested on a Varian TrueBeam linear
accelerator (Varian Medical Systems, Palo Alto, USA). The accuracy of dose calculations
and delivery was verified by measurements with the ArcCheck Phantom (Sun Nuclear,
USA).

A.3 Results
A.3.1 Feasibility
The UIMAT plans were generated for 15 cases, as summarized in Table A.1. UIMAT
plans employed only one arc, while most of the clinical VMAT plans required two arcs.
The number of MLC control points in the UIMAT plans were less than the VMAT plans
for all but one case (see Table A.1), but more than in the IMRT plans. The estimated
delivery times for UIMAT plans were not significantly different from the VMAT plans
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(p=0.22) but they were significantly faster than multiple-field IMRT plans (p=0.01). No
significant difference in delivery time was observed between the UIMAT plans and the
VMAT and IMRT plans taken together (p=0.75).
An ArcCheck measurement in each treatment site was made to verify the accuracy of
UIMAT dose calculation and feasibility of delivery. All tested plans had a gamma
passing rate [16] of greater than 95% using our standard clinical parameters of 3% dose
difference and 3 mm distance-to-agreement.

A.3.1 Plan Comparison
A.3.1.a - Head and Neck
The dose metrics used in the evaluation of the head-and-neck cases are presented in Table
A.2. Plans which have multiple PTVs, as listed in Table A.1, have one conformity index
(CI) reported for each PTV. For patient 5, the low doses associated with most OARs are
related to the small treatment volume which is restricted to the laryngeal region of the
neck. For the five head-and-neck cases, the overall average of the mean OAR doses in
Table A.2 was reduced by 8.4% (p<0.001) using UIMAT plans compared to the clinical
VMAT or IMRT plans. As a specific example, comparison of the dose distributions and
DVHs between a UIMAT and a VMAT plan for a head-and-neck case is shown in Figure
A.3. It shows that the UIMAT plan produced lower OAR doses with similar PTV
coverage compared with the clinical VMAT plan.
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Table A.2: Dose volume parameters of interest for five head-and-neck cases. The mean PTV dose is represented as a
percentage of the prescription dose. Certain OARs were not contoured for some patients, either because the OAR was well
outside the treatment volume or because it was completely enclosed within the PTV. The conformity indices correspond to
the target volumes listed in the third-last column, and similarly for the mean PTV doses. Since not all patients had the same
number of PTV dose levels, P values and average doses for PTVs were calculated for the highest dose level only.
Oral
Left
Right
PTV(s)
Larynx Larynx
Cord
PTV(s)
Brainstem
Conformity
̅
Cavity Parotid Parotid
Pres.
𝐷𝑚𝑎𝑥
𝐷𝑚𝑎𝑥
𝐷
̅ [%]
𝐷𝑚𝑎𝑥 [Gy]
Index
𝐷
̅ [Gy] 𝐷
̅ [Gy] 𝐷
̅ [Gy]
[Gy]
[Gy]
[Gy]
[Gy]
𝐷
Clinical
28.4
6.9
-31.8
62.3
15.0
22.4 64/60/5 0.21/0.77/0.63 99.8/101.5/103.5
1
4
UIMAT
22.6
2.4
-26.8
61.2
9.5
24.5
0.14/0.79/0.63 101.9/102.6/103.7
Clinical
30.0
5.9
61.0
27.8
62.6
13.8
36.7
0.85
101.3
2
60
UIMAT
27.7
3.3
60.8
26.3
63.1
10.9
37.4
0.80
101.5
Clinical
33.2
25.9
25.6
--32.2
36.9
0.83/0.79
100.0/101.8
3
70/56
UIMAT
29.9
23.1
22.4
--33.3
44.3
0.70/0.70
101.7/102.6
Clinical
39.3
25.3
25.4
48.6
65.1
44.3
44.8
0.78/0.72
100.6/104.5
4
70/56
UIMAT
37.3
22.5
22.9
47.7
58.0
46.0
23.4
0.82/0.71
100.7/103.6
Clinical
0.2
0.2
0.2
55.5
64.2
0.2
0.2
0.89/0.73
101.0/109.6
5
61/50
UIMAT
0.2
0.2
0.2
55.5
64.0
39.8
23.6
0.93/0.73
101.6/108.6
Clinical
26.2
12.8
28.0
40.9
63.6
21.1
31.8
0.72
102.4
Avg.
UIMAT
23.6
10.3
26.6
39.0
61.6
20.0
34.9
0.7
102.9
P value
0.02
0.01
0.09
0.09
0.17
0.23
0.04
0.11
0.08
̅
Abbreviations: PTV, planning target volume; OAR, organ at risk; UIMAT, unified intensity modulated arc therapy; 𝑫, mean dose;
Dmax, maximum dose; Avg, average
No.

Plan
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Figure A.3: Comparison of dose distributions between a clinical VMAT plan (top left)
and a UIMAT plan (top right) and corresponding dose volume histograms (bottom) for a
head-and-neck case (patient 1).
A.3.1.b - Lung
The dose metrics used in the evaluation of the lung cases are presented in Table A.3.
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UIMAT yielded significant reductions for the mean doses for heart and esophagus, and
maximum cord dose compared with clinical IMRT or VMAT plans, while the difference
in V20, mean lung dose, conformity index, and mean PTV dose is not statistically
significant. The overall average of the mean OAR doses in Table A.3 was reduced by
5.7% (p<0.001) using UIMAT plans compared with clinical IMRT or VMAT plans
Table A.3: Dose volume parameters of interest for five lung cases. The mean
PTV dose is represented as a percentage of the prescription dose.
No.
6
7
8
9
10

Plan
Clinical
UIMAT
Clinical
UIMAT
Clinical
UIMAT
Clinical
UIMAT
Clinical
UIMAT

Lung
V20
[%]
15.1
14.9
21.9
22.1
30.5
27.8
20.7
20.7
35.6
34.4

Lung
̅ [Gy]
𝑫
9.8
9.2
14.0
14.0
17.2
15.5
11.8
11.5
18.6
18.1

Esophag Heart
̅ [Gy] 𝑫
̅ [Gy]
us 𝑫
17.1
15.7
22.4
21.2
25.0
22.7
24.4
23.3
36.2
35.5

1.2
1.0
10.1
8.3
11.0
10.6
4.8
3.8
30.6
29.4

Cord
𝑫𝒎𝒂𝒙
[Gy]
29.5
27.9
35.6
34.8
47.8
47.4
43.3
41.2
43.4
42.5

CI
0.72
0.87
0.87
0.91
0.79
0.91
0.78
0.81
0.92
0.88

PTV
̅ [%]
𝑫
101.7
102.0
101.3
101.3
103.5
101.5
101.3
101.3
100.2
101.0

24.8
14.3
25.0
11.5
39.9
0.82
101.6
24.0
13.7
23.7
10.6
38.8
0.88
101.4
P value
0.12
0.05
0.003
0.01
0.01
0.08
0.37
Abbreviations: PTV, planning target volume; CI, conformity index; V20, percent
̅ , mean dose; Dmax, maximum dose;
volume of lung receiving at least 20 Gy; 𝐷
UIMAT, unified intensity modulated arc therapy; Avg, average
Avg.

Clinical
UIMAT

As a specific example, comparison of the dose distributions and DVHs between a
UIMAT and a 5-field IMRT plan for a lung case is shown in Figure A.4. The UIMAT
plan produced more conformal and uniform dose to the PTV and lower doses to left lung,
esophagus, and spinal cord compared with the IMRT plan.
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Figure A.4: Comparison of dose distributions between a clinical IMRT plan (top left)
and a UIMAT plan (top right) and corresponding dose volume histograms (bottom) for a
lung case (patient 6).
A.3.1.b - Prostate
The dosimetric parameters of UIMAT and clinical VMAT plans for five prostate
cases are shown in Table A.4. The multiple conformity indices for patient 14 correspond
to the multiple PTVs within the plan. No significant dosimetric difference was observed
between UIMAT and VMAT plans for the prostate cases studied. The overall average of
the mean OAR doses listed in Table A.4 was reduced by 3.5% (p=0.009) using UIMAT
compared with VMAT plans. As a specific example, comparison of the dose distributions
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and DVHs between a UIMAT and a VMAT plan for a prostate case is shown in Figure
A.5. In this case, the UIMAT plan is dosimetrically similar to the clinical VMAT plan.

Figure A.5: Comparison of dose distributions between a clinical VMAT plan (top left)
and a UIMAT plan (top right) and corresponding dose volume histograms (bottom) for a
prostate case (patient 14).
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Table A.4: Dose volume parameters of interest for five prostate cases. The bowel was not contoured for
two patients as it lay well outside the treatment volume. The conformity indices correspond to the target
volumes listed in the third-last column, and similarly for the mean PTV doses. Since not all patients had
the same number of PTV dose levels, P values for PTVs were calculated for the highest dose level only.
Rectum Bladder Bowel Lt. Femur Rt. Femur
PTV
PTV(s)
Conformity
̅
̅
̅
̅
̅
̅
Pres. [Gy]
Index
𝑫 [Gy] 𝑫 [Gy] 𝑫 [Gy]
𝑫 [Gy]
𝑫 [Gy]
𝑫 [%]
Clinical
41.4
15.0
-19.0
22.6
0.83
101.4
11
76
UIMAT
39.2
12.3
-16.3
17.6
0.85
101.9
Clinical
41.4
54.3
53.1
22.4
16.5
0.82
98.2
12
66
UIMAT
42.8
55.5
52.2
20.8
20.8
0.87
98.1
Clinical
34.2
34.2
28.8
16.1
15.3
0.78
103.4
13
45
UIMAT
32.2
33.4
26.3
16.2
13.8
0.84
101.9
Clinical
45.6
45.5
31.6
22.9
21.5
0.91/.0.60 102.0/107.0
14
76/50.4
UIMAT
46.4
43.8
29.7
19.4
21.6
0.88/0.59 102.2/106.6
Clinical
32.3
17.9
-23.4
23.3
0.91
100.9
15
66
UIMAT
32.1
17.8
-21.7
22.5
0.84
100.9
Clinical
39.0
33.4
37.85
20.8
19.8
0.81
102.1
Average
UIMAT
38.6
32.6
36.1
18.9
19.3
0.81
101.9
P value
0.29
0.16
0.03
0.02
0.37
0.39
0.26
̅
Abbreviations: PTV, planning target volume; Lt, left; Rt, right; Pres, prescription; 𝐷, mean dose; UIMAT, unified
intensity modulated arc therapy
No.

Plan
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A.4 Discussion
We have shown that it is feasible to optimize and deliver UIMAT which combines
VMAT and IMRT within the same arc. We have also shown how the degree of intensity
modulation can be naturally incorporated into an algorithm which dynamically varies the
angular density of the beam control points. Compared with clinical VMAT or IMRT
plans, UIMAT has the potential to produce efficient and superior radiation dose
distributions, especially for complex anatomy such as in head-and-neck cancers. On the
other hand, for the sites with more rotational symmetry, such as prostate, UIMAT may
not yield significant advantages as it resulted in plans with comparable dosimetric
performance but less efficient delivery compared with VMAT.
One of the virtues of our proposal is that the switch from the current VMAT
technique to our unified approach would, in principle, be seamless. Treatment planning
for UIMAT would be the same as for VMAT as no selection of static beam directions is
required. Similarly, radiation therapists delivering the treatment would not need to
perform any additional steps beyond what is commonly done for stand-alone VMAT
delivery, although they must be made aware of the stopped gantry during IMRT phases
of UIMAT delivery. Another benefit of our proposal is the ease at which it can be
incorporated into a working clinical system, thus decreasing both cost and time between
conception and clinical implementation. Of course, in practice, the introduction of this
technique, as with all new techniques, would require additional quality assurance and
testing.
Compared with other IMRT/VMAT combination techniques [7-12], our proposal
offers simplicity in integration, optimization, and delivery. Our UIMAT proposal is not
simply an IMRT/VMAT hybrid technique. It would be more correct to refer to it as a
more fully-realized implementation of VMAT with fuller range of gantry speed that even
permits gantry stalls, thus allowing for optimal beam modulation. What we have
demonstrated is one specific implementation of UIMAT, and in principle, it could be
generalized further. UIMAT could be further developed with more robust segmentation
and optimization algorithms, as well as more degrees of freedom such as collimator
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angle, couch position, and couch angle. Such future developments could hopefully
address certain limitations within our initial implementation of UIMAT. For example,
once the initial gantry directions are chosen for IMRT phases at the start of optimization,
they cannot be altered at a later point in the optimization. For most cases this should not
be a problem, except if the objective function changes dramatically between initial and
final optimization. It should be noted that the same is true for VMAT and IMRT
planning. After the fluence map conversion takes place, it becomes much easier for the
optimization routine to become trapped in local minima.
In the planning comparison portion of this work, we acknowledge the usual biases
and confounders inherent in such an approach. For example, there is a natural tendency
towards demonstrating that a new treatment is superior to the standard-of-care. More
effort may be spent optimizing the new technique, or choosing comparison endpoints that
naturally favor the new method. Unfortunately, requiring the matching of equal planning
effort is not practical, but we were conscious in avoiding “over-optimizing” the UIMAT
plans. In this retrospective study, the actual difference in planning time was not logged
precisely. Depending on the complexity of the case, clinical planning in our experience
requires 1 to 4 hours. To ensure a fair planning comparison, we restricted UIMAT
planning times to fall within a similar range.
We acknowledge that the number of cases tested in this feasibility study is very
limited and so the statistics reported only highlight general trends. More cases are needed
for each treatment site to confirm the conclusions reached. Finally, as mentioned earlier,
dynamic jaws are needed when treating large volumes with a single arc due to the finite
speed and length of the MLC leaves. This is an obvious advantage for UIMAT as it
allows more freedom for collimating the beam; however comparable degrees of freedom
were still available in our clinical plans but required more than one arc with differing jaw
positions.
Compared to other published techniques [7-12] combining IMRT and VMAT,
UIMAT is unique in that it possesses all of the following features: 1) it creates VMAT
and IMRT phases automatically; 2) it optimizes VMAT and IMRT phases
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simultaneously; 3) the VMAT and IMRT phases are combined and delivered in a single
dynamic arc; 4) the algorithm has been implemented on a commercial treatment planning
system; 5) the UIMAT plans have been validated using the ArcCheck phantom, delivered
in clinical mode on a Varian TrueBeam linear accelerator. Theoretically, it is known that
the increased degrees of freedom afforded by the IMRT phases of the arc will in principle
lead to a superior plan, all other things being equal. What we have shown is that this
appears to be the case, even with this simple initial implementation. Further
improvements in the optimization beyond what is possible within a commercial treatment
planning software should lead to even better results. Last but not least, our work shows
that the UIMAT delivery speed is improved over IMRT or when multiple VMAT arcs are
required.

A.5 Conclusion
We have demonstrated the feasibility of a novel radiation therapy delivery technique
termed UIMAT. This technique combines VMAT and IMRT optimization concurrently
and delivers radiation in a single arc. The optimal fixed-gantry IMRT phases are chosen
automatically during the optimization. Optimization of both the VMAT and fixed-gantry
IMRT phases of delivery occur simultaneously and the final plan is an integrated UIMAT
plan. Initial results show that the UIMAT has the potential to be superior to either standalone IMRT or VMAT in terms of dose distribution quality and efficiency of delivery.
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Appendix C – Supplemental Data for Chapter 2
This content of this appendix was previously published with the article “Evaluation of
unified intensity-modulated arc therapy for the radiotherapy of head-and-neck cancer” by
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Supplemental Figure 2.1: OAR dose-volume histograms averaged over: a) & b) all
cases; c) & d) VMAT cases only; e) & f) IMRT cases only.
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Supplementary Table 2.1: Summary of UIMAT and clinically delivered treatment plans. Patients with
several prescriptions had multiple target volumes, each with the listed dose levels.
Dose
Beam Arrangement
Delivery Time [s]
IMRT QA [%]
Prescription
[Gy]
Patient
Site
Clinical
UIMAT
Clinical UIMAT Clinical UIMAT
o
o
99.4
97.5
1
Right Parotid
64/60/54
2 - 210 Arcs 1 - 360 Arc
115
145
o
o
99.3
99.5
2
Right Parotid
60
2 - 225 Arcs 1 - 230 Arc
121
161
o
o
98.5
97.6
3
Neck/Parotids
70/56
2 - 360 Arcs 1 - 360 Arc
194
180
o
o
94.4
96.9
4
Larynx/Neck
70/56
2 - 360 Arcs 1 - 360 Arc
177
176
98.3
98.7
5
Right Parotid
50
2 - 180o Arcs 1 - 190o Arc
92
135
o
o
99.6
98.5
6
Left Neck
66/64/60/54 2 - 360 Arcs 1 - 360 Arc
182
131
o
o
96.0
96.1
7
Whole Neck
70/56
2 - 360 Arcs 1 - 360 Arc
174
198
o
o
99.4
97.5
8
Left Parotid
50
2 - 180 Arcs 1 - 180 Arc
109
81
99.3
98.0
9
Hypopharynx
66/60/56
2 - 360o Arc 1 - 360o Arc
166
125
o
o
97.2
96.6
10
Right Neck
54
2 - 360 Arcs 1 - 360 Arc
171
159
o
o
99.6
97.4
11
Left Neck
50
2 - 210 Arcs 1 - 190 Arc
120
154
o
o
98.3
97.8
12
Right Neck
72/65
2 - 360 Arcs 1 - 210 Arc
168
82
100.0
98.0
13
Right Neck
55/45
2 - 180o Arcs 1 - 210o Arc
101
135
o
o
97.7
96.0
14
Oral Cavity
66/64/60/54 2 - 360 Arcs 1 - 360 Arc
174
97
o
o
98.8
97.2
15
Larynx/Neck
70/56
2 - 360 Arcs 1 - 360 Arc
168
123
o
99.8
97.9
16
Left Neck
64/60
4F SS-IMRT 1 - 190 Arc
188
108
98.0
97.8
17
Left Head
64/60/54
4F SS-IMRT 1 - 190o Arc
204
144
o
99.6
97.2
18
Ethmoid
70/63/56
4F SS-IMRT 1 - 210 Arc
127
109
o
99.3
97.8
19
Left Parotid
50
4F SS-IMRT 1 - 210 Arc
224
167
o
99.3
98.9
20
Right Neck
50/45
5F SS-IMRT 1 - 230 Arc
269
182
99.8
96.7
21
Right Neck
70/56
5F SS-IMRT 1 - 240o Arc
313
94
o
99.2
97.6
22
Left Neck
60/54
6F SS-IMRT 1 - 360 Arc
339
136
o
98.9
95.1
23
Hypopharynx
70/63/56
6F SS-IMRT 1 - 360 Arc
320
214
o
98.4
95.7
24
Hypopharynx
70/56
6F SS-IMRT 1 - 360 Arc
348
147
97.9
99.6
25
Larynx/Neck
70/63/56
6F SS-IMRT 1 - 360o Arc
287
111
o
98.0
97.9
26
Right Neck
50/45
4F SS-IMRT 1 - 360 Arc
235
148
o
93.4
94.7
27
Hypopharynx
60/54
6F SS-IMRT 1 - 360 Arc
358
192
o
99.4
97.5
28
Left Neck
64/60/54
4F SS-IMRT 1 - 360 Arc
262
202
97.6
98.3
29
Tonsils
70/63/56
6F SS-IMRT 1 - 360o Arc
296
117
o
99.4
96.4
30
Right Neck
60/54
4F SS-IMRT 1 - 360 Arc
244
154
*Abbreviations: UIMAT, unified intensity-modulated arc therapy; nF SS-IMRT, n-field step-and-shoot
intensity-modulated radiation therapy.
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Supplementary Table 2.2: Comparison of dose metrics between the unified plans and the clinically delivered VMAT plans. PTV mean doses and D95 (dose
to 95% of the volume) are given as percentages of the prescribed dose to the target volume(s). Max doses are defined as the dose to 2% of the volume. Missing
dose metrics are a result of OARs which were not contoured, for example due to an OAR being completely enclosed within the PTV.
Oral
Left
Right
Left
Right
Planning Target Volume(s)
Cavity Parotid Parotid Larynx Cord Brainstem Cochlea Cochlea
Mean
Mean
Mean
Mean Max
Max
Max
Max
No.
Plan
Conformity Index
Mean (%)
D95 (%)
(Gy)
(Gy)
(Gy)
(Gy)
(Gy)
(Gy)
(Gy)
(Gy)
VMAT
0.21/0.77/0.63
99/101/103
97/97/97
28.3
6.9
33.8
20.4
14.0
6.2
25.3
1
Unified
0.16/0.80/0.63
101/102/104
99/97/98
15.6
2.0
26.2
13.5
6.0
2.1
17.6
VMAT
0.87
101
98
30.0
5.9
60.9
27.9
31.9
11.1
5.6
27.6
2
Unified
0.86
101
97
23.1
2.6
60.8
22.2
23.4
5.1
1.6
10.6
VMAT
0.78/0.71
101/105
99/98
39.5
25.3
25.5
48.7
37.0
40.4
27.3
32.4
3
Unified
0.74/0.66
101/106
99/99
35.0
22.6
22.6
45.5
32.4
31.4
13.5
26.3
VMAT
0.83/0.79
100/102
98/97
33.2
25.9
25.6
35.8
25.7
3.8
2.9
4
Unified
0.82/0.78
101/103
99/99
21.3
26.1
24.6
29.4
11.0
4.0
2.3
VMAT
0.74
101
98
5.8
2.0
0.4
16.5
20.3
2.3
50.0
5
Unified
0.76
102
99
5.0
2.6
0.4
9.2
11.7
2.5
50.0
VMAT 0.19/0.44/0.77/0.67 102/102/102/103 99/99/98/99
39.5
39.9
30.6
50.5
39.8
42.3
25.2
19.8
6
Unified 0.15/0.37/0.73/0.65 101/102/103/103 99/99/97/99
35.8
39.8
30.8
52.2
35.1
39.8
19.5
20.0
VMAT
0.84/0.75
101/106
98/98
30.5
29.7
30.4
64.7
37.0
35.0
19.0
9.8
7
Unified
0.85/0.75
102/107
98/98
22.7
31.0
32.1
65.2
31.2
24.6
9.6
4.6
VMAT
0.72
102
99
5.2
43.9
1.3
0.2
7.3
6.2
17.1
1.2
8
Unified
0.68
104
99
3.6
44.3
1.1
0.2
5.6
2.8
9.4
1.0
VMAT
0.75/0.55/0.72
100/103/107
97/99/98
37.7
37.3
32.9
65.8
37.5
39.6
11.9
12.2
9
Unified
0.74/0.54/0.71
101/105/106
97/101/97
35.7
34.0
29.5
66.7
36.7
31.0
7.3
7.5
VMAT
0.92
101
97
4.7
6.6
20.3
0.7
41.6
40.5
4.3
7.9
10
Unified
0.87
101
97
3.0
4.2
16.1
1.0
36.8
32.4
1.8
6.2
VMAT
0.80
101
98
18.1
7.8
31.0
18.3
21.5
50.8
8.2
11
Unified
0.79
101
98
14.8
2.2
24.1
14.3
7.5
51.6
2.0
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Planning Target Volume(s)
No.

Plan
VMAT
12
Unified
VMAT
13
Unified
VMAT
14
Unified
VMAT
15
Unified
VMAT
Med.
Unified
P-value

Conformity Index
0.52/0.83
0.45/0.85
0.68/0.73
0.58/0.66
0.42/0.26/0.71/0.65
0.27/0.24/0.68/0.66
0.74/0.73
0.71/0.70
0.73
0.70
0.003

Mean (%)
101/101
101/102
100/109
101/110
100/101/102/103
100/102/103/103
103/105
103/107
101.5
102.3
0.001

D95 (%)
97/96
98/96
96/105
97/98
90/99/97/98
89/99/96/96
101/100
100/100
98.0
98.2
0.695

Oral
Cavity
Mean
(Gy)
22.6
10.2
8.9
8.0
44.0
43.0
29.2
22.7
29.2
21.3
0.002

Left
Parotid
Mean
(Gy)
4.7
2.8
33.4
33.2
24.3
19.5
25.3
22.6
0.173

Right
Parotid
Mean
(Gy)
46.4
46.5
28.8
26.3
25.0
20.0
27.2
25.5
0.071

Larynx Cord
Mean Max
(Gy)
(Gy)
36.1
19.7
28.0
14.5
27.8
25.0
24.1
20.1
55.0
40.2
55.5
37.7
37.9
32.9
33.8
35.8
26.2
29.4
0.173 0.001

*Abbreviations: D95, dose to 95% of the volume; VMAT, volumetric modulated arc therapy; Med, Median.
†

P-values were calculated using the Wilcoxon signed-rank test.
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Left
Brainstem Cochlea
Max
Max
(Gy)
(Gy)
18.6
5.2
7.9
1.6
4.3
3.1
4.4
3.1
57.3
64.6
56.9
65.5
37.1
13.8
29.7
5.9
25.7
11.9
11.7
5.9
0.001
0.011

Right
Cochlea
Max
(Gy)
25.0
12.1
12.3
6.9
35.0
29.5
16.1
8.2
16.1
8.2
0.001

Supplemental Table 2.3: Comparison of dose metrics between the unified plans and the clinically delivered IMRT plans. PTV mean doses and D95 (dose to
95% of the volume) are given as percentages of the prescribed dose to the target volume(s). Max doses are defined as the dose to 2% of the volume. Missing
dose metrics are a result of OARs which were not contoured, for example due to an OAR being completely enclosed within the PTV.
Oral
Left
Right
Left
Right
Planning Target Volume(s)
Cavity Parotid Parotid Larynx Cord Brainstem Cochlea Cochlea
Mean
Mean
Mean
Mean Max
Max
Max
Max
No.
Plan
Conformity Index
Mean (%)
D95 (%)
(Gy)
(Gy)
(Gy)
(Gy)
(Gy)
(Gy)
(Gy)
(Gy)
IMRT
0.19/0.11
101/102
96/96
33.9
10.2
41.0
40.4
32.1
29.9
5.0
16
Unified
0.18/0.11
101/102
96/96
27.5
7.8
41.1
37.3
24.2
25.7
4.5
IMRT
0.17/0.67/0.60
100/102/102
96/97/97
20.5
9.9
32.0
33.9
22.2
40.2
13.4
17
Unified
0.16/0.60/0.60
101/102/103
98/99/97
16.7
4.9
27.0
28.9
22.2
29.2
7.0
IMRT
0.76/0.63/0.54
100/102/112
95/98/103
34.1
28.0
6.3
0.6
34.6
44.0
59.9
25.2
18
Unified
0.81/0.65/0.55
101/102/109
96/99/101
32.8
27.1
5.2
0.6
27.0
41.0
56.3
17.7
IMRT
0.81
101
95
14.0
7.9
24.8
30.9
20.7
23.8
8.2
19
Unified
0.83
101
96
12.4
3.9
22.3
24.8
8.0
14.1
4.0
IMRT
0.81/0.59
101/102
97/99
16.2
8.0
34.6
27.6
18.9
8.5
22.9
20
Unified
0.79/0.61
101/102
96/99
13.8
3.7
30.5
15.9
6.4
2.5
9.7
IMRT
0.85/0.63
101/105
95/99
29.5
58.0
40.0
25.3
14.6
1.5
24.3
21
Unified
0.86/0.68
102/104
97/99
23.3
58.1
38.5
23.3
6.6
1.4
11.4
IMRT
0.70/0.68
101/103
97/97
41.0
28.3
25.0
55.2
37.1
36.5
13.6
13.8
22
Unified
0.76/0.70
101/102
98/97
40.1
26.4
15.7
54.1
30.6
23.5
5.3
5.2
IMRT
0.71/0.67/0.53
100/103/104
95/95/97
51.3
33.0
30.2
71.3
41.5
45.0
7.2
9.8
23
Unified
0.71/0.68/0.56
99/103/105
95/95/99
45.6
31.0
28.4
70.6
39.4
38.8
5.1
6.2
IMRT
0.84/0.60
100/106
95/98
46.0
52.0
39.4
40.9
46.9
6.1
6.8
24
Unified
0.83/0.63
102/107
97/99
35.4
48.3
36.6
39.0
35.9
5.9
5.7
IMRT
0.82/0.66/0.71
100/102/105
95/98/96
37.4
25.2
29.4
40.5
25.4
8.1
17.5
25
Unified
0.83/0.62/0.69
102/104/106
97/100/99
27.7
20.9
26.1
39.6
20.2
8.2
11.2
IMRT
0.71/0.64
102/105
99/98
39.0
42.7
8.6
37.4
25.3
19.9
26.3
2.0
26
Unified
0.78/0.69
102/104
98/99
30.8
40.0
3.2
30.9
21.3
10.6
23.3
1.3
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Planning Target Volume(s)
No.

Plan
IMRT
27
Unified
IMRT
28
Unified
IMRT
29
Unified
IMRT
30
Unified
IMRT
Med.
Unified
P-value

Conformity Index
0.74/0.61
0.74/0.59
0.54/0.61/0.56
0.47/0.67/0.56
0.76/0.58/0.57
0.77/0.56/0.59
0.75/0.59
0.73/0.56
0.67
0.67
0.256

Mean (%)
99/103
101/102
100/101/101
102/102/101
101/106/103
103/105/104
100/102
101/103
101.8
102.2
0.011

D95 (%)
95/97
97/99
96/97/96
98/98/99
97/101/98
98/102/98
96/98
97/100
96.7
98.0
0.004

Oral
Cavity
Mean
(Gy)
33.2
23.5
27.7
23.7
61.3
57.7
23.1
10.0
33.9
27.5
0.001

Left
Parotid
Mean
(Gy)
29.9
25.3
37.8
36.1
3.4
2.6
29.1
26.7
0.005

Right
Parotid
Mean
(Gy)
30.7
26.0
4.7
2.7
29.6
21.0
58.6
58.3
27.2
18.4
0.001

Larynx Cord
Mean Max
(Gy)
(Gy)
25.3
38.0
15.3
36.7
39.6
34.5
37.6
28.8
58.1
39.6
55.8
35.3
30.3
35.3
20.9
30.3
37.4
35.3
30.9
30.3
0.002 0.001

*Abbreviations: D95, dose to 95% of the volume; IMRT, intensity-modulated radiation therapy; Med, Median.
†

P-values were calculated using the Wilcoxon signed-rank test.
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Left
Brainstem Cochlea
Max
Max
(Gy)
(Gy)
34.4
4.8
32.8
4.5
23.5
2.2
11.6
2.1
46.6
32.8
32.4
16.5
3.4
0.7
4.5
0.6
25.4
8.5
22.2
5.9
0.001
0.001

Right
Cochlea
Max
(Gy)
3.3
3.1
0.9
0.9
9.5
7.0
2.4
2.0
9.5
5.7
0.001

Appendix D – Supplemental Data for Chapter 3
This content of this appendix was previously published with the article “A fast
inverse direct aperture optimization algorithm for intensity-modulated radiation therapy”
by Michael MacFarlane, Douglas Hoover, Eugene Wong, Pedro Goldman, Jerry J.
Battista, and Jeff Z. Chen, Medical Physics, Early View (2019). Permission to reproduce
this article was granted by John Wiley and Sons and is provided in Appendix B.3.

Supplemental Figure 3.1: Dose-volume histograms of the prostate case after undergoing
FMO and aperture sequencing (dotted) and when optimized with the FIDAO (solid) and
the standard (dashed) DAO algorithms.
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Supplemental Figure 3.2: Dose-volume histograms of the liver case after undergoing
FMO and aperture sequencing (dotted) and when optimized with the FIDAO (solid) and
the standard (dashed) DAO algorithms.

Supplemental Figure 3.3: Dose-volume histograms of the head-and-neck case after
undergoing FMO and aperture sequencing (dotted) and when optimized with the FIDAO
(solid) and the standard (dashed) DAO algorithms.
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Supplemental Table 3.1: PTV dosimetric and volume statistics for each plan. Note that P.S. stands for the Post Sequencing plan. R50 is defined as the ratio
of the 50% prescription isodose line to the PTV volume.
Homogeneity
D98
[Gy]
D02
[Gy]
Conformity
Index
Index
R50
No. Of Volume
Case
PTV
Voxel
[cc]
P.S. Std. FIDAO P.S. Std. FIDAO P.S. Std. FIDAO P.S. Std. FIDAO P.S. Std. FIDAO
7429
94.7
40.0 46.3 46.3
50.8 52.8 52.8
0.4 0.7
0.8
17.4 9.0
9.5
4.5
4.8
4.7
TG119
PTV50
9491
1020.7 32.3 53.0 52.5
54.4 60.4 60.6
0.0 0.2
0.2
33.4 8.4
9.1
9.8 12.8 12.9
Prostate PTV56
6770
259.6
50.2
64.0
64.2
68.0
69.7
69.9
0.3
0.6
0.6
20.9
6.1
6.1
6.7 10.0 10.1
PTV68
6954
156.5
38.7 43.2 43.4
46.2 46.1 46.2
0.8 0.7
0.8
11.4 4.1
4.2
3.2
5.4
5.4
Liver
PTV45
2104
94.7
38.5 54.9 54.8
53.4 57.1 57.3
0.0 0.0
0.0
20.1 2.9
3.2
18.5 40.5 40.5
PTV56
Head60.9 67.5 67.4
0.0 0.5
0.5
44.4 9.7
9.9
1.5
3.5
3.5
PTV63 22682 1020.7 26.4 59.1 58.8
and5768
259.6
45.6 67.4 67.3
68.2 71.4 71.4
0.1 0.7
0.7
26.1 4.5
4.5
5.2 12.6 12.6
neck
PTV70
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Int.
Dose
P.S.
Std.
FIDAO
2.8 x 106
2.7 x 106
2.7 x 106
6.6 x 106
8.0 x 106
8.0 x 106
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5.0
23.0
0.3
77.0

23.0
0.3
77.6

0.1

0.1

5.2

0.0

0.0

0.1

0.3

0.3

0.1

45.3

45.4

77.0

0.0

0.0

77.6

70.6

70.5

46.4

39.7

40.3

46.4

65.4

65.8

74.6

73.2

31.3

69.3

68.9

32.1

81.3

80.5

71.5

60.4

58.9

71.6

26.8

Std.

27.3

FIDAO

Max [Gy]

3.1 x 106
2.9 x 106
3.0 x 106

29.5

0.4

12.2

5.4

0.1

45.2

46.9

0.1

0.0

0.2

44.5

0.0

69.8

44.4

56.6

26.2

66.6

51.7

66.0

72.1

49.6

27.1

P.S.

0.7

0.0

0.8

0.8

0.0

1.2

4.5

0.0

0.0

0.0

2.6

0.0

68.0

12.7

35.0

13.2

57.2

17.2

32.9

10.1

4.0

13.0

FIDAO

0.7

0.0

0.8

0.8

0.0

1.2

4.4

0.0

0.0

0.0

2.5

0.0

68.0

12.0

34.7

13.0

57.3

17.4

32.9

10.1

3.9

12.7

Std.

Mean [Gy]

Nodes

0.7 Normal Tissue

0.0 Duodenum

0.7 Stomach

1.0 Spinal Cord

0.0 Small Bowel

1.5 Skin

7.4 Liver

0.0 Large Bowel

0.0 Rt. Kidney

0.0 Lt. Kidney

7.5 Heart

0.0 Celiac

63.2 Prostate Bed

14.0 Rt. Femoral Head

19.6 Rectum

11.1 Penile Bulb

47

13.7 Lt. Femoral Head

30.1 Bladder

8.2 Normal Tissue

4.1 Body

16.1 Core

P.S. OAR

Supplemental Table 3.2: OAR dose statistics for each plan and structure.
TG119
Prostate
Liver

Int.
Dose
P.S.
Std.
FIDAO

59.4
60.0
37.5
66.7
40.6
63.3

60.1
38.4
67.4
40.8
62.6

1.2

1.2

59.8

0.7

0.7

26.5

70.0

69.9

27.5

81.4

80.4

52.6

29.5

30.3

53.1

67.5

67.2

65.5

26.0

26.2

64.4

Std.

FIDAO

Max [Gy]

3.5 x 106
5.7 x 106
5.7 x 106
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39.6

24.4

40.4

27.1

31.0

35.6

13.5

22.4

40.1

0.5

0.3

42.5

65.9

23.3

26.7

18.3

P.S.

54.5

11.2

16.5

17.0

22.0

22.1

9.0

13.4

35.1

1.0

0.6

64.0

18.1

20.7

23.0

6.7

FIDAO

54.8

10.9

16.6

16.7

21.9

21.8

8.8

13.2

35.4

0.9

0.6

64.0

18.2

20.0

23.2

6.6

Std.

Mean [Gy]

35.5 Lt. TM Joint

7.9 Rt. Temp Lobe

5.9 Lt. Temp Lobe

11.8 Spinal Cord

12.1 Rt. Parotid

13.4 Lt. Parotid

5.7 Rt. Optic Nerve

6.5 Lt. Optic Nerve

22.1 Lips

0.4 Rt. Lens

0.3 Lt. Lens

30.9 Larynx

8.6 Normal Tissue

15.4 Chiasm

9.5 Cerebellum

8.9 Brainstem

P.S. OAR

Head-and-neck

Appendix E – Supplemental Data for Chapter 5
This content of this appendix was previously published with the article “Patient-specific
calibration of cone-beam computed tomography data sets for radiotherapy dose
calculations and treatment plan assessment” by Michael MacFarlane, Daniel Wong,
Douglas A. Hoover, Eugene Wong, Carol Johnson, Jerry J. Battista, and Jeff Z. Chen,
Journal of Applied Clinical Medical Physics, 19 (2): 249-257 (2018). Permission to
reproduce this article was granted by John Wiley and Sons and is provided in Appendix
B.4.

Supplemental Table 5.1: Summary of Patient Treatment Information
Primary
No.
Disease Site
Delivery Method
Re-planned After
1
Tongue
2 Coplanar 360o Arcs
18/35 Fxns
2
Mouth Floor
2 Coplanar 360o Arcs
9/30 Fxns
3
Right Neck
2 Coplanar 360o Arcs
27/35 Fxns
4
Tongue
2 Coplanar 360o Arcs
29/35 Fxns
5
Oropharynx
2 Coplanar 360o Arcs
17/35 Fxns
6
Mouth
2 Coplanar 180o Arcs
12/30 Fxns
7
Tonsils
2 Coplanar 360o Arcs
21/35 Fxns
8
Tonsils
2 Coplanar 360o Arcs
17/35 Fxns
9
Tongue
2 Coplanar 360o Arcs
14/35 Fxns
10
Tonsils
2 Coplanar 360o Arcs
26/35 Fxns
11
Tonsils
2 Coplanar 360o Arcs
20/35 Fxns
12
Tongue
2 Coplanar 360o Arcs
27/35 Fxns
13
Tongue
2 Coplanar 360o Arcs
24/35 Fxns
14
Neck
2 Coplanar 360o Arcs
21/35 Fxns
15
Nasal Cavity
2 Non-coplanar Arcs
17/30 Fxns
Abbreviations: Fxns, fractions.
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Supplemental Table 5.2: Summary of the planning CT acquisition.
X-Ray Exposure
Acquisition Energy Current
Time
No.
Device
Date
[kV]
[mA]
[ms]
Brilliance Big Bore 11/27/2012
1
120
283
1060
2

Brilliance Big Bore

3

Brilliance Big Bore

4

Brilliance Big Bore

5

Brilliance Big Bore

6

Brilliance Big Bore

7

Brilliance Big Bore

8

Brilliance Big Bore

9

Brilliance Big Bore

10

Brilliance Big Bore

11

Brilliance Big Bore

12

Brilliance Big Bore

13

Brilliance Big Bore

14

Brilliance Big Bore

15

Brilliance Big Bore

4/5/2016
5/15/2015
5/11/2016
8/14/2013
9/25/2013
12/9/2013
12/3/2013
1/27/2014
5/13/2014
6/8/2015
6/24/2015
4/11/2016
4/11/2016
9/23/2015

120
120
120
120
120
120
120
120
120
120
120
120
120
120

245
281
242
283
281
244
281
281
283
244
208
281
283
244

1224
1068
1240
1060
1068
1230
1068
1068
1060
1230
1447
1068
1060
1230

Supplemental Table 5.3: Summary of the re-planning CT acquisition.
X-Ray Exposure
Acquisition Energy Current
Time
No.
Device
Date
[kV]
[mA]
[ms]
Brilliance Big Bore
120
244
1230
1
1/8/2013
2

Brilliance Big Bore

3

Brilliance Big Bore

4

Brilliance Big Bore

5

Brilliance Big Bore

6

Brilliance Big Bore

7

Brilliance Big Bore

8

Brilliance Big Bore

9

Brilliance Big Bore

10

Brilliance Big Bore

11

Brilliance Big Bore

12

Brilliance Big Bore

13

Brilliance Big Bore

14

Brilliance Big Bore

15

Brilliance Big Bore

5/26/2016
7/8/2015
6/29/2016
9/19/2013
10/21/2013
1/28/2014
1/10/2014
2/28/2014
6/27/2014
7/24/2015
8/11/2015
5/26/2016
5/10/2016
11/3/2015

120
120
120
120
120
120
120
120
120
120
120
120
120
120

244
244
244
244
281
244
281
244
281
244
281
244
281
245
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1230
1230
1230
1230
1068
1230
1068
1230
1068
1230
1068
1230
1068
1224

Exposure
[mAs]

Slices

Voxel Size
[mm]

300
300
300
300
300
300
300
300
300
300
300
301
300
300
300

146
141
135
155
126
151
140
158
136
134
120
135
140
121
124

1.01 x 1.01 x 3
1.10 x 1.10 x 3
1.00 x 1.00 x 3
1.22 x 1.22 x 3
1.02 x 1.02 x 3
0.97 x 0.97 x 3
1.09 x 1.09 x 3
1.00 x 1.00 x 3
0.93 x 0.93 x 3
1.02 x 1.02 x 3
1.18 x 1.18 x 3
1.30 x 1.30 x 3
0.93 x 0.93 x 3
0.93 x 0.93 x 3
1.05 x 1.05 x 3

Exposure
[mAs]

Slices

Voxel Size
[mm]

300
300
300
300
300
300
300
300
300
300
300
300
300
300
300

153
137
167
131
158
144
156
153
137
134
146
137
143
145
125

1.20 x 1.20 x 3
1.08 x 1.08 x 3
1.13 x 1.13 x 3
1.10 x 1.10 x 3
1.13 x 1.13 x 3
1.04 x 1.04 x 3
1.19 x 1.19 x 3
0.98 x 0.98 x 3
1.16 x 1.16 x 3
1.03 x 1.03 x 3
1.05 x 1.05 x 3
0.97 x 0.97 x 3
1.15 x 1.15 x 3
1.03 x 1.03 x 3
1.11 x 1.11 x 3

Supplemental Table 5.4: Summary of the CBCT acquisition.
X-Ray Exposure
Acquisition Energy Current
Time
No.
Device
Date
[kV]
[mA]
[ms]
100
20
7000
Clinac iX
1
1/8/2013
2

Truebeam

3

Truebeam

4

Truebeam

5

Clinac iX

6

Truebeam

7

Clinac iX

8

Truebeam

9

Clinac iX

10

Clinac iX

11

Clinac iX

12

Clinac iX

13

Clinac iX

14

Clinac iX

15

Clinac iX

5/26/2016
7/15/2015
7/5/2016
9/19/2013
10/21/2013
1/28/2014
1/10/2014
2/28/2014
6/26/2014
7/23/2015
8/11/2015
5/26/2016
5/10/2016
11/3/2015

100
100
100
100
100
100
100
100
100
100
100
100
100
100

20
20
20
20
20
20
10
10
20
20
20
10
20
20

7450
7450
7500
7050
7250
7000
7200
7000
7250
6950
7200
7000
7200
7000
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Exposure
[mAs]

Slices

Voxel Size [mm]

140
149
149
150
141
145
140
72
70
145
139
144
70
144
140

70
93
93
93
70
89
70
70
70
70
70
70
70
70
70

0.65 x 0.65 x 2.5
0.51 x 0.51 x 2.0
0.51 x 0.51 x 2.0
0.51 x 0.51 x 2.0
0.65 x 0.65 x 2.5
0.51 x 0.51 x 2.0
0.65 x 0.65 x 2.5
0.49 x 0.49 x 2.5
0.65 x 0.65 x 2.5
0.65 x 0.65 x 2.5
0.65 x 0.65 x 2.5
0.65 x 0.65 x 2.5
0.65 x 0.65 x 2.5
0.65 x 0.65 x 2.5
0.65 x 0.65 x 2.5
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